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This PhD thesis has as main objective  to offer an innovative tissue 
engineering strategy for Huntington's disease by combining nanocarriers 
delivering siRNA in mesenchymal stem cells and microcarriers  releasing 
therapeutic proteins . This project  is  part  of  a general strategy of the 
laboratory INSERM U1066 "Biomimetic Micro and nanomedicine" from 
Angers and the department "Pharmacy and Pharmaceutical Technology" from 
Santiago de Compostela  proposing an alternative and safe treatment in 
neurodegenerative disorders .  
Huntington’s disease (HD) is an inherited autosomal dominant 
neurodegenerative disorder with prevalence in Europe of about 10 per 
100,000 births (Figure 1.)  [1, 2].  HD appears in mid-life leading to death 15-
20 years later and involves the triad signs and symptoms: involuntary 
movement disorders called Huntington’s chorea,  cognitive impair ment and 
psychiatric manifestations.  
 
Figure 1. Worldwide estimates of the prevalence of HD. Overall, the 
prevalence of HD is much higher in European populations than in East Asia [3]. 
HD is one of the nine neurodegenerative disorders caused by the 
expansion of cytosine-adenine-guanine (CAG) triplet  repeat sequence  [4].  
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This disorder is  characterized by an unstable repetition of triplet  cytosine -
adenine-guanine (CAG) of the Huntingtin (htt) gene in exon 1 of chromosome 
4. It is translated at  the protein level by a polyglutamine expansion at  the 
NH2-terminal part of the protein huntingtin ( HTT) [5]. The htt  gene is 
considered as normal when it contains less than 27 CAG repeats and generally 
more than 40 repeats defines the adult -onset HD. The age of HD onset is  
inversely correlated with the length of the expansion, with variable age -
dependent penetrance between 36 and 39 CAG repeats,  but full penetrance at  
40 or more repeats. In other words, people with 36-39 CAG repeats are at a 
risk of developing all the HD symptoms [6] and conversely,  a larger number 
of repeats is  usually associated with an earlier onset of signs and symptoms 
[7].  
The HTT protein has ubiquitous roles in apoptosis  [8],  regulating 
microtubule-based transport  [9] and scaffolding of cytoskeletal  molecules at  
synapses [10].  Therefore,  mutant HTT (mHTT) primarily affects the central 
nervous system (CNS). The translated wild-type huntingtin protein is a 350-
kDa protein containing a polymorphic stretch of between 6 and 35 glutamine 
residues in its N-terminal domain [11]. For the length superior to 35 CAG 
repeat in the htt  gene, the accumulation of polyglutamine in the protein le ads 
to its aggregation in specific areas in the brain such as:  striatum, cortex, 
thalamus, hypothalamus and the substancia nigra pars compacta.  mHTT has a 
toxic gain of function that  causes cell  death vi a very different mechanisms, 
which still  remain unclear . However, it  is known to  result  in transcriptional 
dysregulation as well as mitochondrial dysfunction and energy deficits (for 
review see [1,12]).  The accumulation of the mutant htt  protein progressively 
compromises survival and normal neuronal functioning, primarily in the 
striatum (caudate/putamen).  The mutant htt lead s also to proteosomal 
dysfunction, induction of autophaghy, release of Calcium from intrace llular 
stores and excitotoxicity at  extrasynaptic NMDA receptors.  It  particularly 
affects the GABAergic neurons,  called medium spiny neurons (MSN) situated 
in the striatum, which have axonal projections  to the globus pallidus and 
substantia nigra. They express Dopamine- and cAMP-Regulated neuronal 
PhosphoProtein of 32kDa (DARPP32). The progressive loss of these neurons 
is accompanied by a corresponding ventricular enlargement and gliosis 
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(Figure 2) .  The disease progresses with the degeneration of cortical 
pyramidal neurons, mainly projecting to the caudate/putamen [13]. Many of 
the symptoms of HD result  from the loss of inhibitory connections from the 
striatum to other structures such as the globus pallidus  (Figure 3).  The cause 
of such specific regional and sub -population neuronal loss and the absence of 
cell loss in other t issues remain uncertain . Brain pathological hallmarks  
leading to 25% of brain weight loss in HD develop well  before evident 
symptoms appear.  
 
Figure 2.  Brains' comparison by MRI between healthy and Huntington's 
disease subjects [14]. 
The most visible symptom of HD is the presence of involuntary jerky 
movements named chorea. During the first stage of the disease, the chorea 
dominates and when the disease progress, dystonia,  rigidity and bradykinesia 
are also observed. Cognitive impairments also progressively appear as well as 
emotional disturbances  marked in the most case by anxiety,  memory loss,  
dementia, depression and psychosis [15]. They frequently lead to considerable 
distress and psychologic difficulty for patients , which have more prevalence 
than the general population to commit suicide. The unequivocal presence of 
chorea in a person with a family history or genetic confirmation of risk for 
HD forms the basis for clinical diagnosis. Recently, the Ameri can Academy 
of Neurology published guidelines to evaluate the motor and cognitive 
function, behavioral  symptoms and functional capacity  based on the Unified 
Huntington’s Disease Rating Scale -Total Motor Score [16].  
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Figure 3. Different areas involved in HD explaining symptoms. The cortico-striatal 
system is essential for the execution of movements (left). In patients with HD, progressive 
degeneration of neurons in the striatum, and later also in cerebral cortex, disrupts function 
in the cortico-striato-pallidal circuit and induces severe impairments in both motor and 
cognitive functions. The striatal GABAergic projection neurons provide an inhibitory 
control of two major striatal output structures, globus pallidus and pars reticulata of the 
substantia nigra (not shown). Loss of these neurons, in animals with striatal lesions or in 
HD patients, results in disinhibition of pallidal outflow (right) [17]. 
 
There is  no effective treatment for the progressive neurodegenerative 
process underlying HD, and management includes pharmacological  
symptomatic control  of the movement disorder and psychiatric  features, as 
well as non-pharmacological  treatments, such as parenteral  feeding and 
therapy services [18]. When the physiotherapy is not enough, tetrabenazine is 
the first choice of medication for uncomplicated chorea. Tetrabenazine is 
acting to decrease dopamine levels  and can be helpful to reduce movement 
disorder but presents various side effects like the increase of depression or 
psychiatric disorders. Neuroleptics or benzodiazepines can also be prescribed 
and mood stabilizers such as anti-depressants and anti -anxiety reducing 
psychological dysfunctions  are also proposed [18]. Unfortunately,  many of 
these medications have adverse side effects that can worsen HD symptoms. In 
order to help to define the  best treatment The Unified Huntington’s Disease 
Rating Scale-Total Motor Score classified the level of evidence for drugs to 
reduce chorea based on a review of randomized clinical  trials  [19,20].   
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Nowadays, two approaches are under pre-clinical  evaluation: disease 
modifying treatments, more particularly by reducing polyQ repeats and more 
recently by the suppression of the mRNA of the HTT gene  with interference 
RNA (iRNA) [21]. Another approach consists in recent  tissue engineering 
strategies to replace lost neurons by new ones obtained in vitro  from stem 
cells. These methods need to be further improved and developed in order to 
be validated in the in vivo models of HD [18].  
Most animal models of HD fall  into two broad categorie s, genetic and 
non-genetic. Historically, non-genetic models have dominated the field of HD 
research. Although George Huntington first  described HD in 1872, 
researchers did not identify the actual genetic mutation responsible for the 
disease until 1993, which delayed the development of appropriate genetic 
models until  the last  decade [22].   
The emergence of genetic and molecular technology allow ed the 
development of animal  models expressing a truncated [23] or full  length 
[24,25]  form of mutant htt  (mhtt)  (Table 1) .  Animal models are divided in to 
two genetic categories: transgenic or knock -in.  Transgenic models result from 
the random insertion of mutated human htt. The R6/1 and R6/2 transgenic 
mouse models were the first  characterized [26]  (Table 1).  These mice express 
only mutant exon 1 of the human htt gene with di fferent length repeats. These 
principal models containing only the truncated human mhtt gene are st ill  the 
most used nowadays, together with yeast artificial chromosome's (YAC) 
models [24]. The latter consist  on the cloning of an artificial  yeast  vector that 
contains the entire human mhtt with different expanded CAG repeats (YAC 
46, YAC 72, YAC 128) which are then integrated into the rodent genome [27] 
(Table 1) .  Alternatively,  the knock-in models result by the insert ion in the htt  
mouse genome of the CAG repeats of human mhtt,  which are then within the 
context of the rodent mhtt  gene [28,29] (Table 1) .  In all of these animal 
models the pathophysiology of the disease appears in adult age as for the HD 
patients.  
2. IN VIVO MODELS OF HUNTINGTON’S DISEASE 
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In any case none of these models exactl y reproduce the human 
pathology. Moreover, the existence of various genetic animal models did not 
allow predicting HD symptoms. Indeed, we can believe that the progression is 
correlated with the number of CAG repeat length, but the mechanism of the 
disease seems to be more complicated. Moreover,  it  has been shown that  
therapeutic success in animal models is  not always paralleled by clinical  
success in patients .   
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Animal 
models 
Transgene product CAG 
repeat 
length 
Promoter and transgene 
expression 
Method of cell 
death 
Symptoms Ref 
Truncated N-terminal fragment models 
R6/1 mice 67 amino acids of 
N-terminal fragment 
(human HTT) 
116 1kb human HTT 
promoter. 
Transgene expression ~ 
31%  
Aggregation and 
nuclear inclusion of 
htt 
 Slow progression of 
the symptoms, brain 
atrophy, dystonic 
movements, motor 
performance, grip 
strength and body 
weight loss 
[30] 
R6/2 mice 67 amino acids of 
N-terminal fragment 
(human HTT) 
144 1kb human HTT promoter 
Transgene expression 
~75% 
Aggregation and 
nuclear inclusion of 
htt 
High progression of 
the symptoms, brain 
atrophy, dystonic  
movements, motor 
performance, grip 
strength  
[30] 
Full length HD models: knock-in models 
HdhQ92 
mice 
Full length chimeric 
human HTT exon 1: 
mouse Htt 
92 Endogenous mouse Htt 
promoter  
Transgene expression ~ 
100% 
Nuclear inclusion 
but not cytoplasm 
inclusion, 
aggregation of htt, 
Not communicated  [31] 
HdhQ111 
mice 
Full length chimeric 
human HTT exon 1: 
mouse 
111 Endogenous mouse Htt 
promoter  
Transgene expression ~ 
100% 
Nuclear inclusion 
but not cytoplasmic 
inclusion, 
aggregation of htt 
Not communicated but 
model to study 
juvenile HD 
[31] 
zQ175mice Full length chimeric 
human HTT exon 1: 
mouse 
188 Endogenous mouse Htt 
promoter  
Transgene expression ~ 
100% 
Nuclear inclusion 
aggregation of htt 
Tremor, hypokinesia, 
abnormal gait, poor 
grooming, lost 
coordination, deficit in 
grip strength 
[32] 
Full length HD models: transgenic models 
YAC46 
mice 
Full length human 
HTT 
48 Human HTT promoter 
and regulatory elements 
Tansgene expression 
~40% 
Increased 
intracellular calcium 
concentration  
Any obvious abnormal 
behavior, 
electrophysiological 
abnormalities 
[24] 
YAC72 
mice 
Full length human 
HTT 
72 Human HTT promoter 
and regulatory elements 
Tansgene expression 
~40% 
Very few nuclear 
inclusion, 
aggregation of htt 
Symptoms YAC line 
dependent, tremor, 
ataxia, brain reduction 
[24] 
YAC128 
mice 
Full length human 
HTT 
128 Human HTT promoter 
and regulatory elements 
Tansgene expression 
~100% 
Nuclear inclusion, 
aggregation of htt 
Slow progression of 
the symptoms, brain 
atrophy, hypokinesia,  
[33] 
BACHD 
mice 
Full length human 
HTT 
97 Human HTT promoter 
and regulatory elements 
Tansgene expression 
~100% 
Progressive nuclear 
inclusion, 
aggregation of htt 
Very slow progression 
of the symptoms, brain 
atrophy, dystonic 
movements, not body 
weight loss 
[34] 
Table 1. Most used of genetic model of rodent animals to model HD available nowadays. 
Following early ideas that  lesions of the striatum were responsible for 
HD, non genetic animal models used intrastriatal injections of neurotoxins 
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with glutamatergic targets such as kainic acid (KA) [35], ibotenic acid (IA), 
quinolinic acid (QA) [36] [37] and N-methyl-d-aspartate (NMDA) [38]. 
Indeed, glutamatergic excitotoxicity is involved in the pathophysiology of the 
disease.  These lesions induced death of striatal  medium spiny neurons similar 
to the neuropathology present in HD patients . The symptoms most commonly 
associated with the diseased state induced by the neurotoxins are loss of 
weight, possible tremor or seizures, eventual paralysis, recumbence, and often 
death representing the later stages of the disease. But these mode ls do not 
allow investigation of disease progression or the mechanism of 
neuropathology because the htt  protein does not present the mutation.  In 
addition, genetic and non-genetic models need proper care and animals must 
be daily monitored. Immediately after toxin administration or in later stages 
in genetic models, euthanasia may be necessary for moribund animals. To 
reduce the number of animal experiments ex vivo  models represents an 
excellent compromise between single cell  cultures and animal studies.  
Another way for modelling HD consists in using organotypic brain 
slices, which have been also reported for modelling Parkinson's disease  and 
cerebral ischemia. Brain slices are kept alive during several  weeks in culture 
and represent a simple method to model the neurodegeneration and evaluate 
potential treatments before in vivo  studies.  
Brain slice models offer unique advantages over other in vitro  platforms 
in that  they can replicate many aspects  of the in vivo  context.  Slices preserve 
largely the tissue architecture of the brain regions that they originated from 
and maintain neuronal activities with intact functional local synaptic circuitry 
[39]. Nevertheless, brain slices remain fragile, they can be easily distorted, 
and often flatten during the culture.  In other word, organotypic brain sl ices 
are delicate and frequently become damaged during the preparative stages, so 
brain slice preparation and culture need experience. Functional outcome of a 
therapeutic strategy cannot be evaluated with this technique , but as brain 
slices can be maintained for a few weeks in culture they offer the possibility 
to screen a large quantity of therapeutic strategies.  Pharmacologicals [40], 
3. EX VIVO MODELS OF HUNTINGTON'S DISEASE 
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gene manipulation strategies with the goal to reduce the CAG repeat on HD 
[41] or injection of growth factors or cells can be evaluated for their 
neuroprotective or neurorestorative abil ity of damaged structures (Figure 4).  
Furthermore, organotypic slides represent a powerful tool for understanding 
the interaction between grafted cells and resident cellular matrix, or for 
comprehending the mechanisms of experimental  treatments in HD [42].  
  
 
Figure 4. The use of organotypic slices for the evaluation of innovative 
treatment in HD [43]. 
As in vivo  models,  organotypic brain slices of HD are divided in 2 
categories: genetic and non-genetic models. Genetic models can be derived 
from adult animals already described above, presenting the MSN 
degeneration, or by transfecting the mutated htt within the organotypic 
culture.  However,  these organotypic cultures are difficult  to generate due to 
the diminished neuronal plasticity and the fragility of these brains . Non-
genetic models can be generated from pups or young animals by neurotoxin 
administration directly in the organotypic slice culture.  The first HD 
organotypic model was developed in 1986 by injecting KA in the striatal  
organotypic slices [44]. Over the years, brain slice cultures have been 
successfully established with QA and/o r 3-NPA, and KA after addition in the 
media of striatal organotypic slices to mimic the disease. In order to study 
later stage of onset  disease all  these neurotoxins have been injected in the 
frontal  cortex, hippocampus or caudate nucleus for modeling HD in rat  [45–
47] (Table 2) .  But the use of neurotoxins leads to a heterogeneity in the 
results obtained, which must be taken in consideration. Furthermore,  with that 
type of model,  only the cellular aspect  of HD can be studied, they cannot take 
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into account the genetic component of the  pathology. Advantages are the 
speed and low-cost associated to  this model when normal rodents are used 
[42].  
Neurotoxins  Ex vivo models Cells modification Ref 
Kainic acid (KA) Striatal organotypic 
model 
Enlargement of mitochondria, 
dilation of rough endoplasmic 
reticulum, presence of 
numerous vacuoles, glial 
fibrillary changes 
[44] 
Quinoleic acid (QA) Corticostriatal 
organotypic model 
Excitotoxic damages, presence 
of numerous vacuoles 
[48,49] 
α-Amino-3-hydroxy-
5-methylisoxazole-4-
propionic acid 
hydrate 
 
Corticostriatal 
organotypic model 
Excitotoxic damages, presence 
of numerous vacuoles 
[50] 
3-nitropropionic 
acid (3-NPA) 
Striatal and 
corticostriatal 
organotypic model 
No described but reductions of 
complex II–III Activity, 
mitochondrial function is 
impaired 
[46] 
QA + 3-NPA 
Striatal organotypic 
model 
No described. 
[51,52] 
Table 2.  Non genetic models for modeling Huntington with brain slices. 
During the past years,  many preclinical  studies initially reported the 
efficacy of human fetal striatal tissue to replace and provide functional 
recovery in a variety of rodent and non-human primate models of HD. Some 
teams demonstrated the feasibility and the safety of this therapeutic strategy 
[53–57] and functional improvements were obtained in the study led by 
Bachoud-Lévi.  They reported graft survival, which contained  striatal  
projection neurons and interneurons,  and received host -derived afferents 
[53,54].  But the survival is  sti ll  very poor and the comparisons of these 
clinical trials are very difficult  because of the heterogeneity in their design  
and the lack of controls . Nevertheless, the reported improvements in these 
trials appear to be modest and transient (for review see [58]). Moreover, the 
use of human fetal brain for striatal transplantation derived from elective 
abortions is limited by the lack of standardization inevitably correlated with 
the use of such a source as well as ethical, practical , and regulatory concerns 
and is dependent upon availability of donor tissue [59]. Stem cell -based 
4. EXPERIMENTAL TREATMENT IN HUNTINGTON’S DISEASE 
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therapies can provide a limitless source of cells due to their self -renewal 
capacity and their neuronal differentiation potential,  but good cell  
engraftment remains a drawback.  On this basis, the development of cell 
replacement strategies for regenerative medicine and  more particularly tissue 
engineering has been under light the last decade  for HD.  
4.1 TISSUE ENGINEERING AND REGENERATIVE MEDICINE 
Tissue engineering and regenerative medicine are fields which have a 
unique tactic to solve clinical  problems aforementioned by combini ng the 
principles of engineering, clinical medicine,  biology and materials science 
[60]. Tissue engineering, according to the National Institute of Health (NIH), 
is a broad field which involves “  biomaterials development and refers to the 
practice of combining scaffolds, cells, and biologically active molecules into 
functional t issues”[61] and regenerative medicine as the development of “  
therapies to restore lost,  damaged, or  aging cells and tissues in the human 
body”. Those approaches may include, but is not limited to,  th e use of soluble 
molecules [62], gene therapy, stem cell s transplantation [63],  reprogramming 
of cells. The strategic introduction of these bioactive and soluble molecules,  
as well  as stem cells into the human body is directed not only to replacing 
tissue but also at  inducing regeneration and revascularization by host tissue . 
Various cells can be considered in t issue engineering , stem or modified cells 
to replace lost neurons and somatic cells for t heir neuroprotective properties  
(Figure 4).  Biomaterial scaffolding is often employed to provide a supporting 
spatial  and biomolecular environment for transplanted cells. This approach 
named “top-down” in which cells are seeded onto a scaffold with 
biocompatible and biodegradable propertie s is the most used (Figure 4).  
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Figure 5. Schema of the three pillars of regenerative medicine. To bring 
tissue engineering into reality, it is crucial to sufficiently advance and combine 
the three. Currently, there is increasing recognition of the importance of cell 
culture methods, scaffolds supporting cells and drug delivery of signaling 
molecules. 
Regenerative medicine for brain stem cell therapy has been primarily 
developed with neuronal cell  lines (PC12 cells),  due to their availability and 
ease of expansion,  or with cultured dorsal root ganglion (DRG) neurons and 
fetal NSCs, owing to their natural ability to integrate and differentiate within 
the brain.  
The scaffold can also release bioactive molecules able to act as 
neuroprotectors.  In the case of HD, two neurotrophic factors have been used 
for regenerative medicine:  ci liary neurotrophic factor (CNTF) and brain-
derived neurotrophic factor (BDNF). Clinical  trials were performed using 
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CNTF-producing cells  with stage 1 and 2 HD pat ients [64,65]. During this 
phase 1 study,  subjects received one capsule implanted into the right lateral 
ventricle,  and the capsule was exchanged every 6 months during 2 years.  
While the CNTF-induced sparing of s triatal  neurons and maintenance of 
intrinsic circuitry in animal models was impressive, the effect in human was 
less than that seen in rodents. Finally, human clinical trials did not present 
relevant positive effects, and progressively the supplementation of CNFT in 
human has been given up. To our knowledge, no clinical trial has been 
conducted with BDNF. 
4.2 POTENTIAL THERAPEUTIC USE OF THE NEUROTROPHIC FACTOR BDNF  
Neurotrophic factors a re essential  for the survival of  the central  nervous 
system neurons and demonstration of their reduced availability in HD 
indicates that they may play an important role in this disorder. Indeed, the 
reduction of BDNF in HD contributes to the disease onset and or progression 
[66,67]. BDNF is essential in sustaining the physiological processes of 
normal intact  adult  brain [68]  and more particularly for GABAergic striatal 
neurons (Figure 5) .  Indeed, although widely expressed in the adult  
mammalian central  nervous system, BDNF is particularly abundant in the 
hippocampus and cerebral cortex where it is anterogradely transported to i ts  
striatal  targets via the corticostriatal  afferents [69]. Several evidences 
demonstrate the role of BDNF in the maturation of striatal  neurons and how 
BDNF promotes the survival of DARPP-32 positive neurons [70,71].   
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Figure 6. Role of BDNF in developing, adult, and HD striatum. (A) A 
proposed model showing that BDNF and NT3 anterogradely transported from 
mesencephalic dopaminergic neurons regulate survival of immature neurons in 
the indirect and direct pathways, respectively. Ctx, cerebral cortex; Stm, striatum; 
SN, substantia nigra. (B) Cortical BDNF in the adult striatum mediates dendritic 
complexity and spine number and morphology. (C) Mutant htt reduces BDNF-
TrkB signaling by inhibiting BDNF gene transcription, axonal transport of 
vesicles containing BDNF, retrograde dendritic transport of TrkB-positive 
endosomes to the cell body [72]. 
The supplementation of BDNF in the case of HD has been evaluated  and 
promising results show that BDNF treatment prevent striatal  degeneration in a 
chronic model of HD.[73]. More interestingly,  the supplementation of BDNF 
protein increases the survival  of enkephalin-immunoreactive striatal neurons,  
reduces striatal interneuronal loss and improve s motor function in HD animal 
models [74–76]. Despite these data, the BDNF supplementation raises a 
number of problems such as the stabili ty of BDNF as it cannot cross the 
blood-brain-barrier.  Moreover, an uncontrolled BDNF administration may 
interfere with neuronal plastici ty and even give rise to serious s ide effects 
[77]. One way to avoid this limitation is the encapsulation of BDNF within 
the scaffold necessary for tissue engineering.  
4.3  POTENTIAL THERAPEUTIC USE OF SCAFFOLDS  
To overcome the poor cell surv ival and engraftment usually observed 
after transplantation, several  strategies have been developed and among them, 
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two methods seem particularly promising: in situ  controlled drug delivery and 
implantation of cells adhered on biomaterial -based scaffolds.  Such scaffolds 
should provide an adequate 3D support  for transplanted cells, thereby 
increasing cell survival and even guiding cell differentiation and fate in vivo  
[78,79]. However, delivery of cells with scaffolds to the damaged brain still  
remains challenging due to practical l imitations of delive ry [80]. Ideal  
properties of a scaffold for brain tissue engineering are biocompatibility,  very 
small  size,  controlled biodegradability with non -toxic derivative products, 
and three-dimensional (3D) matrices with appropriate mechanical  p roperties 
to mimic the extracellular matrix [81,82].  
An innovative scaffold for tissue engineering combining the se ideal  
properties with a biomimetic 3D approach and the release of bioactive 
molecules has been developed in our laboratory. This scaffold or 
microcarriers named Pharmacologically activ e microcarriers (PAMs) are 
constituted of a synthetic polymer based on poly(lactic-co-glycolic acid) 
(PLGA) [78]. They are obtained by a non-denaturing solid-in-oil-in-water 
(s/o/w) emulsion evaporation/extraction t echnique. The protein is first  
nanoprecipitated with poloxamer 188 a biocompatible hydrophilic polymer 
that protects the protein against irreversible denaturation [83]. PAMs are 
biodegradable and biocompatible with a mean size of 60 µm, covered by a 
biomimetic surface providing a 3D support  for the cells and delivering a 
therapeutic protein in a prolonged manner . All these combined properties 
stimulate the survival and differentiation of the transported cells [84]. Their 
small  size allows their implantation into the brain through a needle or 
catheter and after the complete degradation of the polymer the cells may 
integrate the parenchyma. These PAMs have been successfully employed for 
different tissue engineering strategies, in neurodegenerative disorders, 
cerebral ischemia, myocardial infarction, and cartilage re pair (Figure 6)  
[85,78,86,83,87] .  For these strategies the appropriate growth factor and 
extracellular matrix protein have been combined to either progenitors or stem 
cells.  In this work we will use stem cells combined with PAMs presenting a 
biomimetic surface of laminin ,  which stimulates neuronal differentiation [88]  
and delivering BDNF as a therapeutic strategy for HD.  
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Figure 7. Concept of PAMs: the biomimetic surface of PAMs is obtained by 
coating their surface with extracellular matrix proteins that can favor cell 
adhesion. During their formulation, the encapsulation of neurotrophic factor is 
performed. 
4.4 . POTENTIAL THERAPEUTIC USE OF STEM CELLS  
During the last decade, several preclinical experiments have used cell  
replacement strategies in order to restore MSN using HD animal models.  
Different human stem cell sources are being actively explored for potential  
cell replacement therapy including  embryonic stem cells (ESCs),  induced 
pluripotent or neural stem cells (iPSC or NSC), fetal  and adult neural 
precursors and mesenchymal stem cells (MSCs). Both ESC, iPSC have been 
successfully committed into MSN in vitro and then grafted into rodent models  
of HD [37,89,90].  But after human ESC transplantation into rat  brains , tumor 
formation has been reported, which was not the case for iPSC -MSN-derived 
cells,  which were further committed with in this lineage. In addition, the 
ethical issues related to the use of ESCs and the lack of availability of fetal  
neural precursors drive us to focus in other cell  sources.  To find the best way 
to obtain the most important benefits with less ethical  and pr actical  
constraints,  mesenchymal stem cells have been investigated.   
Human MSCs, as Friedenstein reported,  are capable of differentiating 
into cells deriving from the mesodermal  layer, such as osteoblasts,  
chondrocytes and adipocytes.  Along with their self -renewal property,  MSCs 
secrete tissue repair factors, such as growth factors,  which affect the 
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surrounding microenvironment to promote angiogenesis, decrease 
inflammation, and enhance tissue repair  [91]. In this way, MSCs are being 
widely evaluated in many clinical  trials for cell  therapy  showing the 
feasibility of this approach. Recent advances in s tem cell biology hold great  
promise in the development of MSCs-based therapy for tissue engineering . It  
was also demonstrated that  these cells could differentiate to  an ectodermal  
neural/neuronal phenotype, particularly under the influence of specific fact ors 
[85] [79,92] enabling their use for cell therapy for neurodegenerative disease 
including HD. The principal limitation is that  MSCs are a heterogeneous 
population with cells presenting different differentiation properties.  To  avoid 
these limitations a homogenous subpopulation of MSCs, named “Marrow-
Isolated Adult  Multilineage Inducible” (MIAMI),  which present an unique 
genetic profile expressing several pluripotency markers (Oct4, Sox2, Nanog, 
SSEA4) and secrete many varied cytokines (Figure 7) are interesting for the 
treatment of neurodegenerative disorders [93,94].   
 
 
Figure 8. Soluble factors secreted by MIAMI cells involved in the tissue 
repair. [93,94] 
They are able to generate cells derived from all three embryonic germ 
layers and cultured on fibronectin;  they are capable of differentiating into 
neuron-like cells under treatment with various factors. After  treatment, the 
cells show neurites,  express neuronal factors and present some 
electrophysiological  characteristics similar to those observed in mature 
neurons [95].  Recently, in a rat model of Parkinson's disease (PD), striatal  
implantation of MIAMI cells pre -committed towards the dopaminergic 
phenotype adhered to microsphere releasing bio active molecules  improved 
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stem cell survival and showed dopaminergic differentiation. This led to the 
protection/repair of the nigro -striatal pathway and to functional recovery of 
the PD rats.  Furthermore, implantation of pre -treated MIAMI cells also 
induced functional recovery in PD rats,  probably due to the release of glial  
cell line derived neurotrophic factor (GDNF) [88]. But MIAMI cells ' abil ity 
to differentiate into  neurons,  although better than the  simple MSC needs to be 
improved. 
4.5 POTENTIAL THERAPEUTIC OF SMALL INTERFERING RNAS FOR MSC 
DIFFERENTIATION 
The conventional methods of generating neurons from MSC s, through 
bolus supplementation of small molecules or neurotrophic factors (growth 
factors: GF), still  lack in efficiency in neural conversion and lineage 
selection. One possible reason may be the inadequacy of GFs to  control  gene 
expression. Cell differentiation may be achieved by RNA interference (RNAi) 
strategies and more particularly by small interfering RNA (siRNA), which 
selectively knock-down the expression of only a few pivotal  genes.  Indeed,  
siRNAs are synthetic duplex of 21–23 nucleotides,  approximately 7.5  nm long 
and 2 nm in diameter , which are capable of specifically target ing one gene 
and silencing it  in a post-transcriptional way. SiRNA are  rapidly taken up 
into an enzyme complex, RNA induced silencing complex (RISC), that  
degrades the mRNA through guidance to a specific target  mRNA resulting in 
specific gene si lencing. At RISC one siRNA strand is t aken into the effector 
complex, the catalytic subunit Argonaute2, and then serves as a template,  
guiding the hydrolysis of complementary or near complementary mRNA 
sequences [96]. Initially siRNA emerged as a potential therapeutic treatment 
for cancer. Although current applications in stem cells remain largely 
restricted to studies on molecular pathways and s ignalling, RNAi can be used 
as a biomedical  strategy to direct  li neage-specific differentiation of stem cells 
for therapeutic purposes [97]. One key factor that can possibly be adapted 
into the siRNA strategy for directing neuronal differentiation of neural stem 
cells,  is  the repressor element 1 (RE-1) silencing transcription factor (REST) 
[98]. In most differentiated non-neuronal cells and uncommitted neural stem 
cells,  REST functions as a transcriptional repressor fo r a myriad of neuronal 
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specific genes such as ion channels, synaptic vesicles proteins,  and 
neurotransmitter receptors by binding to a highly conserved DNA sequence 
known as RE-1. During neurogenesis, REST is rapidly down regulated in 
embryonic stem cells (ESCs) and neural  stem cells upon differentiation into 
neurons [99]  (Figure 8) .   
 
Figure 9. REST expression during the neurogenesis [100]. 
Conversely,  induced down regulation of REST has been shown to 
promote neuronal commitment in mouse ESC and mouse MSCs. Specifically,  
the knockdown of REST in ESCs induced neural progenitors formation [101] 
(Figure 8) and when applied to MSCs, cross -lineage differentiation to 
neurons was observed [102,103]. Although the knockdown of REST holds 
great potential , its  therapeutic applications  in neuronal differentiation is  
hindered by poor cellular uptake of siRNA molecules and their rapid 
enzymatic degradation [104]. siRNAs' molecular weight (∼13 kDa) and strong 
anionic charge due to the presence of aphospho-diester backbone (∼40 
negative phosphate charges),  make them incapable of freely crossing the cell  
membrane. The electrostatic repulsion from the anionic cell  membrane 
surface results in the failure of siRNA to passively diffuse through the cell 
membrane (Figure 9). Moreover, the synthetic siRNA molecules show low 
stability in physiological fluids, poor tissue/cell specificity,  and rapid 
clearance [105]. Therefore, successful siRNA therapeutics requires effective 
and safe carrier systems to overcome the inherent limitations  of siRNA and 
achieve maximum gene silencing effect . In the last decade, two different 
approaches for siRNA delivery have been developed: viral and non -viral  
vectors. In particular, the advantages of non -viral vectors are their low 
immunogenicity,  their relatively low production cost  and reproducibility 
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potentially.  These reasons make them promising carriers  for siRNA delivery 
[106].  
 
Figure 10. The benefits and limitations of synthetic siRNA application. The 
representation of the limitations involved in the siRNA delivery. [107] 
5.1 DIFFERENT TYPES OF NANOCARRIERS 
Nanocarriers (NCs), including nanoparticles and nanocapsules were first  
developed for the potential  delivery of therapeutic factors such as 
5. NANOCARRIERS 
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chemotherapeutic agents to tumors or,  when combined to stem cells,  mostly 
for stem cell  imaging [108].  First ,  the use of nanocarriers  aims to protect  an 
active ingredient against  a potential  degradation , and secondly to modify the 
natural  distribution  of the active substance in the body and in cells.  It  is  
theoretically possible to accumulate the active ingredient  to the desired si te 
of action and away from undesirable sites to limit  side effects.  NCs ranging 
from 1 to 1000 nanometer sizes are divided into 2 main categories:  
-  Organic NCs which include liposomes, lipid nanoparticles,  solid 
nanoparticles and dendrimers .  
-  Inorganic NCs with quantum dots, carbon nanotubes, iro n or gold 
nanoparticles [109] .   
The organic NCs and more particularly lipid based NCs are interesting to 
transfect  cells because lipid based nanoparticles can contain lipids present in 
the biological membranes which help the entry of nanoparticles. Cationic 
charges contained in some lipids are able to int eract  with nucleic acid.  In 
addition, the risk of undesirable immunogenic reactions to lipids is  also 
relatively lower than most of the polymeric materials which generally have 
higher molecular weights  [110]. Furthermore, some clinical trials have been 
conducted with siRNA and lipids based nanoparticles [111,112]. To our 
knowledge, clinical  trials with nanoparticles and MSCs have not been 
performed in HD. When compared with l iposomes, l ipid -based nanoparticles 
such as solid lipid nanoparticles generally have solid,  lipophilic core regions 
so it is  inherently difficult to truly encapsulate the hydrophilic, poly -anionic 
RNA molecules.  As a result , there are relatively few lipid nanoparticles for 
RNA delivery [113,114].  
5.2 LIPID NANOCAPSULES 
Lipid nanocapsules (LNC) are nanocarriers  developed and recently 
patented. These nanocapsules  are constituted by oily core of tryglicerides and 
a shell made of surfactants particularly polyethylene glycol hydroxystearate .  
They are obtained by a phase inversion temperature dependent process. This 
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solvent-free process  requires little  energy and allows easy large-scale 
transposition [115].  
The formulation is based on a simple process,  named emulsion's  phase 
inversion, developed and patented  in 2002. This is  realized by oil  in water 
emulsion (O / W) using the various consti tuents  described above.  This 
emulsion is subjected to an increase of temperature  which induces a change in 
the hydrophilic /  lipophilic  balance.  Several  temperature cycles (between 50 
and 90°C) are produced and the addition of cool water final stablizes and 
solidifies LNCs. 
Previous studies demonstrated the possibility to encapsulate plasmid  
DNA within the LNCs to develop a gene therapy strategy [116]. For this, the 
DNA is complexed with cationic lipids  by electrostatic interactions  leading to 
formation of complexes  called lipoplexes  which are added to  other 
components of the LNC. Moreover, the phase inversion temperature  was 
reduced to avoid degradation of the  plasmid [116].  This strategy has 
demonstrated the capacity of LNCs to transfect in the in vivo  models of 
gliobastoma [117–119].  
5.3 SOLID SPAN NANOPARTICLES 
Solid span nanoparticles have been recently developed and patented 
[120]. These nanocarriers are based on sorbitan esters,  which are components 
widely used in the pharmaceutical industry due to its non -ionic surfactant 
properties at low concentrations .  These nanoparticles can be prepared using a 
simple,  one-step and easily scalable procedure  
(https://www.youtube.com/watch?v=fda9CtJ5zF0 ) and they can associate 
different components and/or bioactive molecules . The internal structure of 
this nanocarrier is  not an aqueous inner space surrounded by a lipid  bilayer  
nor i t  is based on nanoemulsions,  but rather it  is  a homogenous 
nanoparticulate solid structure.  It is also possible to incorporate various 
additional components.  These addit ional components allow to modulate the  
nanosystem features conferring a great  versatility in terms of physical -
chemical characteristics and interaction with other components, and facilitate 
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the incorporation of active ingredients : hydrophilic and l ipophilic nature  
[121].  
Solid span nanoparticles  (SP) based on sorbitan monooleate (Span® 80) 
have been specifical ly adapted to provide effective DNA association [122].  
They have the capacity to provide higher in vivo  t ransfection levels than 
adeno-associated viral vectors (AAV2). Indeed, it  has been recently patented 
their use in gene transfer or gene deliv ery and described an in vivo  proof of 
concept in a disease animal model showing the safety and clinical  efficacy of 
a gene therapy approach based on these nanocarriers  [123].  
The evaluation of a regenerative medicine  strategy may be easily 
performed in a simple ex vivo model before pre-clinical  study in vivo .  
Although, the transplantation of MSCs showed promising results the 
differentiation state needs to be improved. In order to ameliorate this point, 
the homogenous more pluripotent population  of MIAMI cells seem to be a 
good option. Although MIAMI cells can be committed into neural/neuronal 
precursors their maturation sti ll  needs to be safely improved. Consequently,  
the transfection of siREST with nanoparticles seems to be a safe way to help 
induce a neuronal differentiation process. However, in order to control  the 
behaviour of the cells after transplantation and enhance/maintain their 
differentiation their combination to PAMs delivering BDNF seems 
appropriate.  Furthermore, the delivered BDNF may also induce the 
neuroprotection of the damaged tissue. In consequence, this study aims to 
develop an innovative and safe regenerative medicine strategy combining 
siREST nanoparticle-engineered MSCs, combined to PAMs with a laminin 
biomimetic surface and delivering BDNF for HD (Figure 10).  
 
The principal objectives of this study are:  
-  The development of a simple ex vivo  HD model to evaluate a tissue 
engineering strategy.  
6. OBJECTIVES OF THIS THESIS 
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-  The development, the understanding and the optimisation of two 
nanocarriers (LNC and SP) transporting a siRNA (siREST).  
-  The evaluation of their efficacy to deliver this siRNA into MSCs and 
the selection of the best nanocarrier for this application.  
-  The evaluation of the capacity of si-REST to induce a neuronal 
commitment and i ts capacity to improve the differentiation of MIAMI 
cells  
-  The evaluation of the neuroprotective effect of modified MIAMI cells 
combined with PAMs coated with laminin and  delivering BDNF 
-  The evaluation of the regenerative capacity of these complexes 
(MIAMI/LM-PAM-BDNF) and their engraftment in the ex vivo  HD 
model  
Nanocarriers formulation : siREST-
LNC; siREST-SP-AP
Differentiation in neuronal 
progenitors
Complexation with PAMs Injection in brain slices
2 dimension 3 dimension
SP LNC
Transfection
Improved survival
Drive differentiation
Neuroprotection
Decrease rejection
BDNF
Encapsulation
 
Figure 11. The tissue engineering strategy envisaged in this work. 
This manuscript reports a bibliographic work with a review (submitted 
for publication) and results obtained during this study organized into 3 
chapters.   
The first chapter is enti tled "MODELIZATION OF HUNTINGTON 
DISEASE". The goal was to develop an innovative and simple model of HD 
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without the addition of neurotoxins into the media and to model the 
neurodegeneration of medium spiny neurons  (Publication n°1).   
Then the second chapter "INNONATIVE STRATEGY TO MODIFY 
STEM CELLS FOR TISSUE ENGINEERING" shows by the development, the 
characterization and the optimisation of two nanocarriers capable of 
transfecting mesenchymal stem cells and the evaluation of the effect of the 
siRNA against  REST (named siREST)  (Publication n°2).   
Finally,  the third chapter named "P HARMACOLOGICALLY ACTIVE 
MICROCARRIERS AS INNOVATIVE STRATEGY FOR COMMITED MIAMI 
CELLS" describes different protocols used for the differentiation and th e 
interaction between committed MIAMI with siREST and PAMs and a 
preliminary evaluation of their engraftment  (Publication n°3).  
A general discussion comparing the existing strategies will  close these 
studies and open new prospects.  
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With the aim to propose an innovative cell -based regenerative medicine 
strategy for the neurodegenerative disorder HD, stem cells or neuronal 
progenitors derived from these  cells can be considered. The progress in cell 
engineering by reprogramming/programming cells to  obtain induced pluripotent 
stem cells or induced neuron cells have revolutionized this field. It is however 
crucial  to better monitor their proliferation, improve their survival and 
differentiation and hence ameliorate their engraftment after transplantat ion.  
To direct  stem cell fate,  a delicate control of gene expression through RNA 
interference (RNAi) is  emerging as a safe epigenetic approach.  RNAi allows 
selecting specific knock-down the expression of mRNAs by degrading them. 
This epigenetic modification is quite simple,  does not need genetic 
manipulation, is transitory and is now quite well understood. Nonetheless, 
nucleic acids need to be  vectorized to be protected and to be able to cross  
biological membranes.  Thus, the RNAi used for gene suppression strategies in 
many cell  models  are conventionally mixed with cationic lipids .  Their toxicity 
limits their use and thus many nanocarriers have been designed to carry RNA 
inside cells.  
A bibliographic research work has been undertaken here to identify new 
tissue engineering strategies currently under evaluation for HD. The first part  of 
this study is focused on the possible source of cell for tissue engineering, 
presenting thei r advantages and disadvantages.  A detailed review of the 
different formulations available for RNAi transport within stem cells, their 
mode of action and some examples of their use  to control cell behavior follow. 
In the last part, innovative tissue engineering strategies using stem cells, 
biomaterials and epigenetic cell regulation are r eported and discussed.  
This work is submitted for publication in Biomaterials  
Revisions demanded
REVIEW 
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The potential treatments for neurodegenerative disorders will be 
revolutionized by the transplantation of stem cells or neuronal progenitors 
derived from these cells. It is however crucia l to better monitor their 
proliferation, improve their survival and differentiation and hence ameliorate 
their engraftment after transplantation. To direct stem cell fate, a delicate 
control of gene expression through RNA interference (RNAi) is  emerging as  a 
safe epigenetic approach. The development of novel biomaterials (nano and 
microcarriers) capable of delivering proteins, nucleic acids and cells,  open  the 
possibility to regulate cell  fate while achieving neuroprotection and neurorepair. 
This review first provides an overview of stem cell therapy for the 
neurodegenerative disorder Huntington ’s disease .  Within that  context, an 
integrative discussion follows of the control of stem cell  behaviour by RNAi 
delivered by different nanocarriers in vitro prior to  their transplantation. 
Finally,  combined in vivo strategies using stem cells,  biomaterials and 
epigenetic cell  regulation are reported.  
Stem cells;  nanoparticles; microcarriers; t issue engineering; RNAi  
HD, Huntington’s disease;  MSN ,  medium spiny neurons;  ESCs, embryonic 
stem cells; iPS, induced pluripotent stem cells;  NSC, neural stem cells; 
MSC, mesenchymal  stem cells;  RNAi, interference RNA; siRNA, short  
interfering RNA; miRNA, micro-RNA; NPs, nanoparticles;  REST, repressor 
element-1 silencing transcription factor ;  PLGA, polylactide-co-glycolide; 
BDNF, brain-derived neurotrophic factor;  ECM, extracellular matrix. 
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1.1 HUNTINGTON’S DISEASE 
Huntington’s disease (HD) is an inherited autosomal dominant 
neurodegenerative disorder with a general prevalence of about 10 per 100,000 
births [1–3].  HD appears in middle life leading to death 15 -20 years later and 
involves the triad signs and symptoms: involuntary movement disorders called 
Huntington’s chorea,  cognitive impairment and ps ychiatric manifestations.  This 
disorder is characterized by an unstable repetition of triplet  cytosine -adenine-
guanine (CAG) of the Huntingtin gene, translated at the protein level by the 
polyglutamine expansion at the NH2 -terminal part  of the protein hunt ingtin 
(HTT)[4]. The gene is considered as normal when it contains less than 27 CAG 
repeats and generally more than 40 repeats defines the adult -onset HD, with 
people developing the disease at  30-40 years of age. However,  people with 36 -
39 CAG repeats are at  a risk of developing all the HD symptoms [5]. 
Conversely,  a larger number of repeats is usually associated with an earlier 
onset of signs and symptoms [6]. Aggregation of the mutated htt results in 
transcriptional dysregulation as well  as mitochondrial  dysfunction and energy 
deficits  (for review see [1,7]). The accumulation of the mutant htt  protein is 
excitotoxic,  therefore it  progressive ly compromises survival and normal 
neuronal functioning, primarily in the striatum (caudate/putamen). It 
particularly affects the GABAergic neurons,  called medium spiny neurons 
(MSN), which have axonal projections to the globus pallidus and substantia  
nigra. They express Dopamine- and cAMP-Regulated neuronal PhosphoProtein 
of 32kDa (DARPP32). The progressive loss of these neurons is accompanied by 
a corresponding ventricular enlargement and gliosis.  The disease progresses 
with the degeneration of cortical p yramidal neurons, mainly projecting to the 
caudate/putamen [8].   
Currently,  no treatment can prevent the disease or stop the progression of 
HD. Recently,  the American Academy of Neurology published guidelin es for the 
pharmacological symptomatic treatment of HD [9]. It classifies the level of 
1. INTRODUCTION 
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evidence for drugs to reduce chorea based on a review of randomized clinical 
trials using the Unified Huntington’s Disease Rating Scale -Total Motor Score 
(UHDRS-TMS) to choose the best treatment. Tetrabenazine, acting to decrease 
dopamine levels, is the most prescribed treatment but in some cases,  
antipsychotics can help to reduce chore a. Anti-depressants and anxiolytics can 
be prescribed to reduce psychological dysfunctions.  Unfortunately,  many of 
these medications have adverse side effects that can worsen HD symptoms.  
During the past  years,  many preclinical studies initially reported t he 
efficacy of human fetal striatal  tissue to provide functional recovery in a variety 
of rodent and non-human primate models of striatal neuronal loss. On this basis, 
some clinical trials then assessed the potential  of fetal  neural  transplants for the 
treatment of HD. In this review, we will  briefly outline the emergence of fetal  
neural therapy replacement and i ts l imitations.  We will continue by describing 
the pre-clinical  studies performed with different stem cells,  which represent an 
alternative cell source, and we will comment on their limitations, the most 
important one being their limited engraftment. We will  further provide an 
integrative description and discussion of nanoparticles transporting interference 
RNA therapeupic (RNAi) to initiate cell dif ferentiation and increase survival in 
order to avoid some of the limitations described above. Finally,  in order to 
improve their engraftment within the brain parenchyma, increase 
neuroprotection and neuro-repair, we will present combining approaches with 
cell modified with RNAi therapeutics nanoparticles and drug delivery devices.  
1.2 CELL TRANSPLANTATION 
To replace the degenerating neurons in HD patients, some teams explored 
the transplantation of fetal  human brain tissue. They demonstrated the 
feasibility and the safety of this technique [10–14]. Functional improvements 
were obtained in the study led by Bachoud-Lévi.  They reported graft survival,  
which contained striatal projection neurons and interneurons, and receive d host-
derived afferents [10,11]. Comparisons of these clinical trials are very difficult 
because of the heterogeneity in their design, lack of controls,  unblended nature, 
and different methods  used to assess clinical and motor outcome in each. 
Nevertheless, the reported improvements in these trials appear to be modest and 
transient (for review see [15]).  Indeed, limitation of cell  therapies resulted from 
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the extent of damage affecting HD patients.  Moreover,  the use of human fetal 
brain for striatal transplantation derived from elective abortions is limited by 
ethical, practical , and regulatory concerns and is dependent upon availabili ty of 
donor t issue [16]. Besides the limited supply of human fresh fetal t issue, the 
strategy of striatal  transplantation is further complicated by the lack of 
standardization inevitably correlated with the use of such a source.  
One of the challenges is to ident ify an alternative cell  source able to 
differentiate into MSN such as pluripotent stem cells (PSC), which are currently 
under investigation, including embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSC). Adult neural  stem cells (NSCs) and  mesenchymal 
stem cells (MSCs) are also alternative candidates for regenerative medicine  
(Figure 1).   
1.3 PLURIPOTENT STEM CELLS FOR CELLULAR THERAPY  
PSC are defined by their capacity of self -renewal thus offering the 
possibility of an unlimited supply of cel ls and by their pluripotency that is their 
abili ty to differentiate into all three germ layers. In vitro  differentiation of 
pluripotent stem cells into GABAergic MSNs generally follows a multi -step 
process: i) induction of neural lineages; i i) regional pat terning and the 
differentiation of neural progenitor cells; and iii) specialization of a mature 
neuronal subtype. GABAergic MSNs can be generated using several culture 
methods, including co-culture on feeder cells and suspension culture as 
embryoid bodies.  Additionally,  in vitro  differentiation of pluripotent stem cells 
into MSNs requires cytokine signalling, controlled timing, duration, and 
concentration of exposure to developmental factors and reliable markers to 
identify mature MSNs capable to acquire el ectrophysiology properties.  
1.3.1 Embryonic stem cells 
Human ESCs (hESCs) derive from the inner cell mass of blastocyst stage 
embryos created by in vitro  fertilization. Aubry et  al .,  were the first ones to 
describe the differentiation of hESC into MSNs [17]. The authors proposed a 
novel 3 step-protocol to obtain striatal progenitors using 2 major proteins 
involved in the striatum ontogenesis: Sonic Hedgehog (SHH) and Dickkopf -
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related protein 1 (DKK1). The caudate/putamen or striatum derives principally 
from the lateral ganglionic eminence (LGE) [18],  with DLX2-positive cells 
differentiating into MSNs, the most important population in the striatum. The 
injection into an adult rat model of HD (quinolinate -lesioned adult rats) of an 
early striatal differentiation stage of these hESCs presented massively over -
proliferating neural progenitor cells. However,  later stage striatal progenitors 
engrafted into the quinolinate -lesioned striatum and proved the feasibili ty of 
this cellular therapy [17].  The optimal time and dosage of SHH pathways in 
these cells was further determined as well as a major improvement to obtain the 
optimal commitment stage of  the cells for transplantation [19]. When these 
LGE-like ESC-derived cells were induced to terminal GABAergic differentiation 
in vitro ,  the majority of cells expressed GABA (90%) and DARPP32 (81%) and 
presented appropriate neuronal characteristics as determined by HPLC and 
whole-cell  patch-clamp. In addition, there was no sign of massive overgrowth or 
tumor formation up to 16 weeks after transplantation. The graft -derived GABA-
ergic projection neurons were integrated into the host ne ural  circuitry,  receiving 
dopaminergic inputs from the midbrain and glutamatergic inputs from the cortex 
while projecting fibres to the substantia nigra [20].However, ESC research is 
laden with ethical  concerns, particularly regarding the ideas of personhoo d and 
justice toward humankind that arise from dealing with human life in one of its  
earliest  forms, the embryo. It is  a controversial international issue, and many 
governing bodies have either banned the research altogether or placed 
restrictions on what may be done with embryos and ESCs, limiting their use for 
cell therapy.   
1.3.2 Induced pluripotent stem cells 
Initially,  iPSCs are human somatic cells that are reprogrammed with four 
retroviral -incorporated specific transcription factors to a pluripotent stem -like 
state.  IPSCs gained immediate international attention for their apparent 
similarity to embryonic stem cells after their successful creation in 2006 by the 
group of Yamanaka and in 2007 by Thomson and collaborators [21,22]. Since, 
many methods have been reported to obta in these cells including high 
reprogramming efficiency, introducing non-viral  and non-integrating methods of 
cell reprogramming, and using novel gene editing techniques for generating 
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genetically corrected lines from patient -derived iPSCs, or for generating 
mutations in control  cell  lines [23,24]. Moreover,  striatal neurons derived from 
iPSCs obtained from HD patient s, provide an in vitro  disease model of HD. 
IPSC grafts avoid the ethical issues intrinsic to hESC work whilst also allowing 
autografts to be performed (for review see [25]). This latter strategy is 
intuitively more attractive,  but does bring with it  concerns, particularly in the 
case of HD patients,  that  the disease being treated may develop in the grafted 
tissue given it  is derived from the patient themselves.  iPSCs may appear to 
solve the controversy over the destruction of embryos in ESC research, by 
involving only the genetic reprogramming of somatic cells.  However, further 
analysis of this approach and its subsequent technical and ethical issues such as 
low reprogramming efficacy, genetic instability,  oncogeni c potential, 
conservation of the somatic cell’s epigenetic origin, reprogramming process 
creating totipotent stem cells, could potentially lessen some advantages iPSCs 
seemingly hold over ESC [26].  
Concerning the use of iPSCs in vitro  for striatal differentiation, the most 
recent protocol coupled neural induction via Bone Morphogenic Protein (BMP) 
and Transforming growth factor beta  (TGF-β), and ventral telencephalic 
specification with exposure to the developmental factors SHH and DKK -1, 
followed by terminal GABAergic differentiation. They obtained a neuronal 
population monitored by the appearance of progenitors of the LGE and able to 
mature into GABA- and DARPP-32-positive cells mimicking the striatum 
ontogenesis in 80 days. These cells presented electrophysiological  properties 
expected for fully functional MSNs. The authors did not explore the iPSC 
transplantation but studied the outcome of hESC transplantation with their 
protocol [27]. Results indicated cell survival and extensive axonal projections, 
suggesting integration of the donor cells into the neuronal network of the host 
brain with the reduction of motor asymmetry.  
For both ESCs and iPSCs, a bonafide  differentiation protocol, relies on the 
identification of region and stage specific marker gene determinants of brain 
development. From a practical  standpoint, the general  aim is to recapitulate in 
vitro  the human foetal development up to the specific and committed neuron 
precursors of the desired region. The transplanted cell population for HD will 
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most probably consist of committed LGE progenitors as it  has been shown that 
the highest proportion of s triatal-like cells in humans is obtained from grafts 
comprising the LGE expressing DLX2 under SHH pathways. Further challenges 
consist in defining the proportion of specific phenotypes that  will give the best 
therapeutic outcome after transplantation, and whether it  will  consist  or not of a 
population of pure MSN progenitors [28].   
 
Figure 1. The origin, isolation, & specialization of stem cell to produce neurons in vitro. The 
induction of neuronal commitment can be realized by external and internal factors. Recently the 
combinations of both methods obtain best results.  
 
1.4 ADULT STEM CELLS 
1.4.1 Neural stem cells 
An alternative source of cell transplantation in HD would be neural stem 
cells (NSCs) that  participate i n normal central  nervous system (CNS) 
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development and differentiate into regionally appropriate cell types in response 
to environmental factors [29]. In this way, previous studies have shown that 
NSCs isolated from fetal  or adult  mammalian CNS can be propagated in vitro 
[30] and subsequently intracerebrally implanted i n animal models of human 
neurological disorders including HD [31,32]. In the latter case, some cells 
differentiated in vivo into DARPP32+ neurons replacing neurons primarily 
targeted in this disorder [31]. Also, genetically modified NSCs producing 
neurotrophic factors have been used to protect striatal neurons against 
excitotoxic insults [33]. NSCs derived from human brain exhibited ext ensive 
migration in the rat brain [34,35]  and adult rats receiving intrastriatal 
transplantation of human NSCs prior to striatal damage induced by 3 -NP toxin 
exhibited significantly improved motor performan ce and increased resistance to 
striatal  neuron damage compared with control sham injections [36]. The 
neuroprotection provided by the proactive transplantation of human NSCs in the 
rat  model of HD appears to be mediated by brain -derived neurotrophic factor 
(BDNF) secreted by the transplanted human NSCs. Many studies have also 
demonstrated that BDNF could block neuronal injury under pathological 
conditions in animal models of HD [37,38]. Recently,  human striatal NSCs were 
treated with a hedgehog agonist to generate DARPP -32 cells and transplanted in 
R6/2 HD transgenic mouse brain. The results were disappointing as the outcome 
was the same as a vehicle control injection. This is the only study using human 
NSCs for cell therapy in a HD genetic animal model [39].  
1.4.2 Mesenchymal stem cells 
Since the discovery by Friedenstein, of colony forming unit fibroblast cells 
(CFU-F) [40], MSCs never ceased to amaze by the many advantages they have 
in terms of regenerative medicine. The mechanisms through which MSCs exert  
their therapeutic potential  in tissue repair, although not fully defined, might rely 
on some fundamental key properties of these cel ls: i) their abili ty to secrete 
soluble factors capable to stimulate survival and functional recovery of injured 
cells; ii) the ability to home to sites of damage; iii) the ability to modulate 
immune responses and iv) their easy accessibility and potential  for autologous 
transplantation. Although these cells differentiate to mesodermal l ineage 
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(chondrocytes, adipocytes, osteoblasts) differentiation of MSCs toward non -
mesodermal cells has also been reported (for review see [41]).   
 MSCs may be expanded in vitro with varying degrees of additional 
differentiation towards neuronal l ineages [41,42] enabling their use for cell 
therapy for neurodegenerative disease including HD. MSCs are a heterogeneous 
population with cells presenting different differentiation properties and capable 
of expressing specific embryonic markers.  A homogenous subpopulation of 
MSCs, named “Marrow -Isolated Adult Multilineage Inducible” (MIAMI ),  which 
express several  pluripotency markers (Oct4, Sox2, Nanog, SSEA4) are able to 
generate cells derived from all three embryonic germ layers [43]. They are 
capable of different iating into neuronal-like cells with electrophysiological 
properties of immature neurons under the influence of a sequential addition of 
specific growth factors and respond to dopaminergic inducers acquiring this 
neuronal phenotype [44,45].  Moreover,  they also show some degree of in vivo  
neuronal differentiation and they can secrete high amounts of tissue repair 
factors, some of which are involved in the protection/induction of blood vessels 
ex vivo [46]. Recently,  adult human somatic cells, such as MSCs and dermal 
fibroblasts were shown to contain a small number of se vere stress-tolerant 
pluripotent stem cells, named ‘‘multilineage differentiating stress enduring’’ 
(Muse) cells [47]. These cells expressing pluripotency markers such as Nanog, 
Oct3/4, and Sox, can be isolated from MSCs or from fibroblasts after severe 
stress as stage-specific embryonic antigen-3-positive cells (a marker for human 
ES cells). Most importantly,  they possess specific properties like self -renewal, 
and pluripotency as they are able to generate cells representative of all three 
germ layers from a single cell.  One limitation to the use of Muse cells is l inked 
to their low yield (with the range between 1% –  5%), but their stress-resistance 
makes of them an interesting cell  therapy candidate [47].  
 These cells are implanted either non-differentiated or after a pre-
differentiation stage, as p recursors, relying on the host environment to drive 
selective functional differentiation for cell replacement. However, the lack of 
consistent neuronal differentiation of transplanted MSCs has limited their 
therapeutic efficacy in animal models of HD (Table 1). In vitro and  ex vivo 
characterizations of MSCs have revealed the presence/secretion of many growth 
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repair factors, including BDNF, Glial  cell -derived neurotrophic factor (GDNF), 
vascular endothelial growth factor  (VEGF) and nerve growth factor (NGF) [48–
50]. Researchers have recently explored the secretome of MSCs, with the aim of 
identifying all secreted molecules, which, in turn, m ay provide insight into the 
mechanisms of MSC benefits (for review see [51]). Indeed, intra striatal 
transplanted MSCs integrated in the host  brain and exerted neurotrophic effects 
that  correlated with increased levels of laminin, von Willebrand factor (VWF), 
stromal cell -derived factor-1 (SDF-1) α, and its receptor in the damage d 
striatum [52]. Moreover, after MSCs transplantation into the QA model of HD, 
rats presented a significant improvement in apomorphine -induced rotation tests, 
which correlated with a reduced lesion volume and a lower number of apoptotic 
striatal cells compared to control animals [53]. In the R6/2 mouse HD model 
MSCs transplanted mice showed improved motor functions compared to 
untreated R6/2 controls, although the overall performance continued to decline.  
Interestingly,  mice,  which received MSCs transplantation, displayed a 
significant longer survival time than untreated R6/2 mice [54,55]. The 
improvement may be imputed to BDNF secreted by MSCs into the striatum. 
Moreover,  the secretion of BDNF has been associated with recruitment of 
forebrain neural  progenitors [56][57] .  MSCs pre-differentiated towards a 
neuronal phenotype, in order to better engraft  within the brain parenchyma, may 
also be able to release the required repair factors involved in neuroprotection. 
One study showed that the specification of MIAMI cells towards a neural/early 
neuronal phenotype still  enabled the secretion of neurotrophic factors by these 
cells [45], but the appropriate degree of commitment before transplantation 
needs to be investigated.  
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Table 1. Human mesenchymal stem cells based treatment of Huntington’s disease in 
preclinical animal’s model. 
 
1.4.3 Induced neuron cells  
It  has recently been shown that mouse dermal fibroblasts can be directly 
programmed to functional neurons by forced expression of a set  of neural  
lineage transcript ional factors, named induced Neurons cells (iNs) (for review 
see [61]). The authors initially tested a pool of 19 transcription factors from 
which three (Ascl1,  Brn2 and Myt1l, abbreviated hereafter as BAM factors) 
were found sufficient to generate functional neuronal phenotype from 
fibroblasts [62]. Several different groups, after reprogramming fibroblast from 
Transplanted cells Animal 
models 
Mechanism Functional outcome References 
Adipose MSC Rat, QA Increase CREB, PGC1alpha , 
reduced apoptosis 
Slowed striatal 
Degeneration and decreased 
lesion volume 
[55] 
Bone marrow 
MSC 
Mice, 
QA 
SDF1 and VWF secretion,  
reduced apoptosis 
Improved survival 
Decrease lesion volume 
Improved rotared 
performance 
[58] 
Bone marrow 
MSC 
R6/2-
mice 
SDF1 secretion,Von Willebrand factor 
(VWF) secretion, 
 reduced apoptosis 
Improved survival [58] 
Bone marrow 
MSC 
Rat, QA Expressed BDNF, NGF, GDNF, CNTF Decreased lesion volume 
Improved rotared 
performance 
[59] 
Adipose MSC R6/2-
mice 
Reduction HTT aggregates 
Increase PGC1alpha, Akt/cAMP 
expression 
Improved rotared 
performance 
Improve striatal volume 
[55] 
Adipose MSC YAC 
128 mice 
Increased BDNF, HGF, IGF, LIF, and 
VEGF expressions 
Improved rotared 
performance 
Motor function 
Improved striatal volume 
[54] 
Bone marrow 
MSC producing 
BDNF 
YAC 
128 mice 
Both BDNF-modified and non-
modified MSCs had significant effects 
in reducing the behavioral defects in an 
HD mouse model. 
Improved rotared 
performance 
Reduced hindlimb clasping 
[60] 
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mouse, reported the generation of human iN cells (hiNs) [63–65]. None of the 
groups were successful in producing functionally mature hiN cells using the 
same three transcription factors (BAM) that worked in mouse cells [65].  A 
major limitation of direct conversion to a te rminally differentiated mature cell 
type is the inabil ity to expand the programmed cells in sufficient quantity for 
various applications [66].  Therefore,  direct  conversion to expandable neural 
stem/progenitor cells (NSCs) is desirable in practical applications that  demand 
large amount of cells.  
As described, cells may be “manipulated” to control their proliferation, to 
improve their survival and differentiation and therefore ameliorate their 
engraftment after transplantation. This can be achieved by a previous in vitro 
genetic or epigenetic manipulation of the transplanted cells or by co -
transplanting them with transcriptiona l and/or trophic factors that can be 
delivered by vectors and biomaterials.  The latter being moreover able to provide 
a 3D template of extracellular matrix (ECM) contributing to shape the cells into 
a functional tissue and increase their engraftment [17,45,19,27] .  The real  
challenge consists in controll ing stem cell survival and differentiation by 
monitoring intracellular levels of relevant biomolecules while replacing 
lesioned tissues with these cells.  Moreover,  if  possible,  they should maintain 
their neuroprotective effects,  when  present.  Typically,  cell programming 
(differentiation within the same lineage) or cell reprogramming (reversal to 
pluripotency) consists in overexpression or knocked -down expression of genes 
involved in stem cell  differentiation or transdifferentiation (p assage to a 
different lineage) in a specified manner. The control  of gene expression may be 
achieved by RNAi, by selectively knocking down the expression of only a few 
pivotal  genes.  This epigenetic modification is quite simple,  does not need 
genetic manipulation, is transitory and is now quite well understood.  
RNAi were first used in 2003 to promote differentiation to the myogenic 
lineage from pluripotent P19 teratocarcinoma [67]. Differentiation to the 
neuronal lineage is one of the most popular areas in cell  therapy due to the poor 
regenerative potential of the nervous system. In fact, a large number of studies 
2. EPIGENETIC MANIPULATION 
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have been dedicated to identifying potential knockdown targets to facilitate 
neurogenesis in ESCs, NSCs and MSCs. For example, the use of a lentiviral -
mediated RNAi vector that  down-regulates the expression of REST (repressor 
element-1 silencing transcription factor) was shown to promote MSC 
differentiation into neuronal cells [68]. The unrestricted potential of RNAi  has 
encouraged strategies for large scale si lencing of protein encoding genes in the 
human genome. RNAi can be triggered by three different pathways: 1) a RNA -
based approach where the effectors siRNAs are delivered to target cells as 
preformed 21 base duplexes;  or 2) a DNA-based strategy in which the siRNA 
effectors are produced by intracellular processing of longer RNA hairpin 
transcripts;  3) a RNA-based approach, similar to siRNAs, produced 
endogenously by the cells, the pre-miRNAs stem-loops which are then spliced to 
release the mature miRNA duplex (Figure 2).  
 
Figure 2. Inspired from Cullen, nature genetics 2005, we represent the intracellular trafficking 
of siRNA delivery systems [69]. Internalization of delivery systems can be performed by several 
mechanisms as clathrin, caveole pathways or lipid rafts. Two modalities are observed in this 
phenomenon, a receptor mediated endocytosis and a non-receptor mediated endocytosis. RNAi is 
delivered into the cytoplasm and produces its inhibitor effect. 
In vitro,  RNAi does not readily bind to or cross the cell membrane, so 
RNAi must be introduced in cells by innovate delivery systems. In the case of 
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RNAi, the siRNA or miRNA must be delivered to the RNA -induced silencing 
complex (RISC) in the cytoplasm (Figure 2).  The most common delivery system 
relies on recombinant virus, but although very effective, viral methods for RNAi 
delivery have been associated with immunogenicity and tumorigenicity [70]. 
Non-viral delivery systems are traditionally less effective but can be designed to 
avoid issues typical  of viruses. They have considerable advantages over viral -
based vectors due to the control of their molecular composition, their simplified 
manufacturing, modification and analysis, and their tolerance for cargo sizes, 
while displaying a relatively low immunogenicity [71]. Non-viral gene delivery 
utilizes chemical reagents including lipids, cationic polymers and nanoparticles 
or physical  means such as electroporation. More interestingly,  some 
nanocarriers can secure the control of cellular behaviour. Indeed, materials with 
unique nanotopographical characteristics and size offer properties producing 
similar effects than growth factors [72].  They can be used to induce specific 
biological responses. However, before RNAi reaches its target in vitro  and  in 
vivo  when co-transplanted with delivery vectors ,  it  faces a number of significant 
barriers.  More importantly,  cellular and local delivery strategies have to deal 
with the need for internalization, release,  and distribution in the proper 
subcellular compartment (Figure 2).  Many early efforts at RNAi delivery used 
materials that  were already well  studied for DNA delivery and can be 
applicable, with some limitations,  to the RNAi delivery. Development of 
different strategies to encapsulate and deliver RNAi has been described in 
literature [73] (Figure. 3) .  We will first discuss the properties of these 
nanocarriers, which make them suitable for nucleic acid delivery in general and 
then describe their utility for overcoming barriers spe cific to RNAi delivery and 
their use in stem cells for controlling neuronal differentiation or survival .  
 
[Attirez l’attention du lecteur avec une citation du document ou utilisez cet espace pour 
mettre en valeur un point clé. Pour placer cette zone de texte n’importe où sur la page, faites-la 
simplement glisser.] 
INTRODUCTION 
43 
 
 
Figure 3. Methods of RNAi complexation with delivery systems. The RNAi localization into 
nanocarriers differs according to structure and organization of the delivery system. RNAi can be 
incorporated into a matrix structure and allow a global repartition in the entire volume of the 
sphere (cluster), with polymers components. Other strategies consist in either associating by 
electrostatic or Van der Walls interactions the RNAi on the surface of delivery systems. The 
chemical cross-link is also a possibility. Last organization concerns shell/core structure observed 
for liposomes and some nanoparticles. [74]. 
 
2.1 NANOCARRIERS TO CONTROL STEM CELL FATE 
The use of nanocarriers, also named nanoparticles (NPs) ranging in size 
from 1nm to 1000nm to cont rol stem cell  fate after intracellular incorporation is 
a novel approach. NPs were first  developed for the potential  delivery of 
therapeutic factors such as chemotherapeutic agents to tumours or, when 
combined to stem cells, mostly for stem cell imaging [71] . The nanocarriers 
most commonly used in stem cell research are organic (liposomes, l ipid 
nanoparticles , solid nanoparticles and dendrimers) and inorganic nanocarriers 
(quantum dots,  carbon nanotubes, iron or gold nanoparticles) (Figure 4) .  These 
last  materials with unique characteristics such as carbon nanotubes,  gold 
nanoparticles, and gold nanorods have attracted attention as innovative carriers 
for RNAi (for review see [75]) but have not yet  been used for cell  programming 
in vitro  combined with RNAi. However,  inorganic nanoparticles seem to possess 
certain properties stimulating neuronal differentiation. Iron oxide nanoparticles 
incorporated within rat PC12 cells induced extensive changes in genes related to 
the cytoskeleton, signalling molecules, receptors for growth hormones and ion 
channels, all required and expected to occur during neuronal differentiation 
[76]. One explanation for the effect  on gene expression is that several  inorganic 
particles, including iron oxide nanoparticles, have the potential to release 
inorganic ions. In the case of manganese,  the ions play an important role in 
neuronal differentiation by activating cell adhesion molecules, which interact 
Chemical cross-link 
or absorption 
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with the extracellular matrix and direct  cell binding and signalling. Neuronal 
differentiation is known to be influenced by the amount and subcellular 
distribution of integrin clusters,  i .e.  cell  adhesion [77]. However, the 
mechanism by which metal ions affect  gene expression is still  unclear.  
The encapsulation of hydrophilic drugs such as nucleic acids and also 
proteins has been developed from different formulations. A large variety of 
synthetic materials or polymers, such as polylactide -co-glycolide (PLGA), poly-
caprolactone, and natural materials, such as chitosan, collagen, pullulan, and 
poly-arginine can be used to formulate nanopart icles for medical applications.   
 
Figure 4. Different types of nanocarriers able to control the stem cell fate. Nanoparticles are 
commonly defined as objects with a rank of dimensions of 1-1000nm, which includes micelles, 
reversed micelles, nanoparticles, nanogels, and nanofibers. We represent here the morphology of 
the most commonly particles used ones for siRNA complexation and regenerative medicine. 
 
2.2 LIPID-BASED NANOCARRIERS  
Lipid-based nanocarriers are the most widely used biomaterials for 
nanoparticulate RNAi delivery. Of over 20 siRNA phase I clinical trials, nearly 
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half use NPs as the delivery vehicle, and almost all  of these are lipid -based 
[78]. Although lipid-based nanoparticles have been historically designed for 
lipophilic drug delivery, the idea of using cationic l ipids with their positive 
charged head group to efficiently bind negatively cha rged RNAi became rapidly 
evident.  
2.2.1 Liposomes  
Transfection typically involves the use of packaging particles called 
liposomes to facilitate the cellular uptake of RNAi. Cationic l ipids in the 
liposomes mimic the physical characteristics of natural phospholi pids that 
represent the individual components of a cellular membrane. Liposomes possess 
long hydrophobic chains and a positively charged head group, allowing the 
formation of nano-sized complexes with negatively charged RNAi (lipoplexes) 
that  is  encapsulated by a lipid bilayer.  Since first  being used for gene therapy in 
1990, numerous commercial cationic lipids (also called cytofectins, lipofection, 
oligofection reagents) have been synthesized and used for delivery in cell  
culture [79]. Lipoplexes offer protection to RNAi from enzymatic degradation 
and efficient endocytosis of RNAi by the cell.  Lipid complexation with the 
payload (i.e.  RNAi) simply involves mixing and incubation [71]. Neutral lipids 
such as dioleylphosphatidylethanolamine (DOPE) and cholesterol  are usually 
incorporated in the liposomal formulations, where they serve as helper lipids:  
increasing the transfection efficiency of the gene or molecule -containing 
liposome by facil itating membrane fusion and aid in the destabil i zation of the 
plasma membrane [80]. Liposomes can escape from the endosome through a so 
called ‘proton sponge’ effect  where positively charged cationic l ipids cause 
influx of protons and water leading to endosome swelling and eventually 
disruption to release the lipoplexes to cytoplasm. Safe and e fficacious delivery 
in vivo  is however rarely achieved due to toxicity,  nonspecific uptake, and 
unwanted immune response.  
 Very few studies however transfect human iPS or ESC cells with RNAi to 
drive neuronal differentiation because limited transfection ef ficiencies have 
been reported in this type of cells and transitional action reported with these 
materials is not sufficient on their own to have an effect .  Indeed, in vitro 
transfection efficiency is affected by the type of cell,  proliferative activity of 
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the cell,  the type of culture media and cell  plating density.  It  appears that 
lipoplexe transfection performed well in human MSCs [81,82], but produced 
more inferior outcomes in NSCs [83] and ESCs [84,85].  These results suggest  
that conventional lipoplexe transfection is an efficient RNAi delivery means for 
human MSCs but not for human ESCs. In order to determine guidelines to 
transfect  human ESCs while inducing their differentiation, two groups have 
attempted to knock down Oct4, a pluripotent stem cell gene, in ESCs with 
transfection efficiencies of only ∼60% [84] and 69.8% [85] compared to Lin28, 
another pluripotent marker. This low efficiency for Oct -4 suggests that the type 
of target  molecule will  also affect  the transfection outcome. Interestingly,  the 
transfection efficiencies and the resulting silencing efficiencies were not strictly 
proportional to each other;  with a more efficient Oct4 knock down being 
obtained by the less effective transfection. This is probably attributed to auto -
regulation mechanisms of the levels of Oct4, which were moreover quickly 
restored after 1 day, indicating the need for additional boosters to further 
increase the si lencing efficiency to >90%.  
 Cationic lipids were the first non -viral vectors demonstrating their 
capacity to easily transfect  mouse embryonic stem cells in vitro  with 
microRNAs (miRNA) in order to induce neuronal commitment [86]. In order to 
determine the role of miRNA-125b mimic in human MSC during in vitro  
neuronal differentiation, the cells were transfected or lentiviral infected with 
miRNA-125b resulting in the increased percentage of TH -positive neurons.  With 
the two methods used, similar results were obtained confirming its role in 
dopaminergic differentiation. The miRNA -181* also increases the number of 
TH-positive neurons, intriguingly,  just one of the strands allows this 
differentiation [87].  Furthermore, the role between miRNA 9 and REST to 
promote neuronal commitment was determined. A mutual down -regulation 
between REST and miRNA-9 was observed, which  may contribute to the 
maintenance of a neuronal differentiation program [88]. More interestingly,  
MSCs after liposomal transfection with miRNA -124 and miRNA-145, are able to 
deliver exogenous miRNAs to human NSC in co -culture with astrocytes via 
exosomes. Moreover, the delivered miRNAs altered gene expression in th e 
recipient neural cells and impacted their phenotype and function. The delivered 
miRNA124 increased the expression of the glutamate transporters,  
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EAAT1/EAAT2 in NSC and astrocytes and down-regulated Sox9 expression 
which increased the expression of β3-tubulin, a marker of neuronal precursors 
[89]. Similar results were obtained with MSCs transfected with pre -miRNA-124. 
MSCs can therefore be easily transfected with exogenous miRNA to further 
induce neuroprotection or the differentiation of neuronal progenitors after 
transplantation.  
 The transfection efficiency with these delivery vehicles in vitro  is, in 
part, determined by their stability and particle size. For example, serum proteins 
can decrease transfection efficiency by neutralization of the positive zeta 
potential [90] of the complexes. Toxicity may, in part, result  from the large size 
of the complexes,  and the high positive zeta potential  required for their uptake 
[91]. The toxicity is  normally closely associated with the charge ratio between 
the cationic lipid species and the nucleic acids,  as wel l as the dose of lipoplexes 
administered. So although cationic lipid formulations have been used to deliver 
RNAi in vitro  and in vivo ,  cell toxicity caused by cationic lipid is  stil l  a major 
concern. To bypass problematic toxicity, particle instability and  to maximize 
siRNA delivery, fragments of liposomes or lipoplexes can be encapsulated into 
nanoparticles.  
2.2.2 Lipid based nanoparticles 
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) 
consisting of spherical solid lipid particles in t he nanometer range are an 
interesting alternative to l iposomal toxicity. They are comparatively stable 
colloidal  carrier systems in which melted lipids are dispersed in an aqueous 
surfactant by high-pressure homogenization, solvent injection, solvent 
emulsification or micro-emulsification [92]. The lipids which are used in their 
production are solid at  room temperature,  and most of them have an approved 
status, e.g. GRAS (Generally Recognized As Safe), due to their low toxicity 
[93]. Although cationic lipids are an inherent part  of SLN formulations,  it  is 
unclear to which extent their presence bears relevance to the mechanism by 
which SLNs deliver their cargo. Whether their p olymorphic properties play a 
role in destabilizing cellular membranes,  as discussed above for cationic lipid -
based nanocarriers, remains to be determined. In vitro ,  the comparison of cell 
time retention of siRNA between SLN, lipofectamine®  and liposomes showed 
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that the siRNA is present during five to nine days for SLN and three days for 
commercial  reagents or liposomal formulations.  This property is quite 
interesting for maintaining a differentiated cellular state over time for cell 
therapy applications. However, the percentage of siRNA loading is quite low 
around 35% and stil l  needs to be improved [94]. Nanostructured lipid carriers 
possess the advantage of offering increas ed hydrophilic drug loading and 
decreased drug leakage from the NPs.  
Lipid nanocapsules (LNCs) came into the spotlight as a strategy to 
overcome positively charged lipoplexe toxicity encapsulated within the carriers, 
while enhancing cell uptake and protec ting the nucleic acid from lysosome 
degradation. Our research group has reported innovative LNCs, consisting of a 
lipid liquid core of triglycerides and a rigid shell of lecithin and polyethylene - 
glycol. The simple solvent -free formulation process based on the phase 
inversion of an emulsion makes them an ideal  nanocarrier for translational 
studies.  They are highly stable (more than 3 months) [74]  in comparison to 
SLNs [95] and, in function of their composition and size, can escape the endo -
lysosomal compartment [96].  These LNCs can mediate highly efficient gene 
transfer not only in vitro  but also in vivo [97,98].  They were recently modified 
to encapsulate siRNA, complexed with DOTAP/DOPE lipids forming lipoplexes 
(Fig.  3),  and showed efficient encapsulation and protein inhibition in a glioma 
cell-l ine [98]. Interestingly,  the cellular uptake mechanism with siRNA -LNCs 
seems to be membrane fusion. The study of this mechanism by Fluorescence 
confocal spectral imaging demonstrated the degradation of this nanocarrier and 
the release of siRNA in the cytoplasm explained beside by the presence of 
DOPE lipids in the formulation [99]. LNC-siRNA transfection for neuronal 
commitment and resulting protein inhibition capacity is currently being 
evaluated in MSCs.  
Recently,  our research group has reported a novel lipid nanocarrier based 
on sorbitan monooleate, more commonly known by the commercial  name of 
Span 80 (SP80); a surfactant widely used in the pharmaceutical industry and 
generally recognized as safe (GRAS). However,  instead of using span as a 
surfactant, this component was used as a lipophilic m ain ingredient of these 
nanosystems which have demonstrated different component loading capacit ies 
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(Sanchez et al. ,  WO2013068625A1) [100]. This new system can incorporate 
cationic components such as oleylamine or poly-arginine to complex RNAi by 
electrostatic interaction at the surface (Fig. 3). The capacity to load a variety of 
polymers into the shell offers an adaptable system for all  the types of cells and 
the possible incorporation of na tural  polymers can reduce the cytotoxicity.  
2.3 POLYMER BASED NANOCARRIERS 
Polymer based nanocarriers are a very promising class of biomaterials for 
the delivery of nucleic acids and are an active subject of ongoing research. 
Because many of the polymers used for RNAi delivery were originally 
investigated as DNA delivery materials,  generalities about DNA delivery can be 
extended to RNAi delivery. Polymers used for RNAi delivery can be divided 
into two categories:  (i)  those with synthetic components, such as den drimers, 
polyethylenimines (PEI), etc (ii) those with biodegradable natural components,  
such as collagen and pullulan. We will briefly describe most synthetic polymers 
used for RNAi delivery for stem cell  neuronal differentiation and then we will 
present novel nanoparticles with natural  polymers.  
2.3.1 Synthetic components 
PEIs, presented in branched or linear forms, available in a broad range of 
molecular weights are widely used for gene delivery. In the physiological 
medium, PEI is positively charged due to pro tonation of the amine groups and 
thus can be used to condense nucleic acids.  [101].  Cationic polyplexes, formed 
by PEI and nucleic acids, typically retain a net posit ive charge promoting 
interactions with negatively charged polysaccharides on the cell  surface 
followed by endocytosis .  The polyplexe escape from the endosome by the same 
‘proton sponge’ effect described for cationic l iposomes. PEI is known to 
mediate highly efficient gene transfer,  but also exhibits significant toxicity 
during the transfection process [102]. Therefore, many studies have reduced the 
cytotoxicity caused by PEI-mediated delivery by conjugating PEI to synthetic or 
natural  polymers, such as hyaluronic acid [103]. In this way, several studies 
have shown that PEI-modified polymers can be used to deliver genes to regulate 
stem cell differentiation usually with DNA but also in combination with siRNA 
[104]. In this regard, combined transfection of a Sox 9-bearing plasmid and 
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Cbfa-1 siRNA complexed with PEI–PLGA nanoparticles were found to enhance 
hMSC chondrogenic differentiation [105]. To our knowledge, no neuronal stem 
cell differentiation study has yet  been performed with these polymers.  
Nevertheless, the inhibition of ROCK (with PEG–PEI/siROCK2) increased the 
neuroprotection against an external agent of primary cortical neurons [106]. 
Despite these advances in PEI-based gene delivery, it  remains a challenge to 
balance the transfection efficiency and cytotoxicity of PEI -based delivery 
systems.  
Dendrimers have attracted a great deal of interest in different areas 
including nucleic acid delivery applications for cell  differentiation due to their 
uniform, well-defined, three dimensional structures [107]. The name 
"dendrimer" originated from the greek words which describe a structure 
consisting of a central core molecule that  acts as a root, from which a number of 
highly branched, tree-like arms originate in a well -ordered and symmetrical 
manner [107]. The commercial dendrimers named PAMAM transfection reagents 
(Superfect and Polyfect) are mainly indicated for plasmid DNA and RNAi 
transfection. Amine-terminated PAMAM dendrimers  develop highly positive 
charged densities at their surfaces when they are at physiological pH or 
dissolved in water.  However, double stranded RNA including siRNA and 
miRNA are less flexible than pDNA, which can lead to the incomplete 
encapsulation or the formation of undesirably large complexes. Highly branched 
dendrimers have thus been developed for siRNA efficient delivery [108,109]. 
Different strategies have been further developed to reduce the toxicity of 
dendrimers, such as the neutralization o f the surface charge with PEG, the 
attachment of peptides at the surface [110], or the association with natural 
components such as collagen [111]. PAMAM, with a reported abili ty to trigger a 
proton sponge endosomal escape, showed  an efficient delivery of RNAi in 
neurons in vitro  and in vivo (intracranial injection in rabbits) with very low 
toxicity levels [112]. Interestingly,  the silencing of high mobility group box -1 
(HMGB1, a novel cytokine-like molecule) in primary cortical cultures 
successfully reduced both basal  and H 2O2- or NMDA-induced neuronal cell 
death [113]. A similar approach could be tested with neur onal committed stem 
cells to increase their survival after transplantation in HD paradigm.   
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Nowadays, the combination between siRNA and morphogens are effective 
for stem cell  differentiation. Shah et al.  (2013) developed cyclodextrin-modified 
dendritic polyamine construct  (termed DexAM) for effective stem cell 
differentiation [114]. DexAM present  the ability to s imultaneously deliver 
nucleic acids (siRNA against Sox9) and hydrophobic small molecules (Retinoic 
acid) to achieve a synergistic enhancement in stem cell differentiation. When rat 
NSCs were transfected with siSox9 using these nanoparticles,  they 
differentiated into neurons,  wherein more than 70% expressing the neuronal 
precursor marker B3-tubulin [114].  
2.3.2  Natural components: 
Recently,  siRNA-grafted natural polymers have been proposed as a 
promising strategy for siRNA delivery.  They can be divided into two main 
categories: (i) polymers obtained strict ly from natural  sources,  (ii)  and semi -
synthetic polymers obtained  from natural  sources but which are rationally 
modified with the aim of adapting their properties according to the delivery 
requirements of the therapeutic molecules.  
Chitosan has been widely described in the formulation with RNAi because 
of its  cationic nature,  low toxicity,  biocompatibility,  and degradability in the 
human body and has been designated as safe (GRAS) by the FDA [115].  This 
linear polysaccharide of randomly distributed N-acetylglucosamine and 
glucosamine units is  protonated in slightly acidic conditions,  which permits an 
efficient complexation of nucleic acids into NPs. Recently,  a commercial DNA 
transfection reagent based on a chitosan oligomer has been developed 
(Novafect, Novamatrix). Regarding siRNA delivery, various studies describe the 
importance of chitosan characteristics to achieve good efficiency in vitro,  
including the degree of deacetylation and molecular weight (MW) of the 
chitosan, charge ratio of amine (chitos an) to phosphate (RNA), serum 
concentration, pH and cell  type [116]. However, this system has a significant 
limitation, owing to its low transfection efficiency [117].   
Spermine had been recently shown to enhance transfection when grafted in  
the anionically modified pullulan exhibit ing excellent blood compatibility and 
in vitro  t ransfection. More interestingly a complexation to pullulan–spermine 
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achieved successful  in vitro neuronal gene delivery irrespective of the 
negatively charged complexes with no measurable cytotoxicity at up to 20 g/ml 
DNA [118]. Actually,  the tendency to improve transfection efficiency and 
reduce the cytotoxicity is mixing naturals components with lipids, or inorganic 
components to obtain hybrid systems [119]. 
Although many efforts have been made to drive cells into specific lineages,  
maturity and functionality remains a problem for regenerative medicine.  Most 
probably, two dimensions (2D) culture do not authorize a complete and 
functional differentiation. Number of publications reporting benefits  on three 
dimensions (3D) culture is  increasing, and 3D supports have been demonstrated 
as improving cell survival after grafting. Micro - and nano-scale chemical and 
physical cues from the ECM environment control and direct various key cell  
behaviours including their adhesion, proliferation, migration and differentiation.  
Strategies to achieve brain protection in HD, repair and recovery include 
the delivery of neuroprotective compounds to prevent cellular degeneration, cell 
transplantation to replace lost  cells,  approaches using tissue engineering, and 
methods to enhance plasticity by promoting the intrinsic capacity of the brain to 
regenerate and reorganize. The latter strategy still  has poor control of cellular 
growth processes, differentiation and migration to the appropriate location in 
vivo .  Cell-based therapies have encountered poor cell survival and integration in 
the host. Moreover,  it  is necessary to recapitulate the sophisticated and precise 
architecture and functional wiring present in the cellular and molecular 
environment of the brain.  Therefore,  combined in vivo  strategies using stem 
cells,  biomaterials, growth factors and epigenetic control of gene expression 
with different vectors are nowadays being investigated (Figure. 5).  
3.1 CELL AND TROPHIC FACTOR RELEASING MICROCARRIERS 
Transplanted s tem and progenitor cells can promote the survival of host  
cells by releasing neuroprotective trophic factors. In addition, many studies 
have demonstrated the preclinical  feasibility of encapsulation as a means of 
3. COMBINED STRATEGIES FOR CELL TRANSPLANTATION 
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delivering factors to the CNS, and more par ticularly,  genetically engineered 
cells secreting trophic factors for HD [120]. In general , these studies 
demonstrate that encapsulated cells can be protected and remain viable for 
extended periods of time to produce significant neuroprotective and behavioral 
benefits . Clinical trials have been conducted on evaluating the benefits of 
encapsulated cells deliver ing ciliary neurotrophic factor for HD [121]. In this 
case, the implanted cells were safely tolerated without serious adverse events, 
justifying further clinical evaluation. However, the relatively modest cell 
survival and the heterogeneity of the results in these studies need to be 
improved.  
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Figure 5. Schematic illustrating technologies to spatially control stem cell fate. During 
microcarriers’ process, nanocarriers containing RNAi or neurotrophic factors can be integrated 
directly into these biomaterials. All possibilties for combined strategies for stem cells 
transplantation have been presented. The first consideration for microcarriers tailoring in brain is 
size: microcarriers should necessarily be small enough to be easily implanted into the striatum, 
either via stereotactic implantation or under neuro-navigation. Moreover, small-sized scaffolds 
render repeated implantations possible, with no need for open-surgery [122]. 
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Another way to deliver a growth factor is after enc apsulation within 
polymeric microcarriers that in their turn may transport cells on their surface 
(for review [123]). In this sense, our group has developed the pharmacologically 
active microcarriers  (PAMs) combining these two approaches. These PAMs are 
biodegradable and biocompatible PLGA microspheres conveying cells on their 
biomimetic surface,  therefore providing an adequate 3D microenvironment in 
vivo .  Moreover, the controlled delivery of a trophi c factor in combination with a 
biomimetic surface acts synergistically to st imulate the survival and/or 
differentiation of the grafted cells toward a specific phenotype, therefore 
enhancing their engraftment after their complete degradation [124]. Finally,  it  
should be noted that the delivered molecule might also affect the host 
microenvironment allowing the integration of the grafted cells and/or 
stimulating the lesioned brain repair capacities.  The efficacy of PAMs for cell 
therapy of Parkison's disease in a clinical paradi gm was demonstrated using 
GDNF-releasing PAMs, conveying a small number of embryonic ventral 
mesencephalon dopaminergic cells [44].  Similarly,  PAMs with a biomimetic 
laminin surface delivering Neurotrophin factor -3 and conveying adult stem cells 
showed a neuroprotective and repair effect leadin g to an ameliorated behavior in 
an animal model of Parkinson's disease [125]. This technology can be adapted 
for HD, delivering stem cells and neurotrophic factors able to drive GABAergic 
commitment such as BDNF. However, as described, external factors (media and 
growth factors) are insufficient to significantly control  stem cell fate on their 
own; the ideal strategy relies on their combination with the modification of gene 
expression by RNAi (Fig.  5) .  
Another study demonstrated enhancement of neuronal differentiation of 
NPCs by nanofibrous carriers -mediated release of BDNF and retinoic acid (RA). 
In that study, nanofibrous were constructed with the copolymers of -
caprolactone and ethyl ethylene phosphate.  BDNF and RA were then 
encapsulated in the carrier. Neuronal differentiation of NSCs was enhanced due 
to the synergistic effects of nanofibrous topography and sustained delivery of 
BDNF and RA [126]. These cell -loaded capsules can be implanted into the 
damaged brain area favoring the local , targeted and long-term release of drugs 
or proteins.  
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3.2 RNAI LOADED NANOCARRIERS AND MICROCARRIERS FOR REGENERATIVE MEDICINE 
Conventional approaches using cationic polymers or l ipids usually only 
permit  transient gene expression in stem cells af ter transfection [127]. To 
overcome the limitation of gene delivery using only cationic substances, porous 
3D carriers made of biodegradable polymers,  such as sponges,  particles,  o r 
hydrogels, can be employed as gene carriers and depots for prolonged gene 
delivery. Immobilization or incorporation of gene (DNA, RNA) complexes with 
cationic polymers or lipids in the carriers may facilitate sustained delivery to 
stem cells cultured on the scaffolds,  leading to prolonged transgene expression 
in the stem cells and extended control of stem cell  differentiation [128].  
MSCs osteogenic differentiation was enhanced by decorated nanostructured 
scaffold, composed by poly-ε-caprolactone capable of retaining and delivering 
siRNA, with broad applications for controlling stem cell differentiation in vitro  
and in vivo .  [129].  Recently,  a simple and efficient siRNA delivery system 
based on nanotopography-mediated reverse transfection was developed. The 
authors deposited a self -assembled si lica nanoparticle monolayer on a glass 
cover slip and then coated extracellular matrix proteins and siRNA on top of the 
nanoparticle monolayer [128]. This platform allowed highly efficient 
transfection of Sox9 siRNA into rat NSCs due to nanotopographical  cues for 
stimulating endocytosis and intracellular gene transfer,  which enhanced 
neuronal differentiation of NSCs while inhibit ing glial differe ntiation [128]. 
Low et al. (2010) used nanofibrous carriers -mediated siRNA delivery to enhance 
neuronal differentiation of stem cells.  By using a mussel - inspired coating with 
strong adhesive properties, siRNA complexed with cationic transfection reagent 
(Lipofectamine RNAimax) was immobilized on the electrospun PCL nanofibrous  
scaffolds. Application of this system resulted in significant enhancement of 
neuronal differentiation of mouse neural  progenitor cells due to the synergistic 
effects of 3D nanofibrous topographical cues and carriers -mediated knockdown 
of the REST [130].  
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In the treatment of HD, so far there is  a limited success rate in modifying 
disease symptoms by tradit ional pharmacological agents. Nowadays advances in 
drug delivery and cell/ tissue engineering open the possibilities to achieve, 
beyond symptomatic relief in HD, neuroprotection and neurorepair. RNAi 
engineered nanotherapeutics has emerged during these years as an innovate 
strategy to control stem cell  fate in vitro  and in vivo .  Nano and microcarriers for 
nucleotide delivery offer numerous benefits over  lipoplexe transfection, 
electroporation and lentiviral  transduction. Nano and microcarriers based 
delivery of cells, growth factors and RNAi may be among the best means for 
controlling the differentiation and survival of the delivered cells while 
stimulating neuroprotection and repair.  
This project  is supported by the Education Audiovisual and cultural 
excetutive agency of the European Union throught the NanoFar Erasmus Mundus 
join Doctoral program and financed by the Angers Loire Métropol e.    
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 In vitro  cell culture models are of particular importance in Neuroscience 
Research. While single cell cultures are widely used, the organotypic brain slice 
culture model is  the closest to an in vivo  situation. Indeed, brain slices contain 
all  the cells present in the brain and maintain its  three dimensional architecture 
[39]. Brain sl ice cultures allow maintaining the survival of all cell types, the 
functionality of synapses and neuronal properties. In other words, the basic 
cellular and connective organization of the donor brain regions are well 
preserved, thus the s lice cultures provide an easily accessible platform to study: 
neurodegeneration, mechanisms of disease (Alzheimer,  Parkinson's disease, 
Huntington's disease),  and test  different treatments such as pharmacological  
treatments,  cells  replacement or tissue eng ineering treatments [42,124].  
 The first description of organotypic brain slices have been described for 
the culture of dorsal cerebellum in 1970 [125,126].  Then the culture of brain 
slice model was perfectly developed in 1982 using spinal cord -dorsal  root 
ganglia [127]. The characterization and the improvement of this unique ex vivo  
model was realized by Gähwiler and Hefti  (1984) with roller tube cultures  
[128].The technique was modified as  a permanent culture model on membrane 
inserts [129,130] and is nowadays used by several research groups [131–133].  
Slices can be cultured as single slices from a respective brain area or as a co-
culture where two functional related brain sl ices are connected. Since then ex 
vivo  models of Parkinson's disease, Alzheimer, cerebral ischemia, HD have been 
developed (For a review see [42]) 
 In the case of HD, organotypic model development dates back to 1986 
with the study of the effects of KA administration on glial  cells , both in the 
animal model of HD (which uses this drug to damage GABAergic neurons) and 
in striatal  organotypic cultures  [44]. Since then other genetic and non-genetic 
models have been developed to model HD.  
 Genetic models of HD derive principally from animal models expressing  a 
truncated [23] or full length [24,25] form of mutant htt (mhtt). This model 
mimics the pathology including the genetic aspect of HD and as a consequence 
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leads to the MSN death.  The model acquirement does not demand specific 
knowledge but may be more expensive in a long term  as genetic mice need to be 
purchased. The R6/2 and knock-in Q175 mouse are mostly used, from mice  of12 
weeks old until  1 year or more [134–136].  So usually,  organotypic sl ices 
deriving from genetic models are made with adult brain. These  brain slices are 
more difficult to prepare as the cranium is unbending and the culture of adult  
brain is more complicated. Indeed, most brain slice culture systems have used 
the perinatal rodent brain,  taking advantages of its higher viabili ty relative to 
the older one. The survival of adult  brain slice s did not exceed 1 week in 
cultures [137] with serum and 3-4 weeks without serum [138].   
 Another way to obtain genetic models of HD brain sl ices is the 
transfection of HD-polyQ-GFP plasmids directly onto the slice.  Three different 
non-viral transfection methods were tested on mouse cerebellum organotypic 
slices [139].  And then authors proposed an innovate model obtained in 72h with 
a transfected mutant huntingtin gene which when expos ed to malonate produced 
HD-like lesions and provided a new model of HD, conserving the correlation 
between CAG repetitions and aggregation length  [140]. This new model is 
powerful because in 72h they obtained a genetic model of HD, but even with the 
best  transfection methods the maximum of cells containing the plasmid were 
around 35%. Slice transfection requires high technology equipments  and a 
skilled operator, which make them difficult to use in routine.  
 Non genetic ex vivo models of HD have been performed using neurotoxins 
(KA [44],  IA, QA [48], NMDA [52],  3-NPA [46]) added into the media,  which 
then mainly affect the striatum, the cortex and the hippocampus, inducing 
neuronal loss [36,49,141] . Striatal degeneration of HD can also be caused in 
vivo  by 3-NPA, a mitochondrial inhibitor. This model allows understanding the 
neurotoxicity and the excitotoxicity mechanisms [46].  Although only the 
cellular aspect of HD can be studied, they present many advantages: they are 
easy and rapid to develop and do not involve high economic impact as normal 
rodents are used. For these models, usually newborn or one day old rodent are 
sacrificed and cultured during 3-4 weeks and then brain slice cultures are 
exposed for 48h to neurotoxins.  In thi s way, a model is  obtained in 1 month, 
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which is quite some time. Moreover,  the heterogeneity of the results after 
treatment evaluation prompts to focus on another system.  
 In this work, we propose a novel and simple approach to model HD. We 
developed a coronal organotypic culture model obtained just by vibrosectioning 
of the brain.  This brain slice model allows selecting the area that  we want to 
study. The main areas involved in HD are obtained in a unique slice without 
neurotoxins to induce the GABAergic MSNs depopulation. The aim was to 
induce progressive striatal MSNs degeneration in a single step while preparing 
the slices,  in order to obtain a simple reproducible HD ex vivo model. To our 
knowledge, this is  the first time that  vibrosection was investiga ted for modeling 
HD. We have already demonstrated the interest of vibrosectioning the brain for 
developing a fully characterized ex vivo  PD model. Interestingly, we obtained 
all the areas involved in PD: cortex, striatum, ventral  pallidum the visualization  
of the fibers present in the medial  forebrain bundle and the substantia 
nigra[133]. Based on the same method, we elaborated this unique model of HD.  
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BACKGROUND: Organotypic brain slice cultures represent an excellent 
compromise between single cell cultures and animal. They preserve brain three-
dimensional architecture, synapti c connectivity and brain cells 
microenvironment.  This model has allowed researchers to observe cellular 
interactions and mechanisms through a simple and rapid method. Moreover, 
slice culture model systems provide a unique opportunity to monitor the 
circuits’ repair in a dish after cells  transplantation without any concern about 
the possible interaction between neurotoxins and cells grafted.  
NEW METHODS: We aim to develop a novel model of Huntington’s 
disease.  We have generated a coronal slice from rats '  br ains that includes all the 
areas involved in HD in a single slice preparation, without using neurotoxins to 
induce the lesion.  
RESULTS:  After investigated different axis to cut the rats ' brains, we 
determined that coronal brain slices can be cultured durin g approximatively 3 
weeks with a preservation of normal cyto -architecture except in the striatum. 
After 1 week, we observed a reduced volume of the striatum associated with the 
decrease of GABAergic medium spiny neurons markers mimicking HD cellular 
hallmarks.   
COMPARISON WITH EXISTING METHODS:  This organotypic model 
involves GABAergic MSNs degeneration simply by cutting the tissue with a 
specific axis.  Inversely,  the use of neurotoxins such as quinoleic acid to model 
Huntington’s disease lead to heterogeneity in the results obtained, which must 
be taken into consideration.  
CONCLUSIONS:  This unique model presents a new approach for modeling 
Huntington's disease  in vitro ,  and provides a useful innovative method for 
screening new potential therapies for neurodegenerative diseases .  
Organotypic slices, Huntington's model, neurodegenerescence, 
methodology, DARPP32, GAD67 
DARPP32: Dopamine- and cAMP-Regulated neuronal PhosphoProtein of 
32kDa; GAD67: Glutamate decarboxylase 67; GSBS:  Grey’s Salt  Balanced 
Solution; HD: Huntington's disease;  HTT: Huntington gene; htt: protein 
huntingtin; MEM:  minimum essential medium eagle, MSN: medium spiny 
neurons;  NeuN: neuronal nuclei;  PBS: phosphate buffered saline;  PFA: 
paraformaldehyde.  
ABSTRACT:  
Keywords: 
Abbreviations: 
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 Huntington’s disease (HD) is an inherited autosomal dominant 
neurodegenerative disorder with a general prevalence of about 10 per 100.000 
births [1,2]. This high CAG triplet  repetit ion  is localized in the IT-15 gene of the 
chromosome 4: the huntingtin  gene (HTT). This repeti tion will lead, at  the 
protein level, to a polyglutamine repetition at the NH 2-terminal part of the 
huntingtin protein [3]. The accumulation of the mutant htt protein is  excitotoxic, 
therefore it progressively compromises survival and normal neuronal 
functioning, primarily in the striatum or caudate/putamen and pr ogresses with 
the degeneration of cortical pyramidal neurons, mainly projecting to the 
striatum [4]. Striatal  GABAergic medium spiny neurons (MSN), which constitute 
the majority of cells in this region are affected by this pathology. They extend 
axonal projections to the external segment of the globus pallidus (GP), and to 
the substantia nigra pars reticulata .  The progressive loss of these neurons is 
accompanied by a corresponding ventricular enlargement and  gliosis [5]. 
Clinically,  this neurodegenerative disorder lead s to involuntary movements , 
cognitive impairment and psychiatric manifestations [6]. Medications are 
available to help managing the symptoms of Huntington's disease, but 
treatments can't  prevent the physical,  mental  and behavioral progressive decline 
associated with the disease.  
 Novel drug and cell  therapy approaches in development require extensive 
evaluation before use in humans [7]. Considering the role of mHtt in the 
pathogenesis of HD, this protein has been transfected in different cell lines for 
the study of HD in vitro .  [8] Recent studies have explored the use of embryonic 
stem cells and induced pluripotent stem cells as cellular models for disease 
research and the development of biomedical applications.  Significant  work 
being done in the field is the establishment of human iPSC lines  from patients 
with HD mutations [9]. Although these models are relevant to study important 
hallmarks of HD, allowing the investigation of key intrace llular mechanism 
involved in the disease,  as well as the identification of novel pharmacological 
targets,  in vitro  models do not reflect the complexity of the disease.  The effect 
of the microenvironnement,  and the functional aspects of the disease can only  be 
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provided by in vivo  models.These models can be broadly divided into genetic 
models presenting the mutated htt  gene in various forms or into neurotoxic 
models showing a quite specific GABAergic MSN degeneration [10]. These 
models have been designed to elucidate the pathogenesis, cell  death mechanisms 
and to evaluate therapeutic strategies for HD [11]. But in vivo  studies require 
high technical and financial  resources and they do not allow to simultaneously 
test  several  conditions in the same animal [12–14]. For innovative cell  therapy or 
tissue engineering studies it  is very complicated and time consuming t o 
understand and elucidate all  the interactions between grafted cells and host 
brain. Even more, generally human cells are grafted into rats or mice models 
involving an immunological  component that  needs to be taken into account in 
these models.  
Organotypic brain slices,  which can be maintained in culture for several 
weeks,  are commonly used in brain disease research as they provide unique 
advantages over in vivo  and in vitro  platforms [15,16]. They largely preserve 
tissue structures, maintain neuronal activities and synapse circuitry,  and 
replicate many aspects of the in vivo  context [17]. Further advantages of these 
brain cultures reside in their low-cost,  rapid preparation and the use of many 
brain slices/animal allowing the study of an important number of conditions.  
Thus, gene functions and pathways can be easily studied as in an in vitro  
system.  
 Recently,  organotypic brain slice cultures have been used for HD 
modeling. Two major techniques can lead to this model. The first one uses 
organotypic slices made directly from transgenic mice expressing HD patterns, 
such as R6/2 transgenic mice [18,19]. But these models require the use of adult 
tissue, as mice develop the disease over t ime. This adult t issue is  very difficult  
to manipulate in ex vivo  conditions,  the cranium is unbending and the 
organotypic slices are not viable over time. The survival of adult brain slices 
did not exceed 1 week in culture with serum [20] and around 3 weeks without 
serum [21]. Indeed, most brain slice culture systems have used the perinatal 
rodent brain, taking advantages of its higher viability relative to the older one. 
In the second technique, organotypic slices were prepared from normal rodent s 
and GABAergic neuron loss was obtained by injecting neurotoxic agents such as 
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quinolic acid or 3-NPA, a mitochondrial  inhibitor, added in the media. However, 
the use of neurotoxins leads to heterogeneity in the results, which must be taken 
into consideration. Furthermore only the cellular aspect of HD can be studied, in 
detriment of the genetic component of the pathology [22–24]. Another solution is 
to transfect  the sl ices with HD-polyQ plasmids or with DNA constructs derived 
from the human pathological HTT gene [25–27]. However,  slice transfection 
involves high technology equipment and a skilled operator as org anotypic brain 
slices are delicate and frequently become damaged during the preparative stages 
[16]. Notwithstanding these obstacles, the introduced exogenous proteins into 
both neuronal cells have been consistently difficult to achieve.  
 In this study, we developed a novel approach to model HD. We developed 
a coronal organotypic culture model that includes the main areas involved in HD 
in a unique slice that does not need neurotoxins to i nduce the GABAergic MSN 
depopulation. The aim was to induce progressive striatal MSNs degeneration in 
a single step while preparing the slices, in order to obtain a simple reproducible 
HD ex vivo  model. We first  studied and characterized different axis to cut the 
whole brain to determine the one that induces the degeneration of MSN. Then 
we explored the viability of this unique sl ice containing all  the areas affected by 
the disease and characterized the decrease of striatal  GABAergic neurons 
visualized with  DARPP32 and GAD67. Our study is the first one describing a 
cheap, simple and reproducible model of HD without neurotoxin.  
2.1 PREPARATION OF ORGANOTYPIC SLIDES 
 Animal care and use were in strict accordance with the regulations of the 
French ministry of agriculture and all animal procedures were approved by the 
animal experimentation ethic committee of “Pays de la Loire”.  Every effort  was 
made to minimize animal suffering and the number of animals used.  
 Timed pregnant Sprague-Dawley rats were purchased from Janvier (St 
Berthevin, France), or from SCAHU (Service commun d'animalerie hospitalo - 
universitaire, University of Angers, France). Postnatal  6 to 8 days old pups were 
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used to prepare organotypic slices according to the Stoppini metho d [28] 
recently modified [29] by our team. Before starting the experiment, solution 1 
(Table 1) needs to be prepared and kept at 4°C and the membrane has to be 
hydrated with solution 1 for at least 30 min. Animals were rapidly sacrificed 
after intraperitoneal injection of 80 mg/kg of ketamine ( Clorketam 1000, 
Vetoquirol,  Lure,  France) and 10 mg/kg of xylazine (Rompum 2 %, Bayer 
Health Care, Kiel Germany)  (Figure 1A).  Brain are removed and rapidly 
dissected (Figure 1B) before being glued onto the chuck of a water -cooled 
vibratome. This gesture must be quick in order to preserve the brain, and 
immediately immersed in the buffer solution (Table 1)  at 4°C (Figure 1C) .  
Under aseptic conditions, 400 µm slices were cut in different configurations in 
order to obtain a progressive degeneration of the GABA ergic MSNs. Finally,  
cerebellum and olfactory bulbs/prefrontal cortex were cut off and brains were 
glued, onto the chuck of a water cooled vibratome (Motorized Advance 
Vibroslice MA752, Campdem instruments).  Coronal sections were collected and 
placed in sterile ice-cold Grey’s Salt Balanced Solution (GSBS) (Sigma Aldrich, 
St Louis, USA) supplemented with 6.5 mg/L of glucose and antibiotics (100 
U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 μg/mL amphotericin B) (Sigma 
Aldrich, St Louis, USA) for one hour (Table 1).   
Slices were cultured in two different media.  From days 0 to 3,  a serum 
containing medium was used: 50 % MEM (Minimum Essential Medium Eagle, 
Sigma Aldrich),  25 % Hank’s (Hank’s Balanced Salt  Solution, Sigma  Aldrich), 
25 % of horse serum (decomplemented horse serum, Gibco),  6.5 mg/mL of 
glucose, 1 mM of L-glutamine (Sigma Aldrich, St -Louis, USA) and 1 % of 
antibiotics (Sigma Aldrich, St -Louis, USA) (Table 2).  From days 3 to 18, a 
serum free medium was used: Neurobasal medium (Gibco, Life Technolog ies, 
Paisley, UK) supplemented with 6.5 mg/L of glucose, 1 mM of L -glutamine, 1X 
B27 supplements (Gibco, Life Technologies, Paisley, UK) and 1% of antibiotics 
(Table 2).  The media was changed the first day after of culture and was then 
renewed every two days during the entire culture period.  
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Figure 1. Protocol to obtain organotypic slices. Rats’ anesthesia must be realized with an intra-
peritoneal injection of ketamine and xylazine, in a solution of NaCl 0,9 %. (A) The head must be 
dissected quickly and carefully to preserve brain structure. Cortex and cerebellum should be cut 
(B). Brain is glued onto the chuck of a water-cooled vibratome and plunged in a cold solution 
containing high level of glucose. Under aseptic conditions, 400µm thick whole brain sections are 
cut and collected (C) The brain slices are disposed in a 0.4 µm membrane insert with media 1 
solution and incubate in 5% CO2 and observation of the coronal slice. Cortex (Cx), striatum (St), 
globus pallidus (GP) and Corpus Callosum (CC) can be easily observed (D). 
 Typically,  about 10 slices can be obtained per brain.  The first  two and the 
last two brain slices did not contain the main areas involved in the pathology 
and were discarded. Four slices per animals were next transferred to 30 mm 
diameter semiporous membrane inserts (Millicell -CM, Millipore, Bedford, MA, 
USA) within a 6-well plate and incubated at 37ºC and 5 % of CO2. A total  of 
about 20 rat pups and about 80 organotypic slices were necessary to perform the 
whole characterization. For each conditi on, a minimum of three slices taken 
from three different rat  pups were used.  
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Products Quantity Special instructions 
Gey's balanced salt 
solution  
50 mL Must be at 4°C  
D-glucose 6.5 mg/mL Must be filtrated at 0.22 
µm 
Antibiotics 1 % Streptomycine and 
penicilline 
Table 2.  Description of the buffer solution needed during the first step of organotypic slice 
preparation. This solution must be prepared under aseptic conditions.  
 
Solution Products Quantity Special 
instructions 
Media 1 
 
(From day 0 to 
day 3) 
Minimum Essential 
Medium Eagle 
(MEM) Alpha 
Modifications 
50 % sterile 
Hanks balance 
salt solution 
25 % sterile 
Horse serum 25 % Must be 
inactivated 
D-glucose 6.5 mg/mL Must be filtrated 
at 0.22µm 
L-glutamine 1 mM Must be filtrated 
at 0.22µm 
Antibiotics 1 % Streptomycine 
and penicilline 
Media 2 
 
(From day 3 to 
the end of the 
experiment) 
Neurobasal 
media 
 sterile 
D glucose 3.25 mg/mL Must be filtrated 
at 0.22µm 
L-glutamine 1 mM Must be filtrated 
at 0.22µm 
B27 2 X  
Antibiotics 1 % Streptomycine 
and penicilline 
Table 1. Description of the media needed during all the organotypic slices culture. These 
media should be prepared under aseptic conditions. Media should be renewed every 2 or 3 days 
during culture. 
2.2 SLICE ANGLE SELECTION TO OBTAIN A HUNTINGTON’S DISEASE MODEL.  
Brains were cut with different angles to obtain the most complete 
DARPP32 and GAD67-posit ive cell  degeneration over t ime. For this analysis, 
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three angles have been chosen: sagittal , coronal and transversal . For sagittal 
slices, brain hemispheres were separated and glued onto the chuck of a water -
cooled vibratome and slices were cut alongside of the midline. Concerning 
coronal slices,  cerebellum and olfactive bulbs/prefrontal  cortex were cut off and 
brains were glued, on their dorsal  side,  onto t he vibratome chuck. At last,  to 
perform transversal  slices, the underside of the brain was glued on the 
vibratome chuck. For each condition, 400 µm slices were performed with razor 
blade angle of 14°.  
2.3 HISTOLOGICAL STUDIES 
 At different times, ranging from 0 to 19 days, organotypic slices were 
washed with phosphate-buffered saline (PBS) (Lonza, Verviers, Belgium), fixed 
with 4 % paraformaldehyde (PFA) (Sigma–Aldrich, St Louis, MO, USA) in PBS 
pH 7.4 for 2 h and then washed three times with PBS. Finally,  sli ces were 
removed from membrane inserts and stored at  4°C in PBS until use.  
2.3.1  DARPP32 and GAD 67 Immunohistochemistry 
 A mouse anti GAD67 antibody (5 µg/mL, clone 1G10.2, Millipore SA, 
Guyancourt , France) and mouse anti -DARPP32 (250 µg/mL, clone 15, DB 
science, Le Pont de Claix, France) were used to observe striatal -globus pallidus 
GABAergic pathway. Slices were incubated 48 h with the primary antibody 
diluted into PBS, BSA 4 % at 4°C. After washes, sl ices were incubated with the 
biotinylated anti -mouse secondary antibody (7.5 µg/mL, Vector Laboratories, 
Burlingame, USA). Then sl ices were washed and quenching of peroxidase was 
performed with 0.3 % H 2O2  (Sigma, St Louis, USA) in PBS , at RT for 20 min. 
After PBS washes sl ices were incubated with Vectastain ABC r eagent (Vector 
Laboratories, Burlingame, USA) in PBS at RT for 1  h. Sections were then 
washed and revealed with 0.03 % H 2O2 ,  0.4 mg/mL diaminobenzidine (DAB, 
Sigma, St Louis,  USA) in PBS, 2.5 % nickel chloride (Sigma, St Louis,  USA) 
and dehydrated before mounting.  
2.3.2 Quantification of DARPP32 and GAD 67 positive fibers and cells  
GAD67-positive fibers and DARPP32-positive neurons were quantified in 
the striatum at  different time-points, from 0 until  19 days post -lesion, using the 
CHAPTER I 
79 
 
Metamorph® software from Molecular Devices.  Results were presented as mean 
differences +/ - average deviation and were ca lculated from 6 independent 
pictures taken from 4 different rats for each group.  
2.3.3 NeuN Immunohistochemistry 
An antibody against neuronal nuclei (NeuN) (clone A60, Merck Mill ipore,  
Billerica, MA, USA) was used to observe the viability of cells within the bra in 
organotypic sl ices. Slices were incubated 48 h with the primary antibody diluted 
into PBS BSA 4 % (1/50) at 4°C. After washes, slices were incubated with the 
biotinylated anti -mouse secondary antibody (7.5 µg/mL, Vector Laboratories, 
Burlingame, USA). Then sl ices were washed and quenching of peroxidase was 
made with 0.3 % H 2O2  (Sigma, St Louis, USA) in PBS-T, at  RT for 20 min. 
After PBS washes, incubation with Vectastain ABC reagent (Vector 
Laboratories, Burlingame, USA) in PBS was performed at RT for 2 h. Sections 
were washed and revealed with 0.03 % H 2O2 ,  0.4 mg/mL diaminobenzidine 
(DAB, Sigma, St Louis, USA) in PBS, 2.5 % nickel chloride (Sigma, St Louis, 
USA) and dehydrated before mounting.  
2.3.4 Quantification of NeuN-positive neurons 
 The survival of total neurons in certain organotypic slice regions was 
estimated by immunohistochemestry against NeuN. NeuN -positive neuron was 
calculated, from days 0 to 19 using the Metamorph® software. At each time -
point, six pictures taken from three different slices showing cortex, striatum and 
lateral septum were used. NeuN-positive neuron in these areas was expressed as 
a percentage of NeuN staining at day 0 considered as positive control. Results 
were presented as mean differences ± average deviation.  
2.3.5 Statistical analysis 
 Data are presented as the mean value of three independent experiments ± 
standard deviation (SD), unless otherwise stated. Significant differences 
between samples were determined using an analysis of variance (ANOVA) test, 
followed by a Scheffe post hoc test  which indicates if conditions were 
significantly different. P-value was set to 0.05, unless otherwise stated.  
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3.1 SLICE ANGLE SELECTION TO OBTAIN A HUNTINGTON’S DISEASE MODEL. 
 To determine the best  model of GABAergic MSN neurodegeneration, 
mimicking one of the pathological hallmarks of HD, the neonatal  brain was cut 
following three different axis to obtain the organotypic slices (Figure 2A and 
2B) .  With the three types of sectioning planes the striatum, cortex and globus -
pallidus, the brain areas mainly affected in HD were visible. The progressive 
degeneration of MSN was evaluated by DARPP32, expression. We observed that 
DARPP32 staining was present and observable in the whole striatum 
independently of the slice plane chosen (Figure 2C) .  Moreover, in horizontal 
and sagittal  slices,  DARPP32 positive cells were still  highly present in the 
striatum after 4 days and even after 7 days of culture (Figure 2C) .  In coronal 
sections (Figure 2C),  the number of DARPP32-positive cells was reduced by 
around 30% after 4 days and up to 70% after 7 days. As a quick degeneration of 
DARPP32-positive cells was desired, coronal sections were used for the rest  of 
this study. Moreover, the sections can be kept as a whole therefore containing 
the striatum from the two hemispheres, providing a control  in the same slice.  If  
desired, and in order to increase the viability of the sl ices they can also be cut 
along the midline.  
3. RESULTS 
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Figure 2. Slice angle selection to model HD. Rat's brain was cut in order to obtain saggital, 
coronal or horizontal brain slices (A). Which each different angles, we can vizualized all the areas 
involved in the HD (B) DARPP32 was detected in brain slices obtained by immunofluorescency at 
day 1, 4 and 7 after sagittal, coronal and horizontal (C) sections. 
 
3.2 ORGANOTYPIC SLICES MORPHOLOGY AND VIABILITY OF CULTURED NEONATAL BRAIN 
SLICES. 
 Culture conditions remarkably affect the organotypic culture viability.  We 
already described a protocol using 2 specific media with and without serum [29]. 
Using these conditions, the whole coronal HD organotypic slices can be kept 
viable during at least 3  weeks in culture (Figure 3).  We observed a decrease of 
striatum volume from 4 days onwards and a good conservation of organotypic 
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slice's morphology during 3 weeks (Figure 3A).  No important distortion or 
flattening of the slices was detected. However, an important thinning of the 
striatum within 6 days was observed by bright field microscopy, predicting a 
reduction of viability of the striatal  neurons (Figure 3A).  
 To confirm the viabili ty of  organotypic brain slices, neurons were 
visualized with an antibody against NeuN and quantified at day 0, 7, 11 and 19. 
During the 3 weeks of culture the number of NeuN -positive cells decreased less 
than 20 % +/- 4 % in the cortex and lateral septum compared to striatum, (Figure 
3C and 3D), underscoring the viability of the neuronal cells in these areas.  
However, only 20 % +/- 5 % of NeuN-positive cells were counted in the 
striatum, explaining the decrease of volume observed during the culture and 
confirming the neurodegeneration (Figure 3).   
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Figure 3. Morphology and viability of organotypic slices. Observation of coronal brain slices was 
realized by bright field microscopy (A). Immunohistochemistry against neuronal nuclei (NeuN) 
showing three brain regions: cortex, striatum and lateral septum at day 0, 11 and at day 19 (B) at 
the bottom. Immunohistochemistry against neuronal nuclei (NeuN) showing the striatum (C) 
Quantification of NeuN-positive cells in cortex, striatum and SN shows no important loss of 
staining in the cortex after 19 days in culture (D). While NeuN expression decreased by 80 % and 
27 % in the striatum. ∗: Significantly different results with n = 3 and P-value = 0.05. Pictures 
about organotypic slides until day 19.  
3.3 ORGANOTYPIC SLIDES CULTURES DISPLAY PROGRESSIVE DEGENERATION OF 
GABAERGIC PATHWAY 
 In order to demonstrate the degeneration of medium spiny n eurons in the 
striatum, we followed by immunohistochemistry the progressive decrease of 
DARPP32 (Figure 4A)  and GAD67 (Figure 4B),  which are markers of 
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GABAergic MSNs. These markers were perfectly specific because we didn't find 
any positive cells in the cortex (Figure 4A and 4B).  The number of DARPP32-
positive neurons and GAD67-positive neurons decreased over time with around 
a 50% decrease during the first week when compared to day 0 (Figure 4A and 
4B).  A quantification of the GABAergic marker density GAD 67 shows a 
progressive loss of 30 % at day 4, 45 % at day 7 and 70 % at day 11 when 
compared to day 0. It was almost complete by day 19 with an average of only 1 
% staining left.  However, the staining intensity varied between sl ices due to the 
tissue damage (Figure 4D).  Indeed, a more dramatic loss of DARPP32 staining 
was detected over time with an average of 25 % decrease at day 2, 50 % at day 4 
and 75% at day 7 compared to day 0,  and was complete by day 19 (Figure 4C). 
Even though the average loss of DARP P32 staining was a bit more rapid the 
profile of these 2 graphs are similar, confirming the progressive loss of 
GABAergic neurons in the organotypic sl ices.  
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Figure 4. Modelisation of specific MSN markers. Immunohistochemistry against striatal A) 
DARPP32 positive neurons and B) GAD67 positive neurons at day 0, 7, 11 and 19. C) Striatal 
DARPP32 positive neurons decreased progressively until day 11 and became total at day 19 in 
comparison with day 0 which represents 100% represented with SD in doped lines. D) Striatal 
GAD67 positive neurons quantification with SD in doped lines. A 10% decreased was detected at 
day 2 which reached 30 % at day 4, 45 % at day 7 and reached 100 % at day 19, holding the fact 
that day 0 represent 100 %. N=4  
Organotypic slices have been widely used as model of neurological 
pathologies including Parkinson's disease, brain stroke and cerebral ischemia 
[16]. In the present work an innovative ex vivo model of HD in which 
progressive striatal  MSN degeneration was obtained in a single step while 
preparing the slices,  was developed. The MSN degeneration occurred in around 
4. DISCUSSION 
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three weeks and was specific to the striatum as the viability of the other brain 
regions was mainta ined during this time. We didn't observe morphological  
modification except for the volume reduction in the striatum confirming what is  
observed in HD. This simple model thus allows evaluating different 
neuroprotective and neuroreparative therapeutic strate gies. Organotypic slices 
were obtained from 6 to 8 day old pups  It is  well known and established that 
tissue from embryonic or post  natal donors survive better [30,31]. Slices post-
natal donors is recommended because at  this age, brain slices will  conserved a 
better morphology, an increase survival and we will  obtain a more stable models 
regarding to the lesions.  Animals were sacrificed between days 6 to 8 which 
provides a perfect  time window for establishing brain slice cultures on 
membranes.  More particularly,  for Parkinson's disease the slices are principally 
harvested between 4 and 9 weeks after birth [32,33].  
  Hypothermia has been shown to improve the preservation of 
hippocampus brain slices [34–36]. In our study, in order to preserve brain slices  
we insured that  the brain was kept at  4°C in solution buffer containing high 
percentage of glucose during the whole slice preparation process. We chose not 
to place the head in ethanol 70 % bath as some teams have reported [31] in order 
to maintain physiological  conditions of organotypic brain slices. Within the 
same line,  the media containing horse serum was only used during the first 3 
days even though horse serum diminishes tissue flattening, and promotes 
survival of neurons,  astroglia or microglia in organotypic brain slices [37]. In 
order to diminish the variability between slices due to changes in serum batches 
we then used a serum-free media containing glucose, glutamine, antibiotics and 
B-27® .  Indeed, serum increased the degeneration of neurons in brain slices when 
the media contain serum for a long-time period [21]. In a previous study, we 
confirmed the benefice of using horse serum during a short  period followed by 
“synthetic” media and accord ing to these results, we applied this method to 
culture organotypic brain slices modeling HD.  In this way, we are able to 
maintain the viabili ty of brain ex vivo  for at least  3 weeks,  and obtained the HD 
model in 5 days.  Other studies demonstrated the ben efit to culture organotypic 
slices without serum such as our study, and brain sl ices from transgenic mouse 
or rat brain slice with injection of neurotoxins were principally cultured with 
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art ificial cerebrospinal fluid or specific media containing HEPES (( 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid ) [38–40]. 
  This organotypic model involves GABAergic MSNs degeneration due to 
mechanical cutting of t issue between the striatum and substantia nigra, which 
leads to retrograde and anterograde neuronal degeneration in the substantia 
nigra and in the striatum, respectively.  In this report , a complete 
characterization of the behavior of MSNs and GABAergic pathway was assessed 
by immunostaining through the visualization of the decrease of DARPP32 and 
GAD67, two specific markers of MSNs [5]. It revealed that a rapid loss of 
DARPP32-positive neurons occurred  in the striatum followed by a decrease in 
GAD67 staining. A decrease of 50% and 30% of the DARPP32 and the GAD67 
positive cells respectively was detected 4 days after slice preparation compared 
to day 0. This allows the development of an early model of th e disease, in which 
a window of time of at least 15 days was obtained to study new therapeutic 
approaches.  One important reason to culture brain slices is  to study and 
characterize the interaction between neuronal populations. The coronal section 
allows studying those parameters, thanks to the observation of the globus 
pallidus, the striatum and all  the structures involved in the HD in one slice. We 
can easily imagine testing different molecules with therapeutic effect such as 
growth factors directly onto s lices or in the media and observe their effect in all  
the MSNs afferents and projections [41,42]. [43]. Indeed, with the same method, 
we developed an innovative model of PD and we were able to evaluate new 
therapeutic approaches combining stem cells and biomaterials releasing growth 
factors in order to treat the disease or to reduce the related symptoms. [29]  
 In summary, this model represents a promising tool to quickly and 
efficiently test innovating treatment in the HD such as regenerative medicine 
with stem cells and biomaterials. The development of simple an d non expensive 
model with precise characterization of neurodegeneration could allow to easily 
study the therapeutic effect  of treatment but also the role of microenvironment 
in the response of the treatment.  
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In this study we developed and cha racterized a relevant ex vivo  model of 
HD using membrane techniques culture and specific media. This new model can 
be use to study the early stage of the pathology because we observed the 
reduction of striatum such as in the HD in 4 days. This represents a  perfect  
model to study the relevance of new and innovative treatment.  
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The use of organotypic slices allowed the development of a new simple 
model of Huntington's disease. Indeed, GABAergic MSNs degeneration is 
observed after  mechanical cutting necessary to obtain brain slices.  In this way, 
no other supplementation with neurotoxins, quinoleic acid or 3 -NPA is needed 
for the progressive loss of striatal  neurons,  which reduces the risk of 
heterogeneous results. Usually,  only some areas such as the striatum, the 
hippocampus or cortex and striatum are used in ex vivo  models of HD[42] 
[44,52] Here we have all  the regions involved in HD, the cortico -striatal-globus 
pallidus area of one hemisphere or of both hemisphere s allowing to use one side 
as control.  
Nonetheless, the full  characterization of this model is required. Indeed, we 
followed NeuN and GABAergic markers for only 19 days.  We should know how 
much time brain slices survive and understand exactly the mechanism  of the 
decrease of DARPP32 and GAD67. DARPP-32 is a fundamental  component of 
the dopamine-signaling cascade, and its expression is essential to the ability of 
dopamine to regulate the physiology of striatal  neurons .  In our study, the 
decrease of GAD67 is progressive and comparable to NeuN while DARPP32 
decreased drastically from day 5.  The results presented here suggest a selective 
impairment in several aspects of dopaminergic signaling. Indeed, dopaminergic 
signaling  has been already described in the li t erature to be involved in 
presymptomatic defects and contribute to  HD pathology [142] , and DARPP32 is 
the first  marker decreasing. DARPP32 is  also a mediator of signaling cascades 
in dopaminoceptive neurons which corroborate this hypothesis. So, our model 
seems to be severely impaired in GABAergic neurons' abil ity to regulate the 
physiological  state of striatal neurons via dopamine.  To confirm our hypothesis,  
we can imagine checking the dopamine-regulated ion channels by 
electrophysiological studies and determine if a reduction in the striat al-specific 
dopamine targets, PKA, DARPP-32, ARPP-16, and ARPP-21 is associated, with 
RT-qPCR or immunofluorescence.  
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The aim of this study has been to  develop a simple model to screen 
potential treatment including cell  replacement with MIAMI cells combined  with 
PAMs. This model allows the development of an early model of the disease ,  in 
which a window of time of at least 7 days was obtained  if we considered 
DARPP32 and 14 days if  we considered GAD67 . The timing differences are 
evidenced when comparing this model with those in which organotypic  brain 
slices are cultured during 3 weeks followed by the addit ion of neurotoxins in the 
media in order to mimic HD [44–47]. Thus, stem cell  transplants coupled or not 
with MPA in this model enable the evaluation of the survival and differentiation 
of grafted cells and the study of the behavior of the host  t issue in particular 
related to the evaluation of the secret ion of neurotrophic factors  by stem cells  
that  can be made during 14 days. We can also easily imagine testing different 
molecules with therapeutic effect  such as growth factors directly onto slices or 
in the media and observe their effect in all  the MSNs a fferents and projections 
[143,144]. In summarize,  our model is so much faster, simpler and less 
expensive than the in vivo  model .  
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Transplantation of stem cells for the treatment of HD garnered much 
attention prior to the turn of the century. Several studies using MSCs have 
indicated that these cells have enormous therapeutic potentia l  in this disease 
[145,146]. In the case of HD, the beneficial  effect of stem cel l transplantation 
should be provided by the generation of new graft -derived neurons and by the 
secretome of these cells [147].  MSCs are not only able to differentiate into 
neuron-like cells but they also exert  paracrine effects by modulati ng the 
plasticity of damaged host tissues.   
The trans-differentiation of MSCs into neural lineage has been achieved in 
vitro by culturing them with specific media. This media is  often composed of 
growth factors or small molecules involved in neuronal linea ge differentiation. 
The degree to which the cells will differentiate varies depending on the protocol 
and cells used [148,79,149] .  In all cases, although the MSCs were committed to 
neuronal linage, the functionali ty at  the end of the process was still  lacking. 
Attempting to understand how to improve the di fferentiation, REST also known 
as neural-restrict ive silencing factor (NRSF) has been proposed as it  functions 
as a master negative regulator of neurogenesis [150]. REST is a zinc finger 
transcriptional repressor able to bound the RE -1 sequence in his target gene 
promoter which allows recruiting histone deacetylases and methyltransferase  to 
modulate the chromatin structure [151,152]. In non-neural cells , REST is 
abundant and represses neuronal genes.  Importantly,  REST itself is  
differentially regulated throughout neural development.  In MSCs, the role of 
REST was first investigated by Trzaska et al. (2008) with the goal to obtain 
mature dopaminergic neurons.  Indeed, the down -regulation of REST with 
lentivirus has been demonstrated to promote neuronal commitment [102].  
Knock-down of gene expression can be obtained by different ways and in 
this study, we retained the siRNA epigenetic strategy to silence REST (siREST) 
in MSCs as it  specifically targets the expression of the gene of interest as 
presented above (Introduction and aims) . To introduce siREST, we chose two 
nanocarriers  which present all  the advantages that  we discussed above 
INTRODUCTION 
CHAPTER II 
95 
 
(Introduction and aims). We focused on two innovative systems: lipid  
nanocapsules and solid span nanoparticles.  
Concerning LNCs, previous studies demonstrated the possibility to 
encapsulate plasmid  DNA to develop a gene therapy strategy [116]. For this, 
theDNA is complexed with cationic lipids  by electrostatic interactions  leading 
to formation of complexes  called lipoplexes , which are added to other 
components of the LNC. This strategy has demonstrated the capacity of LNCs to 
transfect  in vivo  models of gliobastoma [117–119]. Strong of these results, the 
encapsulation of siRNA in LNCs was successfully performed [153] and this 
system was able to transfect  melanoma and glioma cells  in vitro [154,155]. 
Nonetheless, the instabili ty over-time of this system needed to be improved. In 
this way, the optimization of LNC -siRNA had to be performed with two goals: 
improving the stability over time of LNCs and protecting the siRNA from 
denaturation. In any case this system provides a p ositive surface, which can 
easily interact with negatively charged cell membranes. Although it is well 
known that  nanoparticles with a positive surface charge transfect very well , the 
risk of toxicity is higher with those systems. However,  recent evidence proves 
that  anionic nanocarriers can also be effectively internalized [156],  and that the 
transfection efficiency is not only dependent on the surface charge but also on 
the particle size and composition [157,158]. 
So, to determine the optimal nanocarrier to transfect MSCs, we chose a 
second system: Solid span nanoparticles  (SP) to compare with LNCs. SP  based 
on sorbitan monooleate (Span® 80) have been specifically adapted to provide 
effective siRNA association . Previous studies demonstrated the efficiency of SP 
to associate DNA by incorporating to their composit ion positively charged 
molecules like oleylamine (OA) [159].  This fatty amine is employed in the 
creation of emulsions and other delivery systems  [160]. Poly-L-arginine (PA), a 
cationic moiety broadly used in gene therapy approaches  [161]  was also 
evaluated. OA and PA were used to provide a positive surface charge for the SP 
nanoparticles, thus enabling the association with the negatively charged, nucleic 
acids thus resulting in Span® 80-oleylamine nanosystems (SP-OA) or Span® 80-
poly-L-arginine nanosystems (SP-PA), with a characteristic net negative surface 
charge [122].Their capacity to provide higher in vivo  t ransfection levels than 
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adeno-associated viral  vectors (AAV2) has been recently reported [123]. In this 
work, we conserved SP-PA to transfect  MSCs and further modified the SP 
nanoparticles in order to coat them with  cationized pullulan (AP), a natural 
polysaccharide obtaining SP-AP, as a strategy to easily associate siRNA by 
electrostatic interaction  [162].  
In this chapter,  to improve human stem cell transfection and efficiency 
control of the stem cell fate,  we have designed, optimized, characterized and 
evaluated two different siRNA nanocarriers transpo rting siRNA.  
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ABSTRACT:  
To direct stem cell  fate, a delicate control  of gene expression through 
small  interference RNA (siRNA) is emerging as a new and safe promising 
strategy. In this way, the expression of proteins hindering neuronal commitment 
may be transiently inhibited thus driving differentiation. Mesenchymal stem 
cells (MSC), which secrete tissue repair factors, possess immunomodulatory 
properties and may differentiate towards the neuronal lineage, are a promising 
cell source for cell  therapy studies in the central nervous system. To better drive 
their neuronal commitment the repressor element -1 silencing transcription 
(REST) factor, may be inhibited by siRNA technology. The design of novel 
nanoparticles (NP) capable of safely delivering nucleic acids is crucial in order 
to successfully develop this strategy. In this study we developed and 
characterized two different siRNA NP. On one hand, sorbitan monooleate 
(Span®80) based NP incorporating the cationic components poly -L-arginine or 
cationized pullulan, thus allowing the association of siRNA were designed. 
These NP presented a small size (205 nm) and a negative surface charge ( -38 
mV). On the other hand, lipid nanocapsules (LNC) associating polymers with 
lipids and allowing encapsulation of siRNA complexed with lipoplexes were 
also developed. Their size was of 82 nm with a positive surface charge of +7 
mV. Both NP could be frozen with appropriate cryoprotectors. Cytotoxicity and 
transfection efficiency at different siRNA doses were monitored by evaluating 
REST expression.  An inhibition of around 60% of REST expression was 
observed with both NP when associating 250 ng/mL of siRNA -REST, as 
recommended for commercial reagents.  Span NP were less toxic for human 
MSCs than LNCs, but although both NP showed a similar inhibition of REST 
over time and the induction of neuronal commitment, LNC-siREST induced a 
higher expression of neuronal markers. Therefore, two different tailored siRNA 
NP offering great potential for human stem cell differentiation have been 
developed, encouraging the pursuit of further in vitro and in vivo  in s tudies.  
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Nanocarriers, siRNA, mesenchymal stem cells, neuronal differentiation, 
REST. 
MSC: mesenchymal stem cells; siRNA: small interfering RNA; SP: Span 
80®;  PA: poly-Arginine; AP: ammonium pullulan /  cation ized pullulan; NP: 
nanoparticles; DOPE: 1,2 -dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP: 
1,2-dioleoyl-3- trimethylammoniumpropane; LNCs: lipid nanocapsules; 
REST/NRSF: (Repressor Element -1 silencing Transcription /Neuron -Restrictive 
Silencing Factor-1) 
Mesenchymal stem cells (MSC) are multipotent stromal cells, capable of 
self-renewal and able to differentiate into a diverse set  of cells within the 
mesoderm lineage [1]. They can also be an interesting source of cells for brain 
regenerative medicine because they secrete tissue repair factors, possess 
immunomodulatory properties and, in some conditions,  may differentiate 
towards the neuronal lineage [2–4].  In order to safely implant them in the brain 
parenchyma they should be pre-committed to a neuronal phenotype. However, 
protocols only using external growth factors to drive MSCs into specific 
lineages seem to be insufficient to obtain high percentages of differentiated 
cells [5,6]. A lentiviral-mediated RNA interference vector that down -regulates 
the expression of REST/NRSF (Repressor Element -1 silencing Transcription 
/Neuron-Restrict ive Silencing Factor-1) has been recently used to promote MSC 
differentiation into neuronal cells,  which exhibited neuron -like morphology and 
function [7]. Indeed, REST/NRSF is a repressor transcription factor functioning 
as a master negative regulator of neurogenesis by binding to a specific DNA 
domain named RE1 motif [8,9]. In non-neural cells  and in pluripotent stem 
cells,  REST is abundant and represses neuronal genes [10] Consequently,  the 
loss of REST in neural  progenitors resulted in an acceleration of neuronal and 
oligodendrocyte differentiation [11].  
KEYWORDS 
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Nowadays, a transitory inhibit ion of targeted gene expression in cells may 
be obtained by small  interference RNAs (siRNA) without affecting the genome. 
These siRNA are able to produce a partial  or total extinction of targeted 
messenger RNA (mRNA) and protein levels by degrading the mRNA. This 
epigenetic modification is quite simple,  does no t need genetic manipulation, is 
transitory and is now quite well understood. Although current applications in 
stem cells remain largely restricted to studies on molecular pathways and 
signaling, siRNA can be also used as a biomedical strategy to improve su rvival,  
direct lineage-specific differentiation of stem cells or help maintain a desired 
phenotype [12,13]. Within this line, the inhibition of Noggin with siRNA was 
capable to induce new bone formation in vivo [14].  But the mode of delivery of 
these novel therapeutic agents is of crucial importance for an efficient ex vivo  
or in vivo  therapeutic strategy.  
In the last decade, two different approaches for siRNA delivery have been 
developed: vi ral and non-viral vectors.  Non-viral vectors (also named 
nanoparticles (NP) or nanocarriers) have been formulated to associate and to 
efficiently and safely deliver nucleic acids both in vitro  and in vivo ,  opening 
many possible applications. In addit ion, t hey have many advantages and 
potentialities, including large -scale manufacture, low toxicity and low 
immunogenicity,  and the possibility to customize them to target specific cell 
types [7,8]. Initially, NPs were designed to have a pos itive surface charge, in 
order to improve the interaction with the cell  membrane that  has a negative 
surface, and to avoid electrostatic repulsion [9]. However, recent evidence 
proves that anionic NPs can also be effectively internali zed [15],  and that  the 
transfection efficiency is not only dependent on the surface charge but also on 
the particle size and composition [16,17] . In this frame, our research group has 
reported a novel NP based on sorbitan monooleate (Span ®  80) (SP) that  can be 
prepared using a simple, one-step and easily scalable procedure [18]. SP is a 
component widely used in the pharmaceutical  industry (generally recognized as 
safe (GRAS)) due to its non-ionic surfactant properties at low concentrations 
[19]. These NPs are able to transfect in vivo the retinal pigment epithelial cells  
with a similar efficiency as adeno-associated viral  vectors [20] 
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Transfection techniques currently use packaging particles such as 
liposomes to facilitate the cellular uptake of RNAi. They have s hown high 
biocompatibility and are available in the market such as l ipofectamine ®,  
oligofectamine® ,  ready to be used. However, they exhibit some disadvantages 
such as high positive zeta potentials destabilising cell membrane, low 
transfection efficiencies in human stem cells,  and instabili ty immediately after 
complexation [21]. Moreover,  transitional action reported with these liposomal 
carriers is  not sufficient on their own to have an ef fect  over-t ime .  In vitro 
liposome  transfection efficiency is also affected by the type of culture media 
and cell plating density, and does not provide an efficient protection against  
lysosomal nucleic acid degradation [22]. Lipid nanocapsules (LNCs) consisting 
of a lipid liquid core of triglycerides and a rigid shell  of lecithin and 
polyethylene glycol hydroxystearate, are formulated by a simple and easily 
industrialized solvent-free process based on the phase inversion of an emulsion 
[23,24]. They allow entrapping the liposomes within their core and were thus 
recently modified to  encapsulate the siRNA complexed with DOTAP (1,2 -
dioleyl-3- trimethylammoniumpropane) and DOPE (1,2 -dioleyl-sn-glycero-3-
phosphoethanolamine), protecting the siRNA from degradation [25]. DOTAP 
lipids presenting a cationic charge, allow the fixation of siRNA by electrostatic 
force and the interaction with the cell membrane improving the cellular uptake 
[26–28].  Moreover,  DOTAP and DOPE are able to destabilize lysosome’s 
membranes by a proton sponge effect [29]. However, the stability of these LNCs 
should be improved.  
 
The transfection efficiency of the siRNA delivered by NP is often affected 
by the proliferative activity of human stem cells,  and varies widely depending 
on the type of target cells [30].  To ameliorate the transfection of human stem 
cells and efficiently induce a neuronal -l ike differentiation, we have designed a 
novel SP-based NP conveying REST and further developed LNCs incorporating 
siREST with a good stability over time. [20]. First , we have modified SP NPs 
with cationized pullulan (AP) as a strategy to easily associate siRNA by 
electrostatic interaction thus obtaining a novel NP. Pullulan is a non -toxic 
natural  polysaccharide presenting non-immunogenic properties [31].  This FDA 
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approved component possesses a wide range of industrial  applications including 
health care and pharmacy [31]. Secondly, we further developed LNCs, and 
evaluated different formulations of LNCs incorporating siREST in order to 
obtain a better stability. The siREST -NPs were characterized by dynamic light 
scattering, UV spectrophotometry and electron microscopic methods in order to 
improve the understanding of their organization and structure. After evaluation 
of the long-term storage and stability of siRNA -NPs over time, we tested the 
cytotoxicity of both systems on human (h)MSCs and, finally, we evaluated their 
abili ty to transfect hMSCs and drive the commitment of hMSCs towards a 
neuronal phenotype determined by expression of neuronal genes.  
 
2.1 FORMULATION 
2.1.1 Synthesis of pullulan derivate :  
Pullulan was chemically modified in order to obtain a posit iv ely charged 
derivative (ammonium pullulan, AP) by alkylation of the original polymer.  
Synthesis was performed based on a previously described methodology [32]: an 
aqueous solution (5 mL) of KOH (0.504g, 9 eq),  was prepared in a round bottom 
flask, under st irring, at  60 ºC, to which pullulan (500 mg) and 3.6 2 mL (4.09 g, 
27 eq) of GTMAC were added. After 5 h,  an equal amount of GTMAC was 
added to the mixture, which was allowed to react until the completion of 24 h. It 
was then diluted with 10 mL of miliQ water,  allowed to cool down to room 
temperature, and neutralized with HCl (2M). The resulting solution was dialyzed 
for 3 days, the water being replaced every 24 h,  and the modified polymer 
recovered by freeze drying.  
2.1.2 SP-PA and SP-AP nanoparticles associated with siRNA 
To produce the SP nanoparticles,  a solut ion of 6.6 mg/ml of sorbitan 
monooleate (Span ®  80) (Sigma, Saint-Quentin Fallavier, France)  in ethanol 
(organic phase) was prepared and it was subsequently added under magnetic 
stirring to an aqueous phase,  leading to the spontaneous nanoparticle formation  
2. MATERIALS AND METHODS 
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[18]. To produce SP-PA and SP-AP nanoparticles,  Poly-L-arginine (PA) or 
ammonium pullulan (AP) were dissolved in Mili -Q water at 0.16 mg/ml.  Finally,  
ethanol was removed under reduced pressure on a rotary evaporator and the 
nanoparticles were concentrated to a final volume of 10 ml.  Nanopar ticles were 
isolated by filtrat ion-centrifugation (Amicon  Ultra-0.5 centrifugal filter 
Devices, Merck Millipore, Ireland). The genetic materials (siRNA REST and 
Scramble) were associated to the nanoparticles ' surface at  different 
concentrations (from 0.1mg/ml to 0.5mg/ml) by incubation with nanoparticles at 
a 1:1 (v:v) ratio (100-100 µl) under magnetic starring at  room temperature 
during 2 hours in order to obtain siRNA -SP-AP and siRNA-SP-PA 
nanoparticles.  
2.1.3 Liposomes and lipoplexes 
For liposome preparation,  a cationic lipid DOTAP (1,2-dioleyl-3- 
trimethylammoniumpropane) (Avanti® Polar Lipids Inc.,  Alabaster, AL, USA), 
solubilized in chloroform, was weighted at a 1/1 molar ratio  with the neutral 
lipid DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine) (Avanti® Polar 
Lipids Inc. , Alabaster, AL, USA) to obtain a final  concentration of 30 mM of 
cationic l ipid, (considering the number of charges per lipid molecule), i .e 1 for 
DOTAP. After chloroform evaporation under vacuum, deionized water was 
added to rehydrate the lipid film overnight at  4 °C which was sonicated the day 
after during 30 min.  
Lipoplexes were formulated by simple equivolumar mix of siRNA and 
liposomes. This complex is characterized by the charge ratio [27] corresponding 
to the ratio between positive charge of lipids and negative charge of nucleic 
acids at  5.  
2.1.4 siRNA-LNCs 
LNCs were formulated, as described previously [23] by mixing 20 % w/w 
Labrafac® WL 1349 (caprylic-capric acid triglycerides, Gatefossé S.A. Saint -
Priest,  France), 1.5 % w/w Lipoid S75 -3® (Lecithin,  Ludwigshafen, Germany),  
17 % w/w Kolliphor® HS 15 ( Polyethylene glycol -15-Hydroxystearate HSPEG 
BASF, Ludwigshafen, Germany),  1.8 % w/w NaCl (Prolabo, Fontenay -sous-
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Bois, France) and 59.8 % w/w water (obtained from a Milli -Q system, Millipore,  
Paris, France) together under magnetic stirring. Briefly,  three temperature 
cycles between 60 and 95 °C were performed to obtain phase inversions of the 
emulsion. A subsequent rapid cooling and dilution with ice cooled water (1:1.4) 
at the last phase inversion temperature (PIT) le d to blank LNC formation.  
To obtain siRNA LNCs, the water introduced at  the last PIT was replaced 
by lipoplexes,  i .e. REST siRNA: (sense sequence: 5 ′ - CAG-AGU-UCA-CAG-
UGC-UAA-GAA -3′; Eurogentec, Seraing, Belgium) and control (scrambled) 
siRNA (sense sequence: 5 ′- UCUACGAGGCACGAGACUU-3′;  Eurogentec, 
Seraing, Belgium) complexed with cationic liposomes in a defined charge ratio 
as described above.  
To obtain siRNA LNCs, the water introduced at  the last PIT was replaced 
by lipoplexes,  i .e. REST siRNA: (sense sequence: 5 ′- CAG-AGU-UCA-CAG-
UGC-UAA-GAA -3′; Eurogentec, Seraing, Belgium) and control (scrambled) 
siRNA (sense sequence: 5 ′- UCUACGAGGCACGAGACUU-3′;  Eurogentec, 
Seraing, Belgium) complexed with cationic liposomes in a defined charge ratio 
as described above.  
To avoid the possible denaturation of siRNA by the high temperatures,  the 
addition of lipoplexes at  75°C or 40°C was tested within the classical  
formulation. Two other formulations were performed, one with reduce PIT by 
increasing the NaCl concentration to 8% in the formulation and the last one 
without l ipoid®.   
2.2 CHARACTERIZATION OF BOTH NANOPARTICLES  
2.2.1 Size, zeta potential, transmission electron microscopy and cryo-transmission electron 
microscopy 
Size and zeta potential of LNCs and SP were measured by D ynamic Light 
Scattering (DLS) method using a Malvern Zetasizer ® apparatus (Nano Series ZS, 
Malvern Instruments S.A., Worcestershire, UK) at 25 °C, in triplicate,  after 
dilution in a ratio of 1:100 with deionized water.  These parameters were 
followed daily during one month.  
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The morphological  examination of siRNA -SP-AP was conducted by 
transmission electron microscopy (TEM) (CM 12 Philips, Eindhoven, The 
Netherlands). Samples were placed on copper grids with carbon films (400 
mesh) (Ted Pella, USA) and stained with 2% (w/v) phosphotungstic acid 
solution for TEM observation.  
The morphological examination of siRNA -LNC for cryo-TEM imaging were 
prepared using a cryo-plunge cryo-fixation device (Gatan, Pleasanton USA) in 
which a drop of the aqueous suspension was deposited on a carbon-coated grid 
(Ted Pella Inc., Redding, USA). The TEM grid was then prepared by blott ing 
the drop containing the specimen so that a thin liquid layer remained across the 
holes of the carbon support film. The liquid film was vitrified by  rapidly 
plunging the grid into liquid ethane cooled by liquid nitrogen. The vitrified 
specimens were mounted in a Gatan  910 specimen holder (Gatan, Pleasanton, 
USA), which was inserted into the microscope using a CT -3500-cryotransfer 
system (Gatan, Pleasanton, USA), and cooled with liquid nitrogen. TEM images 
were obtained from specimens preserved in vitreous ice and suspended across a 
hole in the supporting carbon substrate  
2.2.2 Encapsulation efficiency (EE) 
Qualitative BET electrophoresis detection  - The EE and the integrity of 
siRNA molecules after the process of nanoparticle formulation were evaluated 
by agarose gel electrophoresis. A volume of nanoparticle suspension equivalent 
to 2.5 μg of siRNA before and after treatment with Triton® X100 (Sigma, Saint -
Quentin Fallavier, France) was mixed with gel -loading solution (Sigma, Saint -
Quentin Fallavier,  France) and disposed in each well of 1% agarose gel 
containing ethidium bromide (Sigma, Saint -Quentin Fallavier, France) [12]. 
Free siRNA in solution corresponding to 2.5 μg constituted the controls. 
Samples were let to migrate 40 min at  50 V and 10 min at  90V in a Tris –EDTA 
buffer (Sigma, Saint -Quentin Fallavier, France) .   
 Quantitative UV detection  –  A spectrophotometric method based on the 
study recently reported by David et al .,  (2012),  was used to evaluate the EE for 
LNC. Briefly,  siRNA LNCs were mixed with chloroform and water to separate 
respectively hydrophilic and  lipophilic components,  sodium hydroxide was 
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added to destabilize lipoplexes and finally absolute ethanol to destroy LNCs 
[28]. After multiple centrifugations, four compartments were obtained: free 
siRNA, free lipoplexes (i.e. siRNA associated with liposomes),  encapsulated 
siRNA and encapsulated lipoplexes within LNCs.  
siRNA and SP-AP were separated from supernatant using Nanosep® Omega 
30 kD microcentrifuge filters (Pall  Corporation, Ann Arbor,  USA) and siRNA 
was measured in the supernatant.  To determine the concentration of siRNA,  
optical  density of each sample was determined at  260 nm by UV 
spectrophotometer (UV-2600, Shimadzu, Noisiel , France) in triplicate 
conditions. The EE was determined by dividing the experimental drug loading 
by the theoretical  drug loading. EE was followed every week during one month 
by these two methods.  
2.2.3 Encapsulated siRNA stability 
 In order to determine the stabil ity of the encapsulated siRNA during the 
transfection, a spectrophotometric method based on the study recently reported 
by David et al .,  (2012),  was used to evaluate the encapsulated si -RNA of LNCs. 
Briefly,  siRNA LNCs were dissolved at a ratio of 1:10 in Opti -MEM®  media 
(Life technologies,  France) to mimic the transfection condition at  two 
temperatures: 4°C (to mimic the storage condition) and 3 7°C (to mimic 
transfection condition in the incubator). Methods used to separate the different 
phases were described earl ier.  The encapsulated siRNA was determined by 
dividing the experimental drug loading by the theoretical  drug loading and 
taking into account the dilution. It  was followed at different times: 0, 4, 8,  and 
12 h after formulation. To confirm results, the integrity of siRNA was evaluated 
by agarose gel  electrophoresis in the same conditions.  
2.2.4 Freezing  
The long-term storage assessment of siRNA-LNCs and siRNA-SP-AP was 
carried out by freezing at  -20°C. The siRNA-LNCs and siRNA-SP-AP were 
frozen with phosphate buffered saline (PBS) (control solution) or with an 
aqueous solution of trehalose or of glucose as cryoprotectants in a 1:1 (v/v) 
ratio nanoparticles:cryoprotectants with a range from 1% to 15%. They were 
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then analyzed after 1-month storage at -20°C by evaluating size and zeta 
potential measures by Dynamic Light Scattering (DLS) method using a Malvern 
Zetasizer® apparatus (Nano Series ZS, Malvern Instruments S.A., 
Worcestershire,  UK) at 25 °C, in triplicate, after dilution in a ratio of 1:100 
with deionized water. The integrity of siRNA molecules after storage at  -20°C 
of nanoparticle formulations was evaluated by agarose gel electrophoresis.  
2.3 MENSENCHYMAL STEM CELL (MSC) ISOLATION AND EXPANSION:  
Whole bone marrow was obtained from the il iac crest of 15 -yr-old (#34984) 
living male donor (Lonza, Walkersville, MD). Cells were seeded with -MEM : 
BE 12169F (LONZA) supplemented with 10% FBS,  L -Glutamine 2mM (Sigma-
aldrich, France, G7513) FGF 1 ng/ml, Heparin  5 µg/ml, 1% penicillin-
streptomycin (Sigma, Saint -Quentin Fallavier,  France).  The cells were 
maintained at 37°C with 5% CO 2  humidified atmosphere. Passage numbers 
between 5-7 were used for the following experiments.  
2.4 MSC TRANSFECTION  
Experiments were performed in 1mL of MSC Opti -MEM®  media (Life 
technologies, France). Oligofectamine ® (Life technologies, France), which 
served as a positive control, was used with 100 ng or 250 ng of siRNA. SiRNA -
LNCs were filtered with a 0.2  μm filter (Acrodisc PALL GHP, VWR, Radnor, 
USA). siRNA-LNCs and siRNA-SP-AP were incubated with cells at 37 °C in a 
humidified atmosphere with 5 % CO 2  for 4h before serum addition, following 
Oligofectamine–siRNA protocol.  Cells were harvested after appropr iate time 
and assayed for mRNA expression levels by RT -qPCR and protein expression 
levels by western blot.  
2.5 IN VITRO VIABILITY:  
Cytotoxicity assays were performed using MTS (3 -(4,5-dimethylthiazol -2-
yl)-5-(3-carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H tetrazolium) (Promega, 
Madison, USA). and AlamarBlueR  (resazurin) (Invitrogen).  Twenty-five 
thousand cells , cells  were transfected in a 24 -well plate with the siRNA-REST 
and siRNA scramble with increasing concentrations of siRNA (0.05, 0.1,  0.25, 
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0.5 and 1 mg/mL).  To determine the IC 5 0 ,  cells  were subsequently cultured 
during two days and 20 µL of MTS/well was added and plates incubated 2.5 h at 
37 °C in a humidified atmosphere with 5 % CO 2 .  The OD was evaluated by 
Mutliskan Ascent (Labsystems, Fisher Scientific , Wilmington, USA) at 492 nm. 
For the AlamarBlue assay, 10% AlamarBlue assay was added in RPMI media 
without serum and phenol red. After 4h of incubation, the fluorescence was read 
using a SpectraMax fluorescence multi -well plate reader (Molecular Devices,  
Sunnyvale, CA) at 530/590 excitation/emission wavelengths. Three replicates 
were used for each treatment.   
Furthermore,  cell  numbers were also counted after each transfection 
performed. Forty-eight hours after transfection 200.000 cells were resuspended 
by trypsin (0.5  g porcin trypsin, 0.2  g EDTA; Sigma, Saint Louis, USA), washed 
twice with PBS and trypan blue staining was used to count the number of cells 
per well.  
2.6 RNA EXTRACTION, RT-QPCR :  
These experiments were performed following the guidelines of th e PACEM 
core facility ("Plate-forme d'Analyse Cellulaire et Moléculaire”,  Angers, 
France). Sense and antisense desalted primer pairs (Eurofins MWG Operon, 
Ebersberg, Germany) were mixed in RNAse free water at a final  concentration 
of 5 µM (Table 1). Total RNA of cells were extracted and purified using 
RNeasyMicrokit (Qiagen, Courtaboeuf,  France), and treated with DNase (10 U 
DNase I/µg total RNA). RNA concentrations were determined using a ND -2000 
NanoDrop (Thermo Fisher Scientific, Wilmington, Delaware USA ) and used for 
normalization of the input RNA in the RT. First strand complementary DNA 
(cDNA) synthesis was performed with a SuperScriptTM II Reverse Transcriptase 
(Invitrogen), in combination with random hexamers,  according to the 
manufacturer’s instruct ions. Following first -strand cDNA synthesis, cDNAs 
were purified (Qiaquick PCR purification kit,  Qiagen, Courtaboeuf, France) and 
eluted in 40 µL RNAse free water (Gibco).  2,5ng of cDNA was mixed with 
MaximaTM SYBR Green qPCR Master Mix (Fermentas) and pri mer mix (0.3 
µM) in a final volume of 10µL. Amplification was carried out on a Chromo4 
thermocycler (Biorad) or LightCycler 480 (Roche) with a first denaturation step 
at  95°C for 10 min and 40 cycles of 95°C for 15 s,  60°C for 30 s.  After 
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amplification, a melting curve of the products determined the specificity of the 
primers for the targeted genes. Several housekeeping genes,  Glyceraldehyde -3- 
phosphate dehydrogenase (Gapdh), Beta -2-microglobulin (B2M), Beta actin 
(Actb),  and Heat shock 90 kDa protein 1 be ta (Hspcb) were tested for 
normalization. The GeNormTM freeware (http://medgen.ugent.be/ -
jvdesomp/genorm/) was used to determine that GAPDH and ACTB were the two 
most stable housekeeping genes. The relative transcript  quantity (Q) was 
determined by the del ta Cqmethod Q=E(Cq min in all the samples tested - Cq of 
the sample), where E is related to the primer efficiency (E=2 if the primer 
efficiency=100%). Relative quantities (Q) were normalized using the multiple 
normalization method described in Vandesompele  et al [33].  Q 
normalized=Q/(geometric mean of the three most stable housekeeping genes Q). 
The 2(-ΔΔCt) method was retained, using the housekeeping genes and gene of 
interest tested on control sample and treated sample  [34].  
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Gene Full name NM accession 
number 
 sequences 
GAPDH glyceraldehyde-3-
phosphate 
dehydrogenase 
NM_001289745.1 Fwd:CAAAAGGGTCATCATCTCTGC 
Rev:AGTTGTCATGGATGACCTTGG 
ACTB Actin NM_001101.3 Fwd: CCAGATCATGTTTGAGACCT 
Rev: GGCATACCCCTCGTAGAT 
Β3-TUB Tubulin beta 3 class 
III 
NM_006086 Fwd: CCAGTATGAGGGAGATCG 
Rev: CACGTACTTGTGAGAAGAGG 
REST RE1-silencing 
transcription factor 
NM_001193508.1 Fwd: ACTCATACAGGAGAACGCC 
Rev: GTGAACCTGTCTTGCATGG 
SCG10 stathmin 2 NM_001199214.1 Fwd: TGTCACTGATCTGCTCTTGC 
Rev: AGAAGCTAAAGTTCGTGGGG 
NFM Neurofilament, 
medium polypeptide 
(Variant 1) 
NM_005382.2 Fwd: GACCTCAGCAGCTACCAG 
Rev: TAGTCTCTTCACCCTCCAG 
Table 2.  Sequence of primers validated in RT-qPCR 
2.7  WESTERN BLOT:  
Total proteins were isolated by sonication of cells in lysis buffer composed 
of 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, pH 8, 2.5 mM EGTA, 
pH 7.4, 0.1% Tween 20, 10% glycerol,  0.1 mM sodium orthovanadate,  1 mM 
sodium fluoride, 10 mM β -glycerophosphate, 0.1 mM phenylmethylsulfonyl 
fluoride (PMSF), and complete protease inhibitor cocktail  (Roche).  The 
quantification of protein used was performed according to Bradford method  
(26).  
Twenty μg of protein extracts were separated by SDS -10% PAGE and 
transferred to PVDF membranes (GE Healthcare, VWR, Milan, Italy).  The 
membranes were incubated overnight with rabbit  anti -REST antibody (1/200) 
(Abcam, Cambridge, UK), washed with Tris -buffered Saline and incubated with 
anti-rabbit  (1/5000) (32460, Thermo scientific) for 6 hours.  Immunostaining was 
revealed by the Immuno-Star HRP substrate (BioRad, Segrate (MI),  Italy)  
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according to manufacturer’s instructions and quantified by Kodak Ima ge Station 
440CF. The image analysis was performed using the Kodak 1D 3.5 software 
(27). To confirm that equal amounts of protein were lo aded membranes were 
incubated with anti -β actin (Sigma-Aldrich, Italy) and revealed in the same way.  
2.8 STATISTICAL ANALYSIS: 
Three independent biological replicates were performed for all  experiments 
described in this paper. Comparisons between all groups, supposed with normal  
distribution, were performed using a classical analysis of variance (one -way 
ANOVA) followed by a Tukey’s post-hoc  analysis.  The encapsulation 
efficiencies for modified LNCs and non -modified LNC were compared using a t -
test .  Statistical significance was ascribed to a threshold p -value of 0.05 (*p≤ 
0.05; **p≤ 0.01; ***p≤ 0.001).  
3.1 SP NANOPARTICLES: SELECTION OF SURFACE COMPOSITION AND SIRNA DOSE. 
Using SP we can spontaneously form negatively charged nanoparticles 
with a size of about 140 nm and a zeta-potential  of -  17 mV, being these 
nanoparticles stable during at least 1 month (Figures 1A and 1B). However, the 
negative surface charge of this nanocarrier renders a stable interaction with the 
negatively charged siRNA difficult  to accomplish.  In order to modify the 
surface charge of these SP nanoparticles and to easily associate the siRNA to 
the nanoparticle surface we evaluated the effect of incorporating on their 
composition two different cationic molecules, poly-L-ariginine (PA) and 
ammonium pullulan (AP) to the SP formulation. The developed SP -PA and SP-
AP blank nanoparticles (no siRNA associated) showed a nanoparticle size of 180 
nm and 140 nm, respectively,  which did not vary much from the SP 
nanoparticles.  They also presented appropriate positive surface charges of 
3. RESULTS 
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+40mV and +38mV, respectively (Figure 1B).  No change in terms of size or 
zeta potential  were observed when NPs were conserved for 1 month at 4°C 
(Figures 1A and 1B) .  Once developed, we complexed each system with the 
siRNA-scramble and the siRNA REST by simply mixing them together. Similar 
sizes and zeta-potentials were observed with both siRNAs. At day zero, the 
increase in size and the decrease on surface charge for siRNA -SP-PA NPs (280 
nm and -37 mV) and siRNA-SP-AP NPs (205 nm and -38mV) (Figures 1A and 
1B)  indicated an effective electrostatic interaction between siRNA and the 
nanoparticles. On the contrary,  when combining AP and siRNA to form AP -
siRNA complexes as a control  formulation a broad -range particle size 
distribution was observed, being characterized by the presence of aggregates 
rather than nanosystems. We also performed a stability study with siRNA -SP-PA 
and siRNA-SP-AP during 30 days. siRNA-SP-AP and siRNA-SP-PA were both 
perfectly stable in terms of size  and in surface charge (Figures 1A and  1B).  
We selected SP-AP for the rest of experiments because pullulan is a non -toxic 
FDA approved natural  polysaccharide presenting non -immunogenic properties 
with very interesting characteristics.  Indeed, pullulan may  be chemically 
modified in order to afford either hydrophobized or cationized derivatives, the 
former with the abil ity to carry hydrophobic molecules,  and the latter showing 
high affinity towards DNA and RNA [35].   
 To determine the most favorable siRNA co ncentration capable of 
interacting with these NPs, we have tested different concentrations of siRNA 
ranging from 0.1 mg/ml to 0.5 mg/ml and checked the size and zeta -potential for 
each one. Similar particle sizes were obtained in this concentration range 
(around 190 nm). However, the surface charge decreased when the siRNA 
concentration increased, demonstrating the high capacity of AP to complex 
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siRNA on the surface.  In this case,  we therefore speak of association efficiency. 
Above 0.3mg/ml of siRNA, we observed a stagnation of the surface charge ( -45 
mV) (Figure 1C)  revealing a saturation of the system. This observation was 
confirmed by electrophoresis experiments performed to further assess the siRNA 
association ability of the developed SP-AP NPs. The absence of the typical  
bands of free siRNA in the formulations of NPs incubated with 0.1 and 0.3 
mg/ml siRNA corroborated the effective association to the nanosystems in this 
concentration range (Figure 1D).  At 0.3 mg/ml of siRNA the efficiency of 
association with the SP-AP was 33 % +/- 6 and we selected this dose for the 
subsequent 
studies.
CHAPTER II 
115 
 
 
Figure 1. Characterization of SP nanoparticles with different surface composition and siRNA 
dose: (A ) Size of blank nanoparticles based on SP, SP and poly-arginine (SP-PA) or SP and 
cationized pullulan (SP-AP), siRNA-SP-PA and siRNA-SP-AP at days 0 and 30 after storage (D0 
and D30): (B) zeta-potentials at days 0 and 30 after storage; (C) Size and zeta-potentials of 
nanoparticles associating siRNA doses ranging from 0.1 to 0.5 mg/ml; (D) Electrophoresis 
experiments performed with free siRNA (Line 1) and siRNA-SP-AP associating different siRNA 
at different concentrations, such as (2): 0.1 mg/mL of siRNA; (3): 0.3 mg/mL; (4): 0.4 mg/mL and 
(5): 0.5 mg/mL. Free siRNA can be observed in the lines 4 and 5 illustrating the saturation on the 
association efficiency of the nanocarrier. Results are expressed as mean ± standard deviation 
(n=3). No difference was demonstrated on stability of SIRNA-SP-AP using ANOVA 1W, post-
hoc Tukey. 
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3.2 OPTIMISATION OF SIRNA-LNC 
 Initially,  during siRNA-LNC formulation lipoplexes  were added at  the 
beginning of the last phase inversion temperature (PIT) (75°C), but an 
instability of the system has been observed [33]. To improve the stability and to 
avoid the possible denaturation of siRNA by the high temperatures this initial 
formulation was further modified. First, we increased the NaCl concentration to 
8% thus obtaining a PIT at 60°C. In a second experime nt,  a novel formulation 
(modification of some components recently patented -ref: FR 4185991, 24 Sept 
2014) was developed and the lipoplexes were also introduced at lower 
temperatures (40°C). Blank LNCs were used as control because their size and 
zeta potential were perfectly stable for 2 months ( Figures 2A and 2B ). We first 
noticed a difference in size (increased size) and zeta potential (increased 
surface charge) when comparing blank -LNC and the siRNA-LNCs formulations 
developed under the different experim ental conditions (75°C, 60°C and 40°C), 
which suggest  an effective encapsulation of lipoplexes in LNCs. The initial  size 
(D0) of the siRNA-LNCs prepared at 75°C progressively decreased during a 2 
months storage period from an initial  value of 102 nm, where as an increase of 
zeta-potential can be observed. These results suggest and instability and a 
rearrangement of the system (Figures 2A and 2B ).  The same behavior was 
observed with the formulation having a PIT at 60°C. There was an increase in 
size followed by a sharp decrease at D60, as well  as a slight decrease in zeta 
potential.  The last formulation at  40°C had a size of 85 nm with a positive 
surface charge of +7 mV which was perfectly stable over -time (Figures 2A and 
2B).  To evaluate the encapsulation eff iciency of siRNA in LNCs electrophoresis 
experiments were performed. A low fluorescence band may be visible, 
indicating an incomplete encapsulation. The encapsulation yield determined by 
UV spectrophotometry was 43% +/ - 7%, confirming that approximately ha lf of 
the siRNA is stably incorporated within the LNCs. As in the case of SP -AP 
nanoparticles, generally no siRNA was visible probably due to free liposomes 
outside LNC able to complex and protect the siRNA.  
 The encapsulation efficiency was also evaluated  after storage at 4°C under 
the conditions subsequently used in the transfection studies (37°C, 4h of 
incubation in Opti -MEM), in order to determine the stability of the encapsulated 
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siRNA. No differences were observed in both conditions at 0h and at  4h an d no 
significant release was observed at  37°C in the 4h and 12h period.  
 
Figure 2. Optimization of different siRNA-LNCs. Size (A) and zeta potential (B) at different 
storage times (D0, D15, D30 and D60) showing a long-term stability for siRNA LNCs 40°C. EE 
evaluation by UV spectrophotometry of siRNA in LNCs in the Opti-MEM® at 4 and 37°C, 
showing no release during the first 4h (C), further confirmed in the electrophoresis experiments 
(D). Results (n=3) are expressed as mean measure ± standard deviation and the encapsulation 
efficiencies were compared using a t-test. 
3.3 MORPHOLOGICAL COMPARISON BETWEEN BOTH NANOCARRIERS 
The morphology of SP-AP and LNCs was observed by transmission 
electronic microscopy (TEM) and cryo -TEM, respectively. The images illustrate 
the homogeneity of each nanocarrier population ( Figure 3) and are in 
accordance with the sizes obtained by the light scattering technique for both 
siRNA-SP-AP (200 nm) and siRNA-LNC (80 nm) (Figures 3B and 3D).  
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Figure 3. Morphological comparison between SP-AP and LNC observed by transmission 
electronic microscopy (TEM) for Blank-SP-AP (A) and siRNA-SP-AP (B). and by cryo-
transmission electronic microscopy (cryo-TEM) for Blank-LNC (C) and siRNA-LNC (D) showing 
homogeneous populations of spherical nanocarriers of around 200 nm (SP-AP based nanosystems) 
or 80 nm (LNC nanosystems). 
 
3.4  SIRNA-NANOPARTICLE FROZEN STORAGE. 
Table 2  summarizes the NPs size, zeta potential and polydispersity of the 
LNC and SP-AP formulations after 1 month storage at -20°C. The frozen NPs 
can be easily resuspended by gentle shaking. However,  in order to standardize 
the redispersion conditions, the particle size was determined after redispersing 
the frozen samples by vortex stirring. siRNA -LNCs were perfectly conserved 
with 1% of glucose without size or zeta -potential modification and si -RNA-AP 
could be frozen independently with 5% of glucose or trehalose, allowing 
integrity conservation of siRNA. The EE decreased of around 10% (from 43% to 
33%) but the integrity of the siRNAs was still  conserved for each nano carrier as 
the siRNAs were st ill  visible by electrophoresis after freezing and both NPs 
were able to transfect efficiently (data not show).  
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Simples Size (nm) before 
freezing 
Zeta-Potential 
(mV) before 
freezing 
Size (nm) 
after 
freezing 
Zeta-Potential 
(mV) after 
freezing 
siRNA-LNC PBS 81,7 +/- 2,45 4,929 +/- 0,82 6000 ND 
siRNA-LNC 1% 
trehalose 
83,9 +/- 3,15 5,35 +/- 1,56 95 +/- 4,72 17,2 +/- 6,18 
siRNA-LNC 1% 
glucose 
82,34 +/- 1,87 7,23 +/- 2,27 80,6 +/- 0,59 6 +/- 0,25 
siRNA-SP-AP PBS 195,64 +/- 3,90 -36,3 +/- 1,22 275 +/- 7,40 -14,56 +/- 5,3 
siRNA-SP-AP 5% 
trehalose 
202,65 +/- 2,39 -41,2 +/- 0,74 199 +/- 1,98 -27,1 +/- 1,04 
siRNA-SP-AP 5% 
glucose 
202,12 +/- 2,83 -36,7 +/- 3,2 179 +/- 2,57 -27,4 +/- 0,88 
Table 3.  Physicochemical characterization of siRNA-SP-AP and siRNA-LNC after storage at 
-20°C. Formulations were stored at -20°C during 1 month with PBS (control), trehalose or glucose 
(cryoprotectors). Size and zeta-potential were determined using DLS (Zetasizer, Malvern) before 
and after storage. Most relevant results were presented here. Results (n=3) are expressed as mean 
measure ± standard deviation. 
 
3.5 EVALUATION OF NANOCARRIERS TOXICITY AND SELECTION OF THE SIRNA DOSE FOR 
MSC TRANSFECTION:  
 In order to study the toxicity of LNCs and SP -AP we evaluated the cell  
viability after 48 h exposure to different NPs concentrations expressed in terms 
of siRNA concentrations,  ranging from 1µg/mL to 50ng/mL, that  corresponds to 
a range of 60 µg/mL to 1000 µg/mL in the case of LNC nanosystems or 1 µg/mL 
to 20 µg/mL in the case of the SP-AP ones. A decrease in cell  viabil ity 
correlated to an increase in concentration of NPs was observed for both 
nanocarriers. No difference between both formulations was observed for 100 
ng/ml of siRNA. However,  such differences can be app reciated at  higher 
concentrations.  Thus, in the case of LNCs, the most prominent decrease in cell 
viability was observed at 500 μg/mL (corresponding to 500 ng/mL si -RNA). At 
250 ng/mL and 500 ng/mL of siRNA, SP-AP are significantly less toxic than 
LNCs (Figure 4A). On the basis of these results we selected siRNA doses of 
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100 and 250 ng for the initial  transfection studies in human MSCs with siCtl  and 
siREST (Figure 4B ). The RT-qPCR analysis revealed that the down -regulation 
of REST seems to be dose-dependent for SP-AP in contrast  to the LNCs, which 
showed an important effect  at  the lower concentrations assayed. Concretely,  for 
LNC NPs a 77 % decrease of REST expression was observed using a siREST 
dose of only 100 ng, providing higher REST inhibition levels t han the 
Oligofectamine® reagent that served as a positive control . A similar inhibition 
of REST expression of around 60% was observed with all  the nanosystems when 
a concentration of 250 ng/mL of siRNA was evaluated. So, we selected this 
siRNA dose for further experiments. These experiments include the 
quantification of the SCG10 or,  in other words,  the expression of one direct 
target of REST. As we can appreciate in Figure 4C ,  a slight increase of SCG10 
expression can be observed at 48 hrs after transfecti on when using both 
nanosystems at  250ng. The comparison of cell number 48 h after transfection 
with SP-AP, LNC and the Oligofectamine ® reagent revealed the same profile 
with the LNCs and Oligofectamine (53 % of cell death) ( Figure 4 D),  while with 
SP-AP we observed only a 25 % of cell death. These results confirmed that  SP -
AP NPs are less toxic for hMSC.  
 
To confirm the down regulation of gene expression provided by the 
different NPs we determined the protein knock -down by western blot analysis 36 
h after t ransfection at  a siRNA dose of 250 ng. In Figure 4E  we can appreciate 
that  REST protein was strongly inhibited with Oligofectamine ® and LNC 
confirming the RT-qPCR data.  
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Figure 4. Nanosystems cytotoxicity and siRNA dose selection for transfection studies: 
cell survival for the SP-AP and LNC formulations assayed in human mesenchymal stem cells at 
increasing nanosystem concentrations (100% survival corresponded to 200 000 cells) (A), showing 
that SP-AP nanoparticles are the formulation with a lower toxicity at 250 ng/ml of siRNA. 
Quantification of REST inhibition by RT-qPCR 48 h after transfection with SP-AP and LNC, 
using the Oligofectamine reagent as positive control and si-Control (siCtrl) as negative control 
with each nanocarriers (REST expression was normalized to REST expression in MSC with siCtrl) 
(B), showing that REST was equally inhibited by both nanocarriers at a siREST dose of 250 
ng/ml. Quantification of the overexpression of a direct target of REST (SCG10) (The SCG10 
expression was normalized to SCG10 expression in MSC with siCtrl) (C). Cell counting 48h after 
transfection with the different formulations at a siRNA dose of 250ng/ml (D). Quantification of 
REST protein by western blot 56 h after transfection with the different formulations (250 ng/mL of 
siRNAs) to confirm the efficacy of REST knock-down (siCtrl was used as negative control and 
actin served as protein loading control) (mean REST expression ± standard error of mean SEM 
(n=3)) (E). Statistical analysis performed with ANOVA 1W, post-hoc Tukey, * p=0.05 **p=0.005. 
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3.6 MESENCHYMAL STEM CELL DIFFERENTIATION   
In order to determine the efficacy of siREST associated to the different 
formulations to drive neuronal differentiation over time, we quantified the 
mRNA expression for REST, his direct target  (SCG10 ) and two neuronal 
markers: β3-Tubulin (β3 -TUB) an early neuronal marker and a more mature 
neuronal marker, neurofilament medium polypeptide (NFM). MSCs were 
maintained in expansion media and not in differentiation media to exclusively 
evaluate the effect  of REST inhibition.  
 
The inhibition of REST was maximal at 48 h increasing progressively 
until day 9 for all nanocarriers (Figure 5).  siREST-LNC was slightly more 
efficient compared to SP-AP over time and quite comparable to 
Oligofectamine® reagent used as positive control (Figure 5A),  even when no 
statistically significant differences can be found.  
On the other hand, although no real  change was observed in SCG10 
expression over-time (data not shown), the expression of β3 -TUB, which was 
already slightly expressed without treatment increased with both nanocarriers 
conveying siREST, particularly at D9 a fter transfection (until 160 % with 
siREST-LNC vs siCtrl-LNC), demonstrating the neuronal commitment induced 
by siREST. More interestingly,  NFM expression appeared at day 4 and was four 
times more expressed with siREST-LNC than with siCtl -LNC. Its expression 
was also higher in comparison with siREST SP-AP and oligofectamine at D9 
(Figure 5C).  
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Figure 5. Mesenchymal stem cells differentiation: Transfection of hMSC was performed with 
250 ng/ml of siControl and siREST. The expression of genes REST (A), β3 Tubulin, (B) NFM (C) 
was quantified at D0, D2, D4 and D9 after transfection with SP-AP, LNC and Oligofectamine®. 
Results were normalized with the expression of each gene with siControl. Results (n=3) are 
expressed as mean measure ± standard deviation. Statistical analysis performed with ANOVA 1W, 
post-hoc Tukey, * p=0.05 **p=0.005. 
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For brain regenerative medicine, embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPS) have been proposed for transplantation  therapy in 
human neuronal diseases.  But the use of ESC or iPS present the risk of over -
proliferation in the brain, in addition to the numerous ethical  problems [34,35]. 
Research studies need to focus on resolving the choice of cell  type. In order to 
preserve brain function in neuronal disorders, the graft of MSC is considered as 
an alternative therapeutic strategy. In this study we used. MSCs as they are 
easily accessible, al low autologous grafting and present neuroprotective and 
tissue repair properties due to their paracrine activity [36].  Moreover,  many 
clinical  trials have been engaged worldwide in the last  few years d emonstrating 
their safety [37]. The versati le differentiation potentialities of MSCs have been 
demonstrated not only for various cells of mesodermal ori gin, but also for 
ectodermal origin such as neural/neuronal cells under defined culture conditions 
[36,3,38]. For brain protection and repair it  is not necessary to obtain a mature 
neuronal phenotype establishing functional synapses with  the surrounding cells,  
as the grafted cells will mainly function via a paracrine effect.  However, they 
should present a neuronal -like phenotype to avoid any potential  proliferation or 
non-desired mesodermal phenotype. In this study we demonstrated that a 
transitory inhibition of siREST, without altering t heir genome, is enough to 
induce neuronal commitment in vitro  of MSCs. These pre-committed cells may 
thus be safely transplanted in the brain parenchyma and exert  their tissue repair 
function [39].   
Classically,  growth factors and cytokines are added in the media to drive 
the differentiation of stem cells to neuronal -like progenitors [36,40]. The 
incorporation of a RNA interference approach to existing bio -chemical based 
differentiation protocols may provide an alternative synergistic approach to 
enhance the efficiency of directing stem cell  fate. REST, a major negative 
regulator of several  neuronal genes,  thus repressing neuronal differentiation, is 
a target of  choice for this approach [10]. Moreover,  REST is differentially 
regulated throughout neuronal differentiation: highly expressed in embryonic 
stem cells, reduced in neural stem cells and neural progenitors [41] and largely 
4. DISCUSSION 
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absent in mature neurons [8]. The inhibition of REST to improve neuronal 
differentiation has been previously evaluated by a permanent expression of 
siREST in mouse MSCs using a lentivirus carrying siREST [7], or by combining 
its inhibit ion with a cocktail  of growth factors inducing neuronal differentiation 
in MSCs [42,43]. Our results are in agreement with these studies showing that 
the knock-down of REST induced a neuronal differentiation of MSCs [8].  
However,  in our hands, the sole inhibition of REST, without any other 
differentiation media, induced the neuronal commitment of hMSCs. Moreover, 
these NPs effectively delivered siREST to human stem cells which are not easily 
transfected and which generally show a high mortali ty rate [30,44].  The 
development of these biocompatible,  large - scale manufactured NP (SP-AP and 
LNC) delivering siREST to hMSCs and inducing their neuronal commitment 
allow us to envisage this approach in human neuroregenerati ve medicine.  
In this work, we have selected SP based nanocarriers on the basis of their 
demonstrated high in vivo  t ransfection efficacy, being even higher than that  
provided by adeno associated viruses (AAV2) vectors [20]. For effective 
association between SP NP and siRNA we incorporated to these nanocarriers’ 
two different cationic moietes: poly- l-arginine (PA) –  a synthetic polyamino 
acid - and ammonium pullulan (AP) - a cationised polysaccharide-. Although PA 
was initially selected for its  extensive use as a tool for gene delivery and due to 
its capacity for binding siRNA, we rejected PA based SP NP due to the result ing 
large particle size.  We chose pullulan, due to its non-immunogenic, non-toxic, 
non-carcinogenic and non-mutagenic nature. Moreover, pullulan has been 
proposed for regenerative medicine and as a nanocarrier component,  on the basis 
of its potential  in the fields of immunization, gene del ivery, and also in the 
design of imaging tools [45]. Although, pullulan is a promising polysaccharide 
for biomedical applications,  the inherent neutral charge of this sugar does not 
allow its association with genetic materials [45]. To avoid this limitation we 
modified this polysaccharide and cationised pullulan (AP) was used as a 
component to be incorporated in SP nanocarriers [32] to efficiently transfect 
hMSC. Our results show that using AP we can develop homogeneous 
populations of SP-AP, which can be easily chemically modified in order to 
afford either hydrophobized or cationized derivatives, the former with the 
abili ty to carry hydrophobic molecules,  and the latter showing high affi nity 
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towards DNA and RNA. SP-AP NP effectively associated with the siRNA 
showing a spherical morphology that seemed more compact than that  
corresponding to LNCs. We have now managed to ameliorate the EE by 
optimizing the formulation of SP -AP thus obtaining  70% of siRNA 
complexation.  
Concerning LNCs, these NPs were previously used for the encapsulation of 
lipophilic compounds, such as pacli taxel [46] and with MSCs as vehicles to 
deliver drugs into the brain [47]. LNCs were more recently adapted to the 
encapsulation of hydrophilic compounds (DNA, siRNA) [27,24,28] .  However, 
stability over time for siRNA-LNC was not satisfying, especially in terms of 
size.  In addit ion, due to their preparation requirements (phase inversion process 
at 75°C) the siRNA could be denatured during the as sociation to these 
nanocarriers. However, recent experiments confirm the possibility to optimize 
these parameters. The optimization of the process (patent ref: FR 4185991, 24 
sept 2014) and the diminution of the temperature down to 40°C led to LNCs 
with a long stable profile. Furthermore, the addition of siRNA after the phase 
inversion at 40°C avoids their denaturation, while preserving the characteristic 
positive charge on the surface of these nanocarriers.  Recently,  a new method of 
detection has been developed allowing the measure of the EE of siRNA -LNC 
which is now of 75%. 
In this work we decided to evaluate the potential  of transfection of the 
above described two types of nanosystems, which differ in the main properties 
affecting interaction with the bio logical media in general and with cells in 
particular (composition, part icle size and surface charge). S urface charges play 
an important role in the internalisation within the cell  [48].  Classically,  NPs 
have been designed with a positive surface charge to interact favourably with 
the negatively charged phospholipid components of the cell membrane, but this 
interaction causes membrane cell  damages and can be toxic [49]. This has been 
confirmed by this study, as the negatively charged span nanocarriers were only 
slightly toxic,  whereas the higher toxicity of LNCs can be explained by a better 
cell  interaction, internalisation and low cell  density.  Previous  studies using 
LNCs and cancer cells did not show a high toxicity [28,33] because cell lines 
are more resistant than hMSCs and the density of cancer cells was ten times 
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more concentrated than in this study. Moreover, in a previous publication, we 
showed that MSCs can be internalized with higher doses of LNCs without any 
toxicity in 1h [50] and not in 4h as recommended in Oligofectamine’s protocol.  
Indeed, in order to compare  these NPs with a commercial reagent, we used the 
same protocol recommended in the Oligofectamine ® guidelines. In addition, it  is  
noticeable that the negatively charged SP -AP nanocarriers were able to transfect 
hMSCs with the same efficacy than the positiv ely charged commercial reagent 
but avoiding cytotoxic events.  Until  recently,  the internalisation of negatively 
charged NPs was controversial.  Indeed, the internalisation of negatively charged 
NPs is believed to occur through nonspecific binding and cluste ring of the 
particles on cationic sites on the plasma membrane [51]. We here confirm the 
transfection ability of the negatively charged nanocarriers previously reported 
and discussed by our group [52].  Based on the literature we can suppose that 
SP-AP have the ability to undergo in ternalization via caveolae pathways, 
whereas cationic NPs such as LNC, commonly use the clathrin pathways [53–
55].  
The ability of a nanoparticulate system to stabilize various cargos from 
degradation and aggregation during storage represents a major advantage for its 
application. It  is quite well known that aqueous suspension of NPs have a 
tendency to aggregate during long term storage [56]. In order to avoid this,  we 
showed that the proposed NPs (LNC and SP-AP) could be frozen and stored 
while preserving the integrity of the associated siRNA.  Nonetheless the NPs 
stability and genetic material association can be negatively influ enced during 
freezing due to the ice crystals formed [57]. A suitable stabil izer,  usually sugars 
(glucose, trehalose,mannitol…) can be used in the formulation protecting the 
physico-chemical properties of NPs and genetic materials [58]. On this respect, 
we initially thought that  the pullulan -based nanocarrier might be frozen without 
cryoprotectant, due to its natural polysaccharidic nature,  but we found that the 
cationization treatment seems to modify the cryoprotecter capacity of pullulan. 
In any case, the siRNA-SP-AP were easily frozen with different sugars (glucose 
and trehalose), conserving intact the associated siRNA. On the contrary,  siRNA -
LNCs conserved their size and zeta -potential only with glucose. Moreover, the 
loading efficiency after freezing and storage in glucose decreased less than 10% 
allowing using practically the same concentration of NPs. The observed increase 
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of the zeta-potential with trehalose was probably due to the loss of a fraction of 
the siRNA. Such features represent an advantage of LNC and SP -AP as 
compared to commercial  transfection reagents.  Indeed, several  studies have 
demonstrated that lipoplexes (oligofectamine ®) are not stable in l iquid 
suspension for long-term storage [59,57], requiring their preparation 
immediately before use [60].  
The two NPs effectively delivered siREST in a transient manner in hMSCs 
inducing a marked inhibit ion of REST resulting in a  significant increase of 
neuronal markers (NFM and B3-TUB), which was maximal at day 9. This 
induced commitment of hMSCs to a neuronal phenotype in expansion media by 
an epigenetic approach using only synthetic Np is very encouraging. One other 
study reported the transfection of mouse neural progenitors with siREST and 
showed comparable levels of B3TUB expression at day 5 which was further 
increased at 2 weeks when a second transfection was performed to maintain 
REST inhibition [43]. However,  in the cited study they added retinoic acid to 
better induce a neural differentia tion. In  our study we also observed with LNC -
siREST a high increase of neurofilament levels, a mature neuronal marker, 
which was previously described for MSCs, but with a stable inhibition of REST 
using viral vectors [7]. The cell  differentiation process occurs throughout time 
and requires a number of sequential events that lead from one cell 
differentiation state to another. Each new step is facilitated by the previous one, 
and our results show that only a transient inhibition of REST is necessary to 
engage the cel ls towards a neuronal -like phenotype. However,  we didn’t observe 
any significant change of SCG10 expression which is a direct target of REST 
and correlates with neurite out -growth [61]. Studies showing neurite out -growth 
and morphological changes use a stable inh ibit ion of REST with lentivirus or 
shREST [7,42]  which is not our case.  The high level of NFM and B3 -TUB 
observed in this work with LNCs, could be explained by a slow release of 
siRNA from these NPs. Indeed, LNCs remain at least 7 days in MSCs [50] 
compared to commercial  reagents which are able to release siRNA during only 
3-5 days [62].  A very fast  siRNA delivery could saturate the endogenous 
microRNA (miRs) processing mechanisms or enter in competit ion with them. 
For example for the incorporation and retention in RNA-Induced Silencing 
Complex (RISC), which is essential for the silencing mechanism of both 
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interfering RNAs [63]. An over-expression of miR-124 increases neuronal (early 
and mature) markers in MSCs [64].  Furthermore, several  miRs, such as miR -
124, miR-132, miR-9, are essential  for the neuronal differentiation and are 
direct targets of REST [65].  In our study, we can suppose that  the slow release 
of siREST allows the cooperation with miRs to enhance the neuronal 
commitment.  However,  more experiments are necessarily to confirm this 
hypothesis.   
For regenerative medicine s tudies, we can envisage the possibility to elicit 
a synergistic effect  on neuronal commitment of stem cells by the combined 
delivery of a morphogen with a REST knock -down. This approach may be 
applied to SP-AP where siRNA is in the surface letting the core  free. It could 
also be envisaged with LNCs, which have the capacity to associate different 
morphogens, such as retinoic acid [66]. It could be a useful strategy for 
generating functional neurons for therapeutic purposes and drive differen tiation 
directly into the brain in vivo .  
 In this study we designed and optimized two novel nanocarriers capable of 
safely associating and delivering nucleic acids:  LNC and SP -AP. These systems 
were perfectly reproducible and could stand long t ime storage. We have 
demonstrated the capacity of both systems to knock -down REST and 
differentiate human stem cells towards a neuronal phenotype at  least  with the 
same efficacy of a commercial  reagent.  Therefore,  these nanocarriers can be 
considered as promising platforms for the development of effective and safe 
gene based regenerative approaches.  
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DISCUSSION  
The use of non-viral  siRNA delivery seems to be a promising strategy to 
induce a neuronal MSC differentiation prior to cell  transplantation for a 
regenerative and safe therapeutic strategy in HD.  In this study we showed that 
MSCs were only induced to neuronal progenitors with the inhibition of R EST 
which have already described in the l iterature  to play a role in the neurogenesis 
[163]. Indeed, REST is highly expressed in ES cells but it  is  down-regulated to 
a minimal level in neural stem cells and neural progenitors  [99,152]. After the 
differentiation of these progenitors, REST remains present in oligodendrocytes 
[164] and largely absent in neurons [152]. REST is crucial for maintaining the 
self-renewal of neural  progenitors and the ratio of neurons.  In deed the loss of 
REST in neural progenitors resulted in an acceleration of neuronal and 
oligodendrocyte differentiation [165]. We demonstrated the neuronal 
commitment with the significant apparit ion of β3-tubulin and NFM two days 
after transfection  with siREST. Nonetheless, siRNA cannot cross cell 
membranes without modifications or carriers.  So we have designed two 
nanocarriers LNC and SP-AP. In the design of such nanocarriers significant 
factors have been taking into account to overcome limitations associated with 
insufficient siRNA delivery, such as nanocarrier size,  surface charge, shape, 
chemical composition, and stabil ity of f  nanocarriers [166].  
In order to compare these nanosystems, we chose to trans fect the same 
quantity of siRNA, which corresponded to different quantities of nanoparticles . 
As siRNA-SP-AP were non toxic we can easily imagine to transfect MSC s for a 
longer time, repeat the transfection or increase the dose to further induce the 
neuronal differentiation of  these cells. These data are interesting because the 
major problem nowadays in transfection is the toxicity [167].  Indeed, MSCs are 
difficult to transfect without affecting their viability,  resulting in very low 
efficiencies of transfection with range from 2 to 35% [168].   
 While siRNA-LNC had a better capacity to transfect MSC, siRNA -SP-AP 
had the same efficacy as a commercial reagent without any toxicity.  The 
difference in terms of size (less than 100  nm for LNC, more than 100 nm for SP -
AP), the composit ion (both are lipid based nanocarriers but their components 
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are different), the surface charge (posit ive for siRNA-LNC, and negative for 
siRNA-SP-AP), as well  as the localization of siRNA (entrapped in liposomes for 
siRNA-LNC and on the surface for siRNA-SP-AP) could explain the results 
observed.  
Indeed, we can imagine that the positively charged siRNA-LNCs favorably 
interacted with the negatively charged phospholipid components o f the cell  
membrane, and that  this interaction caused membrane cell  damages probably 
explaining their  toxicity [169].  On the other hand, the negatively charged span 
nanocarriers were only slightly toxic . However, the better neuronal commitment 
with siREST-LNC can be explained by a better cell interaction and 
internalization demonstrated . Long-term conservation of those nanocarriers 
represents another advantage of LNC and SP -AP as compared to commercial 
transfection reagents or viral  vectors [170,171]. Therefore, these nanocarriers 
can be considered as promising platforms for the development of effective and 
safe gene based regenerative approaches.  
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Cell  therapy strategies using mesenchymal stem cells  in HD have been 
investigated for the last  20 years because MSCs secrete many tissue repair 
factors favorable for neuroprotection. The paracrine effect  of MSCs on HD was 
investigated by Lee et al. (2009) in cell culture experiments and in vivo  in two 
different rodent HD models [145].  Transplantation of MSCs into QA model of 
HD led to improvement in behavior and reduced the lesion volume. These 
beneficial effect  could be explain ed by the secretion of neurotrophic factors 
including BDNF, CNTF, nerve growth factor, insulin -l ike growth factor 1 and 
epidermal growth factor [147]. Then similar results were obtained in genetic 
models of HD, YAC128, N171-Q82Q and BACHD, demonstrat ing the interest of 
the use of mesenchymal stem cells in this disease [145,146,172] .  More 
importantly,  these studies reveal the stimulation of neuronal differentiation of 
endogenous neural  stem cells by MSCs due to the paracrine effect [146]. 
However,  the lacks of consistent neuronal differentiation of transplanted MSCs 
have limited their therapeutic efficacy in slowing the progression of HD -like 
symptoms in animal models of HD.  
MIAMI cells ,  which are a primitive and unique subpopulation of MSCs 
secreting more tissue repair factors than MSCs [94] seem to be a good 
alternative.  MIAMI cells,  have also been shown to have a neuroprotective effect  
after implantation in Parkinson’s disease and we have already demonstrated 
their neuronal commitment using a pre -treatment with EGF (epithelial growth 
factor) and bFGF (Basic fibroblast growth factor) which i nduced a decrease in 
the expression of stem cells markers such as Oct4A, Notch1 and Hes5 and 
increased markers of neural precursors such as Nestin and β3 -tubuline. 
Recently,  we showed in a rat  model of Parkinson's disease (PD), that  striatal 
implantation of EGF/bFGF pre-treated MIAMI cells had a neuroprotective effect 
leading to functional recovery. This effect was probably due to their secretion 
of GDNF, but also of VEGF as observed in an ex vivo  model of PD [173].  A 
similar neuroprotective effect was also observed for MIAMI cells and 
EGF/bFGF pre-treated MIAMI cells in an ex vivo  and in an in vivo  model of 
cerebral ischemia [174]. PAMs, which can stimulate the survival and 
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differentiation of cells, were combined to MIAMI cells to evaluate their effect  
in these models.  In both of the cerebral  ischemia models as well as in the ex 
vivo  model of PD, if the cells were adhered onto PAMs, an increased survival of 
the transported cells was observed after transplantation leading to an 
enhancement of their neuroprotective effects [84,174].  
In addit ion, MIAMI cells can be induced towards a neuronal phenotype in a 
NT-3 dependant manner and into a dopaminergic phenotype using specific 
inductors  (SHH and FGF8) in vitro .  Moreover,  a laminin substrate favours the 
neuronal differentiation of EGF/bFGF pre -treated MIAMI cells.  The 
implantation of the E/F MIAMI pre-committed towards the dopaminergic 
phenotype and adhered onto laminin-coated PAMs (LM-PAMs) releasing NT-3 
(LM-PAMs-NT-3) led to the protection/repair of the nigro -striatal  pathway and 
to functional recovery of the PD rats.  Moreover, the evaluation of these cells in 
the Parkinson organotypic slices, demonstrated the partial capacity of the E/F 
MIAMI cells adhered onto LM-PAM-NT-3 to differentiate into dopaminergic 
neurons [84]. Based on these promising results,  we wanted to investigate the 
effect of PAMs delivering BDNF as neuroprote ctive strategy in HD. Indeed, 
BDNF has neuroprotective properties and sustain the  physiological processes of 
normal intact  adult  brain [68] and more particularly for GABAergic striatal 
neurons.   
In this Chapter, we described a new strategy to induce neuronal 
commitment using siREST, media, growth factors to improve the differentiation. 
Inspired from the literature,  we tested different protocols to obtain GABAergic 
neurons.  The implantation of cells adhered to PAMs releasing BDNF then has 
been realized into organotypic brain slices modeling HD.  
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Clinical  trials using mesenchymal stem cells in the central  nervous syst em 
are now underway, and are focused on the safety of these cells. Marrow -isolated 
adult multi lineage inducible (MIAMI cells), a subpopulation of mesenchymal 
stem cells raises great interest for cell  therapy in Huntington's disease (HD) 
because they possess immunomodulatory properties and t issue repair capacities.  
Moreover,  they can be differentiated into neurons -like cells under specific 
conditions.  In this study, we investigated the role of REST inhibition in the 
GABAergic differentiation of MIAMI cells. We designed an in vitro protocol 
combining siRNA-nanocapsules,  substrates,  media,  and cytokines to push 
MIAMI to a GABAergic neuronal lineage. We further combined these cells to 
pharmacologically active microcarriers with a biomimetic coating of laminine 
and releasing brain derived neurotrophic factor (BDNF) to improve their 
survival and differentiation. These results show that siREST combined with 
media containing growth factors allowed differentiating MIAMI cells toward the 
neural lineage in vitro .  These data are supported by the slow delivery during 6 
days of siRNA on MIAMI cells due to the nanocapsules. The monitoring of gene 
expression of neuronal and GABAergic markers during the differentiation period 
suggested that GABAergic precursors and finally GAB Aergic neuronal-l ike cells 
were obtained. Importantly,  those cells did not lose their paracrine effect.  
Indeed, the secretion of VEGFa and BDNF are interesting for the 
neuroprotection in HD. Finally,  preliminary data shows that the combination of 
PAMs releasing BDNF improved the survival of cells and drives their 
differentiation. Ours results open the possibility toward cell  based therapy for 
HD. 
Tissue engineering, Huntington’s disease, siRNA, lipid nanocaspules, 
microcarriers.  
MSCs: Mesenchymal stem cells,  siRNA: Small  interfering RNA; NPs: 
Nanoparticles, DOPE: 1,2 -dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP: 
1,2-dioleoyl-3- trimethylammoniumpropane; LNCs: Lipid nanocapsules;  
REST/NRSF: (Repressor Element -1 silencing Transcription /Neuron-Restrictive 
Silencing Factor-1);  DARPP32: Dopamine- and cAMP-Regulated neuronal 
PhosphoProtein of 32kDa; GAD67: Glutamate decarboxylase 67; GSBS: Grey’s 
Salt  Balanced  Solution; HD: Huntington's disease;  HTT: Huntingtin gene; htt: 
protein huntingtin; MEM: minimum essential  medium eagle,  MSN: medium 
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spiny neurons;  NeuN: neuronal nuclei;  PBS: phosphate buffered saline;  PFA: 
paraformaldehyde; PAMs: pharmacologically active microcarriers.  
 Huntington's disease (HD) is a genetic disorder caused by the abnormal 
repetition of CAG in the Huntingtin gene which results in a pathological 
expansion of a polyglutamine (polyQ) tract in the huntingtin (htt)  protein [1,2]. 
This neurodegenerative disorder is characterized by aggregation of htt  in the 
brain,  and more specifically in the striatum [3]. The neuropathological  changes 
in HD are selective, and progressive degeneration of striatal GABAergic 
medium spiny projection neurons is observed [4]. Clinically,  this results in 
involuntary movements ,  cognitive impairment and psychiatric manifestations [5]. 
Typically,  HD eventually culminates in death around 15 –20 years after the onset 
of motor symptoms [6]. Currently,  there is no proven medical  therapy to 
alleviate the onset  or progression of Huntington's disease [7]. 
 Cell  replacement therapies in neurodegenerative diseases have been 
investigated for the last  30 years.  Although the procedures are theoretically 
feasible,  some limitations of the therapy sti ll  give cause for concern. At the 
beginning, fetal striatal tissues were transplanted to modify HD progression in 
humans [8,9]. Nonetheless, some favorable effects have been demonstrated but 
the difficulties in tissue availability and viability remain the major concern. 
Moreover, fetal tissue grafts do not alter the toxic effects of mutant huntingtin 
and has a high risk of rejection. There are also ethical arguments and concerns 
about contamination and heterogeneity of the tissues [10]. Recently,  embryonic 
and induced pluripotent stem cells (ESC and iPS) were shown to successfully 
differentiate into medium spiny neurons [11–13]. But after human ESC 
transplantation into rat brains, tumor formation was reported. Mesenchymal 
stem cells (MSCs),  have emerged for clinical transplantation studies due to their 
easy availability and their capacity to release neurotrophic factors and create a 
neuroprotective microenvironment [14]. Clinical trials using MSCs in the central 
nervous system (CNS) are now also underway for many neurological  disorders 
and have shown the feasibility of this approach [8,10]. Pre-clinical  studies with 
HD models  have shown improvement in behaviour and reduced the lesion 
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volume. These beneficial effects could be explained by the secretion of 
neurotrophic factors including BDNF, CNTF, nerve growth factor, insulin -like 
growth factor 1 and epidermal growth factor [15,16]. 
 The trans-differentiation of MSCs into a neural/neuronal lineage is  
possible but their functional maturity is  still  insufficient. The MSC must commit 
to a neuronal cell and maintain this phenotype and if possible try to  replace the 
damaged neurons. In  order to induce a neural/neuronal differentiation of MSCs 
the si lencing of  a master gene involved in neural specification named repressor 
element 1 (RE-1) silencing transcription factor (REST) [17,18] was obtained by a 
recombinant lentivirus. Nanoparticles have been formulated to associate and to 
efficiently and safely deliver siRNA both in vitro  and in vivo .  In particular, 
lipid nanocapsules (LNC) were recently modified to encapsulate the siRNA 
complexed to lipids into their core, thus protecting the siRNA from degradation. 
LNCs consisting of a lipid liquid core of triglycerides and a rigid shell of 
lecithin and PEG are formulated by a simple and easily industrialized solvent -
free process based on the phase inversion of an emulsion [19,20]. They have a 
high stability and are able to destabilize lysosome’s membranes by a proton 
sponge effect [21]. Recently,  we demonstrated that  LNCs  associated with siREST 
in MSCs were able to induce their neuronal commitment with a better efficiency 
than a commercial reagent (Publication submitted).  MIAMI cells,  which are a 
primitive and unique subpopulation of MSCs secreting more t issue repair factors 
than MSCs [22] seem to be a good alternative because they can be induced 
differentiated in all  three germ layers [23]. The demonstration of the capacity to 
MIAMI cells to differentiate into dopaminergic neurons presenting appropriate 
electrophysiological  properties after commitment with EGF (epithelial growth 
factor) and bFGF (Basic fibroblast growth factor) have already done [24]. 
 The major problem concerning cell  therapy studies is  the survival and 
engraftment of transplanted cells. Brain-derived neurotrophic factor (BDNF) is 
a neurotrophic factor that is widely used in brain regeneration applications due 
to its abil ity to support  the survival of neurons [25,26] and promote neuronal 
differentiation [27]. Moreover, in the case of HD, several studies demonstrated 
that the expression of BDNF is reduced in the patient 's brains. Promising results 
show that the BDNF supplementation increases the survival of en kephalin-
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immunoreactive striatal neurons, reduces striatal  interneuronal loss and 
improves motor function in HD animal models [28–30]. Despite these promising 
results, the therapeutic delivery of human BDNF has raised a number of 
problems related to its, short in vivo  half-l ife, poor availabil ity resulting from 
its degradation after injection, and an uncertain passage through the blood -brain 
barrier (BBB) when administered in the periphery [31].  The delivery of 
therapeutic proteins requires microcarriers able to protect them and control their 
release over-t ime. In this way, pharmacologically active microcarriers (PAMs) 
developed by our laboratory are carriers constituted of PLGA a “Food and Drug 
Administration” approved polymer [32] . PAMs are biodegradable and 
biocompatible PLGA microspheres covered with ECM molecules, t hus 
conveying cells on their biomimetic surface providing an adequate 3D 
microenvironment for the transplanted cells in vitro and in vivo. Recently,  
laminine substrate favours the neuronal differentiation of EGF/bFGF pre -treated 
MIAMI cells, and can integrate to the PAMs surface.  Moreover, the 
encapsulation of protein during the formulation allows a controlled release of 
bioactive molecules.  In this way, BDNF which is also involved in neuronal 
GABAergic differentiation and may maintain the differentiated p henotype of the 
transported cells could be encapsulated in PAMs. So PAMs represented an ideal 
microcarrier able to release active proteins [33–35] and providing a microcarrier 
for MIAMI cells due to their biomimetic surface [36].  
 In this study, we propose an innovative strategy for cell  replacement in 
HD. Inspired by recent studies; a simple protocol will be tested to differentiate 
MIAMI cells into GABAergic neurons -like.  In order,  to improve the 
commitment, the transfection of siREST will be performed with LNC. Finally, 
we plan to combine PAMs releasing BDNF with pre -committed MIAMI cells and 
graft  these complexes in an ex vivo  model of HD to evaluate their impact on the  
regeneration of the lesioned striatal GABAergic cells.  
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2.1 LNC FORMULATION 
2.1.1 Liposomes and lipoplexes 
For liposome preparation, a cationic lipid DOTAP (1,2 -dioleyl-3- 
trimethylammoniumpropane) (Avanti® Polar Lipids Inc.,  Alabaster, AL, USA), 
solubilized in chloroform, was weighted at a 1/1 molar ratio with the neutral 
lipid DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine) (Avanti® Polar 
Lipids Inc. , Alabaster, AL, USA) to obtain a final  concentration of 30 mM of 
cationic lipid.  After chloroform evaporation under vacuum, deionized water was 
added to rehydrate the lipid film overnight at  4 °C. It  was then was sonicated 
the day after during 30 min.  
Lipoplexes were formulated by simple equivolumar mix of siRNA and 
liposomes. This complex is characterized by the charge ratio [37], corresponding 
to a ratio of 5 between positive charge of lipids and negative charge of nucleic 
acids. .  
2.1.2 siRNA-LNC 
LNCs were formulated, as described previously [19] by mixing 20 % w/w 
Labrafac® WL 1349 (caprylic -capric acid triglycerides, Gatefossé S.A. Saint-
Priest,  France), 1.5 % w/w Lipoid S75 -3® (Lecithin, Ludwigshafen, Germany),  
17 % w/w Kolliphor® HS 15 ( Polyethylene glycol -15-Hydroxystearate HSPEG 
BASF, Ludwigshafen, Germany),  1.8 % w/w NaCl (Prolabo, Fontenay -sous-
Bois, France) and 59.8 % w/w water (obtained from a Milli -Q system, Millipore,  
Paris, France) together under magnetic stirring. Briefly,  three temperature 
cycles between 60 and 95°C were performed to obtain phase inversions (PI) of 
the emulsion. A subsequent rapid cooling and diluti on with ice cooled water 
(1:1.4) at  the last  phase inversion temperature (PIT) led to blank LNC 
formation.  
To obtain siRNA LNCs, the water introduced at  the last PIT was replaced 
by lipoplexes,  i .e. REST siRNA: (sense sequence: 5 ′ - CAG-AGU-UCA-CAG-
UGC-UAA-GAA -3′; Eurogentec, Seraing, Belgium) and control (scrambled) 
2. MATERIALS AND METHODS 
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siRNA (sense sequence: 5 ′- UCUACGAGGCACGAGACUU-3′;  Eurogentec, 
Seraing, Belgium) complexed with cationic liposomes in a defined charge ratio 
as described above.  
2.1.3 Fluorescent siRNA-LNC-DID 
 To formulate fluorescent siRNA LNCs, a solution of DiD (1,1′ -
dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate; em. = 644 nm; 
exc. = 665 nm) (Invitrogen, Cergy-Pontoise,  France) solubilized in acetone at  25 
mg/mL was prepared.  
DiD concentration was fixed at  200 µg/mL of LNC suspension or 
corresponding to 1,36 mg of DiD per grams of Labrafac ® [38]. The adequate 
volume of DiD I solubilized in acetone was incorporated in Labrafac ® and 
acetone was evaporated at room temperature. The formulat ion process was 
unchanged and formulation was stored at 4°C, protected from light. For siRNA 
fluorescent LNCs, a fluorescent Alexa488 siRNA (em. = 488 nm; exc. = 524 nm, 
Eurogentec) was used.  
2.2 CHARACTERIZATION OF SIRNA LNCS 
2.2.1 Size and Zeta potential 
 The size and zeta potential  of LNCs were measured by using the Dynamic 
Light Scattering (DLS) method using a Malvern Zetasizer® apparatus (Nano 
Series ZS, Malvern Instruments S.A.,  Worcestershire,  UK) at 25 °C, in 
triplicate, after dilution at a ratio of 1:200 wit h deionized water.  
2.2.2 Encapsulation efficiency  
 A spectrophotometric method was used to evaluate the encapsulation 
efficiency (EE %) as recently described [9].  Briefly,  siRNA LNCs were mixed 
with chloroform and water to separate hydrophilic and lipophilic components, 
respectively.  Sodium hydroxide was added to destabilize lipoplexes,  and finally 
absolute ethanol was added to destroy the LNCs. After two cent rifugations, four 
fractions were obtained: free siRNA, free lipoplexes,  encapsulated siRNA and 
encapsulated lipoplexes into LNCs. To determine the concentration of siRNA, 
the optical  density of each sample was read at  260 nm (UV -2600, Shimadzu, 
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Noisiel , France) in triplicate conditions and compared to a range curve to 
determine the ratio of the encapsulated siRNA per total siRNA detected in the 
formulation (EE%).  
2.3 CELL CULTURE 
2.3.1 MIAMI E/F  
 MIAMI cells were expanded in vitro from passage 4 -5 on fibronectin 
(Sigma Aldrich, St  Louis, USA) coated flasks at  125 cells/cm² in low oxygen 
tension in Dulbecco's Modified Eagle Medium -low glucose (DMEM, Gibco, Life 
Technologies,  Paisley, UK), supplemented with 3% of serum, 30µg/ml ascorbic 
acid and a mixture of lipids (working concentration of 510nM lipoic, 70nM 
linolenic and 150nM linoleic acid,  al l  from Sigma). Then a 10 day treatment 
with an addition of 20ng/mL of EGF and 20ng/mL of bFGF (both from R&D 
systems, Lil le, France) and 5µg/ml of Heparin (Sigma Aldrich, St -Louis,  USA) 
is conducted to enhance neuronal specification. Cells were fed every 3 days by 
changing half of the medium, and split every 5 days.  
2.4  MIAMI CELL DIFFERENTIATION 
2.4.1 MIAMI cell transfection 
 MIAMI E/F cells were seeded at 3000 cells per cm² coated with  laminine 
(2µg/cm², Sigma Aldrich, St -Louis, USA). Experiments were performed in 
MIAMI Opti-MEM®  media (Life technologies, France).  SiRNA -LNCs were 
incubated with cells at 37 °C in a humidified atmosphere with 5 % CO 2  for 4h 
before serum addition. Cells were harvested at appropriate times after culture 
and assayed for mRNA expression levels by RT -qPCR or protein expression by 
immunofluorescence.  
2.4.2 LNC cell time retention 
 MIAMI cells were seeded on glass at  3000 cells per cm² coated with 
laminine (2µg/cm², Sigma Aldrich, St-Louis, USA). Experiments were 
performed in MIAMI Opti -MEM®  media (Life technologies,  France).  SiRNA 
fluorescent LNC and 100 n LysoTracker Red (Molecular Probes,  Eugene, OR, 
U.S.A.) were incubated with cells at  37 °C in a humidified atmosphe re with 5 % 
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CO2  for 4h before phosphate buffered saline (PBS) washing and 
paraformaldehyde fixation or serum addition. After washing, cells were 
visualized from day 0 to day 6 post transfection using a fluorescence confocal 
multispectral  imaging, FCSI (Lei ca TCS SP8, France).  
2.4.3 MIAMI cell neuronal differentiation 
 MIAMI cells were seeded at  3000 cells per cm² coated with laminine 
(2µg/cm², Sigma Aldrich, St -Louis, USA). Then, different conditions were 
tested to obtain the best  GABAergic differentiation proto col (Table 1).  Briefly, 
the differentiation was performed in two steps.  In the first step, allow to obtain 
LGE: DMEM/F12 (Glutamax, Gibco, Life Technologies, Paisley, UK) was 
supplemented with N2 (both from Gibco, Life Technologies, Paisley, UK), and 
200 ng/ml of Sonic hedgehog (SHH, Peprotech, Rocky Hill, USA) during 
fourteen days.  In the second step, for GABAergic differentiation: Neurobasal  
media (Neurobasal,  Gibco, Life Technologies,  Paisley, UK) was supplemented 
with 10µM of valproic acid (Sigma Aldrich, St-Louis, USA) and 30ng/ml of 
BDNF (Peprotech, Rocky Hill,  USA) during fourteen days or followed by BDNF 
treatment during 7 days. Length and surface area were quantified using MetaVue 
software®.  6 pictures from each condition (24 in total) were performe d with X10 
objective and used to determine total area and length. Only cells responding to 
the treatment (with neurite like structures) were evaluated in this experiment.  
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Media DMEM-
F12 
Neurobasal N2 B27 SHH VPA BDNF 
STEP 1: 
Medium 1 X  15%  200ng/ml   
STEP 2: 
Medium 1: 
VPA + BDNF 
 X  2%  10µM 30ng/mL 
Medium 2: 
VPA 
 X  2%  10 µM  
Medium3: 
BDNF 
 X  2%   30ng/mL 
Table 1. Different media tested for the differentiation of MIAMI cells 
2.5  REVERSE TRANSCRIPTION AND REAL TIME QUANTITATIVE PCR 
 The following experiments were performed following the guidelines of the 
PACEM core facil i ty ("Plate -forme d'Analyse Cellulaire et Moléculaire”, 
Angers,  France).  Sense and antisense primer pairs (Eurofins MWG Operon, 
Ebersberg, Germany) were mixed in water at  a final  concentrat ion of 5 µM 
(Table 2).  Total  RNA of cells was extracted, purified using RNeasyMicrokit 
(Qiagen, Courtaboeuf,  France), treated with DNase (10 U DNase I/µg total 
RNA) and its integrity verified on Experion RNA StdSens chip (Bio -Rad). RNA 
concentrations determined with a ND-2000 NanoDrop (Thermo Fisher Scientific,  
Wilmington, Delaware USA) were used for normalization of the Reverse 
Transcription (RT). First  strand complementary DNA (cDNA) synthesis was 
performed with a SuperScriptTM II Reverse Transcriptase (I nvitrogen),  in 
combination with random hexamers, according to the manufacturer‟s 
instructions.  cDNAs were then purified (Qiaquick PCR purification kit,  Qiagen, 
Courtaboeuf, France) and eluted in 40 µL water (Gibco). 3ng of cDNA was 
mixed with MaximaTM SYBR Green qPCR Master Mix (Fermentas) and primer 
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mix (0.3 µM) in a final volume of 10µL. Amplification was carried out on 
LightCycler 480 (Roche) with a first  denaturation step at  95°C for 10 min and 
40 cycles of 95°C for 15 s, 60°C for 30 s. After amplificat ion, a melting curve 
of the products determined the specificity of the primers for the targeted genes. 
Two housekeeping genes,  Glyceraldehyde-3- phosphate dehydrogenase (Gapdh), 
Beta actin (Actb), were tested for normalization. The GeNormTM freeware 
(http://medgen.ugent.be/-jvdesomp/genorm/) was used to determine that GAPDH 
and ACTB were the two most stable housekeeping genes. The relative transcript  
quantity (Q) was determined by the delta Cq method Q=E(Cq min in all  the 
samples tested - Cq of the sample),  where E=2 if the primer efficiency=100%. It 
was normalized using the multiple normalization method described in 
Vandesompele et  al  (Vandesompele et al. ,  2002). Q normalized=Q/(geometric 
mean of the three most stable housekeeping genes Q).  The 2( -Ct) method was 
retained, using housekeeping genes and gene of interest (Livak and Schmittgen, 
2001) tested on control sample and treated sample.  
 
Gene Full name NM accession 
number 
sequences 
GAPDH glyceraldehyde-3-
phosphate dehydrogenase 
NM_001289745.1 Fwd: CAAAAGGGTCATCATCTCTGC 
Rev: AGTTGTCATGGATGACCTTGG 
ACTB Actin NM_001101.3 Fwd: CCAGATCATGTTTGAGACCT 
Rev: GGCATACCCCTCGTAGAT 
β3-TUB Tubulin beta 3 class III NM_006086 Fwd: CCAGTATGAGGGAGATCG 
Rev: CACGTACTTGTGAGAAGAGG 
REST RE1-silencing transcription 
factor 
NM_001193508.1 Fwd: ACTCATACAGGAGAACGCC 
Rev: GTGAACCTGTCTTGCATGG 
SCG10 stathmin 2 NM_001199214.1 Fwd: TGTCACTGATCTGCTCTTGC 
Rev: AGAAGCTAAAGTTCGTGGGG 
NFM neurofilament, medium 
polypeptide (Variant 1) 
NM_005382.2 Fwd: GACCTCAGCAGCTACCAG 
Rev: TAGTCTCTTCACCCTCCAG 
BDNF Brain-derived neurotrophic 
factor  
NM_001143816 Fwd: CAAACATCCGAGGACAAGG 
Rev: TACTGAGCATCACCCTGG 
TrkB Tropomyosin receptor 
kinase B 
NM_006180 Fwd:TTGTCTGAACTGATCCTGGTGGGC 
Rev: AGGTTAGGTGCGGCCAGATTTGC  
GAD67 Glutamic Acid 
Decarboxylase 67 
NM_000817 Fwd: GGTGGCTCCAAAAATCAAAGC 
Rev: CAATGTCAGACTGGGTAGCG 
DARPP32 Dopamine- and cAMP-
regulated phosphoprotein, 
NM_181505 Fwd: GAGAGCCTCAGGAGAGGG 
Rev:CTCATTCAAATTGCTGATAGACTGC 
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Mr 32 kDa 
Pax6 Paired box 6 NM_000280 Fwd: TTTCAGCACCAGTGTCTACC 
Rev: TAGGTATCATAACTCCGCCC 
Oct3/4 Octamer-binding 
transcription factor 4 
NM_203289 Fwd: GGAAGGTATTCAGCCAAACG  
Rev: GTTCGCTTTCTCTTTCGGG 
Nanog Homeobox Transcription 
Factor Nanog 
NM_024865 Fwd: GATCCAGCTTGTCCCCAAAG 
Rev: GCTGTCCTGAATAAGCAGATCC 
Col2A Collagen type II, alpha 1 NM_001844 Fwd: GAGGGGATCGTGGTGACAAAGG 
Rev: TTGCATTACTCCCAACTGGGCG 
FABP4 Fatty acid binding protein 
4, adipocyte 
NM_001442 Fwd: ACAGCACCCTCCTGAAAACTGC 
Rev: TGTTAGGTTTGGCCATGCCAGC 
Runx2 Runt related transcription 
factor2 
NM_001015051 Fwd: ACAAATCCTCCCCAAGTAGC 
Rev: GACACCTACTCTCATACTGGG 
Dlx2 Distal-less homeobox 2 NM_004405 Fwd: GACCTTGAGCCTGAAATTCG 
Rev: ACCTGAGTCTGGGTGAGG 
VEGFA Vascular endothelial 
growth factor A 
NM_001204384 Fwd: CAGCGCAGCTACTGCCATCCA 
Rev: CAGTGGGCACACACTCCAGGC 
NGF Nerve growth factor NM_002506 Qiagen, ref #QT00043330 
GDNF Glial cell line-derived 
neurotrophic factor 
NM_01167.2 Qiagen, ref #QT00001589 
Table 2. Sequence of primers validated in RT-qPCR 
2.6 IMMUNOFLUORESCENCE 
 After treatment,  cells were fixed by addition of 1ml of ice cold 4% 
paraformaldehide (PFA, Sigma, St Louis, USA) in PBS (Lonza, Verviers,  
Belgium) pH 7.4 during 15min. Then cells were washed in DPBS three ti mes. 
Non-specific sites were blocked with DPBS, Triton 0.1% (PBS -T, Triton X-100, 
Sigma, St Louis,  USA), bovine serum albumin 4% (BSA, Fraction V, PAA Lab, 
Austria),  normal goat serum 10% (NGS, Sigma, St Louis,  USA) during 45 min at 
RT. A mouse anti  human β3-tubulin (2ng/ml, clone SDL.3D10, Sigma, St Louis, 
USA), a mouse anti  human neurofilament medium (NFM, 1:50, clone NN18, 
Sigma Aldrich, USA), a monoclonal rabbit anti human dopamine - and cAMP-
regulated neuronal phosphoprotein (DARPP32, 1:400, clone EP721 Y, Abcam, 
Paris, France),  A mouse anti glutamic acid decarboxylase -67 antibody (GAD67, 
5µg/ml, clone 1G10.2, Millipore SA, Guyancourt , France), were used to 
characterize cell differentiation. Cells were incubated overnight with the 
primary antibody diluted  in PBS-T, BSA 4% at 4°C. After washes, slices were 
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incubated with the biotinylated mouse or rabbit  secondary antibody (7,5 µg/ml, 
Vector Laboratories,  Burlingame, USA) for 1 hour at RT. Then slices were 
washed and incubated with Streptavidin Fluoroprobes R488 or R547H 
(Interchim, Montluçon, France) diluted 1:200 in PBS for 1 hour before mounting 
with a fluorescent mounting medium. They were observed observed with a 
fluorescence microscope (Axioscop, Carl Zeiss, LePecq, France).  
2.7 PHARMACOLOGICALLY ACTIVE MICROSPHERES 
2.7.1 BDNF microspheres preparation 
PLGA-P188-PLGA, which was synthesized by IBMM -CRBA CNRS UMR 
5247 (Montpell ier,  France). BDNF Microspheres were prepared using a 
solid/oil/water (s/o/w) emulsion solvent evaporation –extraction process 
previously described [39–41] .  Protein loading was 1 μg of protein and 5 μg of 
human serum albumin (HSA)/mg of MS. BDNF and HSA were nano -precipitated 
separately using a process previously described [39]  but adapted to lyophilized 
BDNF. Briefly the protein powder was first  dissolved in a non -buffered aqueous 
solution of sodium chloride containing poloxamer and this solution was 
introduced into glycofurol. After 30 min at 4 °C, the nanoprecipitated proteins 
were recovered by centrifugation and dispersed in the organic phase (670 μL of 
50 mg PLGA–P188–PLGA dissolved in a 3:1 methylene chloride:acetone 
solution). The suspension was then emulsified in a poly(vinyl alcohol) aqueous 
solution (30 mL, 6% w/v at 1 °C) and mechanically stirred at 995 rpm for 1 min. 
After addition of 33 mL of deionized water and stirring for 10 min, the emulsion 
was added to 167 mL deionized water and stirred for 20 min to extract the 
organic solvent. Finally,  the MS were filtered on a 5 μm High Volume Low 
Pressure (HVLP) type filter, washed and freeze -dried. MS without protein were 
prepared following the same process, and called blank -MS or blank-PAMs when 
covered with laminin.  
2.7.2 LM-PAM preparation & characterization 
 PLGA-P188-PLGA MS were coated with LM and poly-D-Lysine (PDL). 
Coating solutions were prepared in Dulbecco's Phosphate-Buffered Saline 
DPBS. The concentration of the coating molecules was 6 μg/mL of LM and 9 
μg/mL of PDL (corresponding to a 40:60 ratio of LM:PDL). 5 mg of MS was 
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suspended in DPBS and sonicated until full dispersion of the MS. The solution 
containing PDL and LM molecules was mixed to the MS suspension (final 
volume: 10 mL) and placed under rotation at 15 rpm at 37 °C during 1h30min. 
After coating, LM-PAMs were washed 3 times in steri le distilled water 
containing 1% antibiotic, lyophilized and kept at−20 °C. Each tube was covered 
with sigmacote® to prevent product loss on the tu be walls. The laminine surface 
was characterized by confocal microscopy after LM immunostaining. 
Lyophilized PAMs (1 mg) were suspended in DPBS containing 4% bovine serum 
albumin (BSA), 0.2% Tween 20 and incubated for 30 min at  room temperature 
(Rt) under 15 rpm stirring. Samples were then washed three times with DPBS 
and centrifuged (9000 g, 5 min). Anti -LM mouse monoclonal antibody (100 
μg/mL in DPBSBT) was incubated at 37 °C for 1.5 h under rotation. Samples 
were then washed 4 times before incubation with biotinylated anti -mouse IgG 
antibody (2.5 μg/mL in DPBS) for 1 h, at RT, under rotation. After three 
washes,  samples were incubated wi th streptavidin–fluoroprobe 547 (1:500 in 
DPBS) at RT, for 40 min, under rotation. Samples were observed under confocal 
microscopy (Olympus FluoviewTM TU 300, Rungis,  France).  Three independent 
experiments were performed and every condition was observed in  triplicate.  
2.7.3 Formation of PAM-cell complexes 
 MIAMI differentiated cells were detached and pelleted at 295g for 10 min. 
Pellets were resuspended in culture medium supplemented with 3% FBS (Lonza, 
Verviers,  Belgium). Lyophilized microspheres (0.50mg) were r esuspended in 
coated eppendorf tubes (Sigmacote, Sigma, St Louis, USA) containing DMEM -
F12 (Gibco, Life Technologies, Paisley, UK), for 15 min. PAM suspension was 
mixed with 0.5mL of cell  suspension (2.5x105 cells/0.50 mg PAMs). The 
mixture was then gently flushed and plated in 1.9 cm2 Costar ultra -low 
adherence plate (Corning, Avon, France).  Plates were incubated at  37°C during 
4h for to allow cell  attachment on PAM surface.  PAMs/cell aggregates were 
pelleted by centrifugation at 200g for 2 min. Cell  adhes ion to PAM surface was 
assessed by microscopic observation and cells adhered to PAMs were quantified 
using the Cyquant cell proliferation assay (CyQuant Cell proliferation Assay 
kit, Invitrogen). Complexes were further studied using light and fluorescence 
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microscopy and scanning electron microscopy. Samples were prepared for 
scanning electron microscopy analysis as previously described [34].  
2.8 INJECTION OF PAMS-CELLS IN ORGANOTYPIC SLICES 
2.8.1 Organotypic slices preparation  
 Six to eight days Sprague Dawley rat  pups were sacrificed after 
anaesthetic and brains were removed. Cerebral hemispheres were separated and 
glued on the vibratome plate on their central side. 400µm coronal slices were 
obtained using a vibratome (motorized vibroslice,  Campben instruments, 
Loughborough, England) °. Cortico -striatal slices were then dived into Grey‟s 
Salt Balanced Solution (Sigma Aldrich) supplemented with 6,5mg/L of glucose 
(Sigma Aldrich, St -Louis,  USA) and antibiotics (Sigma Aldrich, St  Louis,  USA). 
Three to four slices per hemisphere were next transferred to 30 mm diameter 
semi-porous membrane inserts (Mill icell -CM, Millipore, Bedford, MA, USA) 
within a 6-well  plate and put in culture at  37ºC, 5% CO2. From day 0 to day 3,  a 
serum containing medium was used: 50% MEM (Minimum Ess ential Medium 
Eagle, Sigma Aldrich),  25% Hank‟s (Hank‟s Balanced Salt  Solution, Sigma 
Aldrich), 25% of horse serum (decomplemented horse serum, Gibco), 6.5mg/ml 
of glucose, 1 mM of L-glutamine (Sigma Aldrich, St -Louis, USA) and 
antibiotics (Sigma Aldrich, St-Louis, USA). From day 3 to day 16, a serum free 
medium was used: neurobasal  medium (Gibco) supplemented with 6.5mg/L of 
glucose, 1mM of -glutamine (Sigma Aldrich, St Louis, USA), B27 supplements 
(50x, B27 supplements, Gibco) and antibiotics (Sigma Aldri ch, St-Louis, USA) 
this media was changed every two days.  
2.8.2 Injection of stem cell/ PAM complexes into organotypic slices  
 Five days after organotypic sl ice preparation, treatments were injected 
into the striatum using a 22-gauge needle (Hamilton, Bonaduz, Switzerland) 
connected to a micromanipulator. Three experimental  groups were tested: (1) 
MIAMI siREST SHH cells,  (2) MIAMI siREST SHH LM -PAM, and (3) MIAMI 
siREST SHH LM-PAM-BDNF. Total injection volume consisted of 4µl of 
culture media containing approxim ately 100.000 cells alone or adhered to 0.2 
mg of PAMs. Injections were done at 0.5µl/minute infusion rate. The needle was 
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left in place for 5 min to avoid the cells being expelled from the organotypic 
slices.  
2.8.3 Histological study 
 Seven days after injection , organotypic slices were fixed by addition of 
5ml of ice cold 4% PFA (Sigma, St Louis,  USA) in PBS (Lonza, Verviers, 
Belgium) pH 7.4 during 2 hours.  Then slices were washed in PBS three t imes. 
Nonspecific sites were blocked with PBS, Triton 1% (PBS -T, Triton X-100, 
Sigma, St Louis, USA), BSA 4% (Fraction V, PAA Lab, Austria), NGS 10% 
(Sigma, St Louis ,  USA) during 4 hours at RT under agitation (expect for CD31 
study, in this case, 0.05% Triton is employed).  
MIAMI cells were detected using a mouse anti -human mitochondria 
antibody (10ng/ml, clone MTCO2, Abcam, Paris, France). A monoclonal rabbit 
anti  human dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP32, 
1:400, clone EP721Y, Abcam, Paris,  France),  antibody was used to characterize 
grafted cells differentiation. Slices were incubated 48h with the primary 
antibody diluted in PBS-T, BSA 4% at 4°C. After washes,  slices were incubated 
with the corresponding biotinylated mouse or biotinylated rabbit  secondary 
antibody (7.5 µg/ml,  Vector Laboratories, B urlingame, USA). Then slices were 
washed and incubated with Streptavidin Fluoroprobes R488 or R547H 
(Interchim, Montluçon, France) diluted 1:200 in PBS for 2 hours before 
mounting with a fluorescent mounting medium. Isotypic controls and/or 
omission of the primary antibody were performed to assess the specificity of the 
immunostainings. Slices were observed with a fluorescence microscope 
(Axioscop, Carl Zeiss, LePecq, France).  
3.1 CELLULAR UPTAKE AND LNC TIME RETENTION IN MIAMI CELLS 
 SiRNA delivery and  cell time retention of LNCs was studied on MIAMI 
E/F cells by fluorescence confocal multispectral  imaging, FCSI (Figure 1A).  In 
order to follow both the LNC and the siRNA distribution, double -labelled LNCs 
were generated by loading them with the DiD and w ith the siRNA-Alexa488. 
3. RESULTS 
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Lysosomes were observed with the lyzotracker. Directly,  after transfection, 
named Day 0, we observed a varying number of LNCs in the majority of MIAMI 
E/F cells (Figure 1A and 1B). The heterogeneity of LNC distribution in each 
cell disappeared at Day 2. (Figure 1A) .  The number of positive cells for the 
siRNA decreased progressively but we still  observed 12% of positive cells at 
day 6 (Figure 1B) .  In general , there are more DiD tagged LNCs in the cells than 
fluorescent siRNA as indeed the encapsulation efficiency of siRNA -REST in 
LNC’s is around 50%. Although many LNCs co -localized with lysosomes, we 
clearly observed that the siRNA did not co -localize, suggesting that  it  was 
released.  
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Figure 1. Cellular uptake and retention time of siRNA-LNC in MIAMI E/F cells. After 4 
hours’ incubation, confocal microscopy was performed on MIAMI cells with siRNA LNCs. Cells 
werefixed on glass slide and nucleus staining was performed with DAPI (blue). Double fluorescent 
probes were used to follow siRNA LNCs: lipophilic DiD (yellow) and Alexa488 siRNA (green). 
Analysis confirmed the internalization of siRNA LNCs and it presence until day 6 (A) Positif 
siRNA cells were counting using imageJ. 6 images per conditions in X10 objective were selected 
(B) Scale bar represents 10µm.  
 
CHAPTER III 
158 
 
3.2 MIAMI CELL NEURONAL COMMITMENT 
 We previously described MIAMI E/F as neural precursors [24] . In order to 
obtain neuronal precursors of the lateral ganglionic eminence  like (LGE-like) 
that later give rise to the striatal GABAergic neurons, we used SHH as an 
inductor (Figure 2A).  To investigate the role of REST silencing to better induce 
the neuronal commitment of MIAMI E/F, we transfected siREST and  a siRNA 
control, named siCtl.  Fourteen days after treatment, most of the MIAMI-siREST 
SHH cells exhibited a neuron-like morphological change, with long neurite -like 
structures (Figure 2B). The density of cells dur ing the first step is very 
important and if the confluence is superior to 30%, over -proliferation is 
observed (data not shown). No obvious morphological changes were observed in 
MIAMI-siCtl-SHH under these same culture conditions. There was a tendency to 
increase the cell  surface (Figure 2C),  and the majority of cells presented a total  
length of around 600µm (Figure 2C)  due to the long neurite -like structures. 
Thirty percent inhibition of mRNA of REST was still  observed fourteen days 
after transfection compared with siCtl  expression (Figure 2D).  
 LGE progenitors express Gsx2, Dlx2, and Meis2 and to a lesser degree 
Pax6. To further characterize these cells, we performed RT -PCR analysis to 
detect the decrease of embryonic markers and the increase of neural/neu ronal 
differentiation markers. The expression of pluripotent markers has been 
quantified and some variations on results are observed (supplementary data).  
The expression of Pax6 involved during the neurogenesis decreased slightly 
fourteen days after the treatment as described in the literature (Figure 2D).  
Dlx2, a major gene, characteristic from LGE progenitors is  strongly expressed 
in MIAMI E/F cells and decreased at the end of the commitment (Figure 2D).  
β3-tubulin protein increased during the differentia tion with siREST further 
suggesting obtaining LGE-like progenitors (Figure 2E).  Furthermore, the 
immunofluorescence of neurofilament (NFM) protein revealed a high expression 
in MIAMI-siREST-SHH, which was not detected in MIAMI E/F cells (Figure 
2E).   
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Figure 2. Specification of MIAMI siREST committed into LGE-like progenitors. For neuronal 
commitment, a simple protocol has been designed using sonic Hedgehog protein. Transfection of 
MIAMI E/F was performed with 250 ng/ml of siControl and siREST-LNCs (A). During the 
culture period of 14 days, MIAMI-siCtl-SHH cells show very few morphological changes. In 
contrast, MIAMI-siREST-SHH stretched out short neurite at 7 days, while at 14 days later, almost 
all of the MIAMI-siREST-SHH exhibited a neuron-like morphology (B). The quantification of 
surface area and the measure of cell lenght was performed fourteen days after transfection for 
MIAMI E/F, MIAMI-siCtl-SHH and MIAMI-siREST-SHH (C) the characterization of the 
differentiation was realized by RT-qPCR and immunofluorescence. The expression of genes 
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REST, Pax6, Dlx2 (D), was quantified fourteen days after the commitment. Results were 
expressed in Fold increase. Results (n=3) are expressed as mean measure ± standard deviation. In 
vitro immunofluorescence against β3-tubulin and NFM on MIAMI E/F, MIAMI-siCtl-SHH and 
MIAMI-siREST-SHH (F) Scale bar = 50 μm. 
3.3  MIAMI CELL DIFFERENTIATION TO A GABAERGIC LIKE PHENOTYPE 
 The LGE-like progenitors were further exposed to Valproic acid (VPA) 
for 7 days and then BDNF until day 28 (named VPA/ BDNF) or to a mix of VPA 
and BDNF for 15 days (named VPA+BDNF) (Figure 3A).  At this step, no 
further morphological change was observed. However, siREST increased the 
number of cells responding to the second protocol using VPA (10µM) and BDNF 
(30ng/mL) in the same time treatment (Figure 3B) .  In other words, 45,09% +/ -
3,4 of cells presented neurite-l ike structures with siCtl  and 59,63% +/- 10,4 with 
siREST. At the end of the differentiation, only a slight expression of Dlx2 or 
REST was detected by RT-qPCR (Supplementary data). A high expression of 
β3-tubulin was observed in all conditions.  Importantly, the majority of the 
GABA-like cells were positive for dopamine- and cAMP-regulated phos- 
phoprotein of 32 kDa (DARPP32) and glutamate decarboxylase (67kDA), a 
feature of MSNs. These two proteins appeared when VPA and BDNF were in 
combination (Figure 3C).  With siREST and VPA/BDNF; β3-tubulin, GAD67, 
DARPP32 and GAT1 protein were detected (Figure 3D)  suggesting a 
GABAergic like differentiation enhanced by siREST.  
 MIAMI E/F cells are very interesting because they secrete many t issue 
repair factors [24]. The expression of mRNA in vitro  allowed detecting which 
factors may be secreted by cells alone. In all  cases,  VEGFa, BDNF and NGF 
were expressed demonstrating the potential  neuroprotective effect  of MIAMI 
differentiated cells in the HD (Figure 3C).   Nonetheless, the mRNA of those 
factors were highly present in MIAMI-siREST-VPA+BDNF when compared with 
the other conditions; two-fold higher than MIAMI-siREST-VPA/BDNF. These 
results need to be confirmed.  
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Figure 3. Differentiation and Characterization of GABA neurons. Schematic procedure of 
GABAergic differentiation (A). The quantification of cell length superior to 600µm considered as 
positive response to the treatment, was performed fourteen days after the differentiation for 
MIAMI-siCtl-VPA/BDNF, MIAMI-siRest-VPA/BDNF, MIAMI-siCtl-VPA+BDNF, and MIAMI-
siREST-VPA+BDNF (B). The characterization of the differentiation was realized by RT-qPCR 
and immunofluorescence. The expression of genes Dlx2, REST, β3 Tubulin, DARPP32 and 
GAD67 (C) was quantified at the end of the differentiation Results (n=1).  Cytokines expression 
profile of differentiated cells was also determined by RTqPCR of cells alone at the end of the 
differentiation (C). For both cells VEGFA mRNA is the most expressed followed by BDNF 
mRNA and NGF. Results were in 2^-Delta Ct.  Results (n=1). In vitro immunofluorescence against 
β3-tubulin, DARPP32, GAD67, GAT1 on MIAMI-siREST-VPA+BDNF (D) was performed. 
Scale bar = 50 μm.  
3.4 CARACTERIZATION OF PAM/CELLS COMPLEXES 
 The particle size of PAMs measured using a Multisizer Coulter Counter 
was around 30µm (data not shown). Observation of the microspheres and PAMs 
by bright field microscopy and with scanning electron microscope was 
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performed to ensure the quality of the formulation (Figure 4A and 4C) .  
Microspheres were perfectly spherical  with a smooth surface,  and no pores on 
their surface (Figure 4C).  During the commitment and the differentiation, no 
serum and no ant ibiotics were used. In order to respect these conditions 
different media for cell adherence were tested with MIAMI SHH cells  (Figure 
4A).  Unfortunately,  we observed a high proportion of cells adhered to the 
plastic or cells alone with B27 and N2 media,  whi ch is not the case for 3% of 
serum (Figure 4A).  PAMs with LM surface allowed MIAMI SHH cells 
adherence on their surface in 4hours (Figure 4B and 4D). The percentage of 
cells adhered onto PAMs' surface at  the end of the cell  attachment protocol was 
about 95% (Figure 4E).  The optimal attachment could be explained by the 
homogenous coating of laminin observed with confocal microscopy (Figure 4F).  
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Figure 4. Adherence of MIAMI siRNA-SHH on PAMs. Different media for adherence were 
tested (A). We selected the media with 3% of serum for the rest of experiments. In this condition, 
we observe the adherence onto PAMs by brightfield microscopy at time 0 and 4H after cells and 
PAMs contact (B). Observation of blank PAMs (C) and cells/PAMs complexed (D) by scanning 
electronic microscopy. Cells number after 4h adherence onto PAMs was quantified by Cyquant® 
Reagent (E). Immunofluorescence of laminin on PAM was observed by confoncal microscopy (F). 
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3.5 INJECTION OF PAM/CELLS IN ORGANOTYPIC SLICES HD 
 Cells (MIAMI siREST-SHH) alone or complexed to Blank-PAMs or 
BDNF-PAMS were grafted in organotypic slices at  day 5 which represent 30% 
of GABAergic striatal cell  degeneration. Immunofluorescence against human  
Mitochondria was used to visualize MIAMI cells in rat brain, 7 days after 
graft ing (Figure 5).  PAMs clearly improved survival of cells.  Indeed, 
immunofluorescent staining was faint with cells alone, suggesting that some 
cells died. Blank-PAMs improved the survival compared to cells alone but the 
intensity of fluorescence was higher with B DNF-PAMs  (Figure 5).    
 Immunofluorescence against DARPP32 was used to determine MSN -like 
differentiated MIAMI cells 7 days after graft ing in the HD organotypic slices.  
Very few cells were positive for DARPP32 and only with BDNF -PAMs was 
there  some immunofluorescence clearly different from the background staining, 
suggesting the expression by MIAMI cells of DARPP32 with this condition 
(Figure 5).  Nonetheless, these observations have been realized only seven days 
after grafting, and the mRNA of DARPP32 appea red fourteen days after 
treatment in vitro.  
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Figure 5. Ex vivo GABAergic MSN differentiation of grafted cells. Immunofluorescence against 
Human mitochondria and human DARPP32 for MIAMI cells alone, seven days after grafting of 
cells or complexes with blank or BDNF PAMs. Scale bar is 150µm. 
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 The combination of mesenchymal stem cells and polymeric bioactive 
scaffold to enhance cell survival and differentiation needs to be developed to 
improve therapeutic approaches for HD. In this study we showed that a 
subpopulation of MSCs, the MIAMI cells were able to differentiate towards the 
neuronal GABAergic lineage by an epigenetic ARN interfering approach 
inhibit ing REST expression combined to GABAergic inducers. Moreover,  these 
cells committed towards this phenotype cells could be transplanted with PAMs 
delivering BDNF in an ex vivo model of HD, survive and maintain this 
GABAergic neuronal precursor phenotype, part icularly in response to BDNF.   
 It  has been shown that transplantation of MSCs into QA model of HD le d 
to improvement in behavior and reduced the lesion volume. These beneficial 
effects could be explained by the secretion of neurotrophic factors including 
BDNF, CNTF, nerve growth factor, insulin -like growth factor 1 and epidermal 
growth factor [42]. Within this line,  previous studies have shown that MIAMI 
cells release more tissue repair factors than MSCs [22]. Moreover, in a PD model 
and after stroke their tissue repair capacity allowed neuroprotection of these 
damaged cells [14,34,35]. Indeed, in this study MIAMI cells conserved their 
paracrine effect even at  the end of the differentiation with high level of VEGFA, 
BDNF and NGF mRNA. Although, it  was previously re ported that the addition 
of GDNF on organotypic slices cultures media enhanced the expression of 
DARPP32 in striatal  neurons [30], the low level of GDNF should not increase 
by itself DARPP32 in our model. However, the paracrine effect may be indirect 
and increase the survival not only of the transplanted cells but also of the issue 
parenchyma by an angiogenic effect. Indeed, i t  has been previously shown in an 
ex vivo model of PD that  release of VEGF by MIAMI cells increased the 
vascularization around the graft si te probably participating to the 
neuroprotective effects observed in this paradigm [35]. Secretion of neurotrophic 
factors have not been reported for ESC and iPS cells,  which show the advantage 
of MIAMI cells for a neuroprotective treatment of HD.  The release of these 
factors by the MIAMI cells alone or combined to PAMs needs to be further 
investigated. However, the lacks of consistent neuronal differentiation of 
transplanted MSCs have limited their therapeutic efficacy in slowing the 
4. DISCUSSION 
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progression of HD-like symptoms in animal models of HD. Indeed, their 
capacity to differentiate into neuronal like cells is st ill  i nsufficient.   
 MIAMI cells have already demonstrated their capacity to differentiate into 
dopaminergic neurons, with electrophysiological  properties of immature neurons 
[14,24]. Based on the literature, we developed and tested a simple protocol with 
different steps in order to obtain GABA -like neurons [11–13]. During the first 
step we decided to inhibit  REST and drive the commitment with sonic hedgehog. 
Indeed, we already demonstrated that REST inhibition induced s pontaneously 
neural differentiation, increasing the mRNA of neurofilament (NFM). In 
particular, LNC siREST had a better effect on the differentiation than a 
commercial  reagent ( lipofectamine®) with siREST (paper in press).  In order to 
better comprehend this effect, we followed LNC and siRNA retention time in 
MIAMI E/F cells during 6 days.  The internalization of LNC seems to be by 
endocytosis because we observed concentrated spots exactly as those observed 
after endocytosis phenomenon such as with calcium ph osphate particles recently 
developed [43]. More interestingly,  LNC properties proved their capacity to 
destabilized the lysosomal compartment [21]. In this study, LNCs co-localized 
with lysosomes while this was not the case for th e siRNA. The observation in 
confocal microscopy showed a high proportion of siRNA - positive cells during 
two days,  and a progressive decrease of positive cells until  day 6 where we 
found 15% of cells still  presenting siRNA. Conversely,  in vitro  cell time 
retention of siRNA with lipofectamine and liposomes showed that the siRNA 
was present during only three days [44]. The progressive siRNA delivery in our 
study suggests that this LNC property is quite interesting for maintaining a 
differentiated cellular state for cell therapy applications.   
 The effect of siREST on the neuronal commitment to obtain lateral  
ganglionic eminence was promising. Through 14 days of differentiation of 
MIAMI E/F-siREST under commitment culture conditions [12], these cells 
gradually stretched out long neurite -like structures. The morphological 
similarity of these cells with neurons suggests that REST knock -down allows 
MIAMI cells  to engage into the neuronal lineage. Furthermore, the cells 
presented some similarities to LGE precursor cells with the decrease of Pax6 
(neural stem cell marker),  the sl ight increase of β3-tubulin (neuronal precursor 
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marker) and high expression of NFM (immature and mature neuron marker). 
However, the expression of Dlx2, a marker of GABAergic progenitors [45],was 
more important  in MIAMI E/F or with the siCtl  and the high expression of NFM 
suggests that the cells could be further committed in the GABAergic 
differentiation lineage. At the end of the diffe rentiation, the knock-down of 
REST seemed to have a limited influence on the appearance of DARPP32 
markers or GAD67 (mRNA and proteins). However, it  led to an increased 
response to the best  treatment, which was the combination of VPA with BDNF 
during the last  stage of the differentiation protocol.  
 Pre-clinical  trials with mesenchymal stem cell transplantation suggest  that  
cell therapy is a potential promising option for HD [16,46]. Unfortunately,  
transplanted cells have low survival rate. In this study, we used carriers 
providing a biomimetic support of laminin and the delivery of BDNF, the PAMs, 
combined with MIAMI cells to maximize the resulting protective/reparative 
effects on HD model.  This effect should be double, drive the MIAMI cell 
survival and differentiation as well as increase the neuroprotective effect that 
we hope to observe with LGE-like cells obtained from MIAMI-siREST 
committed cells. Indeed, the secretion of BDNF by MIAMI cells and the release 
by PAMs should have a potent neuroprotective action. As reported earl ier, 
PAMs may improve the integration of PC12 cells and embryonic dopaminergic 
cells within the brain parenchyma, after transplantation in hemi -parkinsonian 
rats, by improving their survival and differentiation. This work clearly 
confirmed previous studies. Cells alone or complexed to LM-PAMs were grafted 
at day 5,  when 30% of degeneration was obtained. A high detection of human 
Mitochondria was observed when the cells were complexed to BDNF -PAMs, 
which suggests that scaffold and BDNF improved the survival. More 
interestingly,  sl ight expression of DARPP32, demonstrated their potential  to 
differentiate into MSN in only seven days, probably driven by the released 
BDNF.  In order to confirm that , secretome analyses with cells complexed to 
Blank or BDNF-PAMs should be performed. In any case, these data provide 
encouraging results arguing for an enhancement of the neuronal differentiation 
of MIAMI cells towards a GABAergic phenotype and a neuroprotective effect 
for HD with this innovative nano and micromedicine safe combinat orial 
strategy.  
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In this study, we tested an innovate strategy combining stem cells and 
biomaterials in ex vivo  model of HD. We demonstrated in this way, the capacity 
to our model to screen new therapy. We proved, in vitro ,  the capacity to MIAMI 
cells to differentiate into GABAergic -l ike neurons by REST inhibition and 
appropriate media.  After graft , the survival of MIAMI cells combined with LM -
BDNF-PAMs seems to be increased, probably due to the synergic effect  between 
the 3D support  and the release of BDNF. Nonetheless, the biological effect of 
committed MIAMI-LM-BDNF-PAMs on the HD environment needs to be 
characterized and understood.  
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 In this study we showed that MIAMI cells could be induced towards the 
GABAergic phenotype in vitro  and that  when transplanted as GABAergic 
precursors in an ex vivo  model of HD they survived better when attached to 
PAMs delivering or not BDNF compared to cells alone. Through this study, we 
also showed that the ex vivo  model developed for modelling HD, can be used  for 
evaluating different strategies in the treatment of this disease.  
 We first  determined that  LNCs were able to release the siRNA during 6 
days explaining the persistent effect  of siREST to induce neuronal commitment 
already observed in normal MSCs. MIA MI cells were first treated with EGF and 
bFGF as these factors induced their specification towards the neural/neuronal 
phenotype. Based on Ma et al.,  2013 discovery, we decided to further treat 
MIAMI cells with sonic hedgehog [89]  after transfection to obtain LGE-like 
progenitors. Indeed, the inhibit ion of REST before the differentiation allowed 
obtaining functional neurons [2].  In our case,  the inhibition of REST during the 
first step of the differentiation had a favourable effect during al l our protocol. 
Even if siREST is not able to silence REST during fourteen days during the LGE 
commitment,  we clearly observed an increase of cells responding to the 
treatment during the GABAergic differentiation. Moreover,  some evidences 
suggested that  we overpassed the LGE stage with the inhibition of REST. We 
observed the protein expression of NFM at the end of the commitment,  which 
was not reported previously with SHH treatment.  A better characterization 
should be performed with for example the evaluati on of the CTIP2 expression in 
the LGE-like progenitors obtained. Indeed, in a recent study, CTIP2 was 
reported as the only transcription factor tested that  was able to directly 
reprogram dermal fibroblasts into DARPP32 +  neurons, suggesting that it  a key 
regulator for GABAergic differentiation [176].  
 As part  of the therapeutic strategy relies on the neuroprotective effect of 
LM-PAMs-MIAMI-committed cells, we also checked  the neuroprotective effect 
by RT-qPCR in vitro .  The high expression of VEGFa at  the end of the treatment 
permits to think that  these GABAergic -like neurons still  retain some 
characteristics from MIAMI cells, and will be able to have a beneficial  effect on  
DISCUSSION  
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brain slices.  It  has already been demonstrated that  VEGFa possesses angiogenic 
capacit ies,  and maintained the blood vessels in the in brain slices [84].  
Furthermore, during the differentiation  VEGFa enhances the gamma-
aminobutyric acid  (GABA) synaptic activity in embryonic spinal motoneurons  
[177]. We can easily imagine that VEGFa will induce an improvement of the 
differentiation of MIAMI cells by stimulating GABAergic synapses. But VEGFa 
was not the only one secreted by MIAMI derived GABA -like cells,  because 
BDNF and GDNF were also detected in those cells. MSCs secreting BDNF and 
GDNF have been already described to improve the behavior of rats with HD 
[145,178,179]. In this way, we can suppose that LM -PAM-LGE-like progenitors 
will reduce the degeneration. But the major advantage of MIAMI cells is  their 
capacity to express DARPP32, a marker of GABAergic neurons,  when grafted 
attached to LM-PAMs-BDNF. These results are very surprising because when 
ES cells differentiated into striatal  progenitors were grafted in quinolinc acid 
treated rats, they exhibited a 15% of DARPP32 positive neurons after 13 weeks 
in situ [37], while a LGE-like progenitors grated reveal a 50% of DARPP32 
expression [89].  The advantage of the prolonged release of BDNF by the PAMs 
should be further investigated. With MIAMI cells we have not quantified yet  the 
pourcentage of DARPP32 expression which could be very interesting in future 
studies 
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 Since the discovery of Huntington' disease in 1872, pharmacological  
treatment or other therapeutic approaches are sti ll  insufficient to cure the 
disease [16]. Progressively,  cell therapy became one of the most promising 
treatments [58].  However,  despite many pre-clinical  and clinical  trials showing 
functional benefits  with this strategy for  CNS disorders,  i t  is still  not used 
routinely. In the last twenty years, the implantation of fetal cells for the 
treatment of HD has demonstrated the possibility of this approach, but shows an 
important diversity of results in clinical trials due to the h eterogeneity in 
protocols [180,55]. Moreover,  the use of ESC or iPS present the risk of over -
proliferation in the brain, in addition to the numerous ethical problems 
previously mentioned [37,90].  Research studies need to focus on resolving the 
choice of cell type, the number of injected cells and the time of injection. 
Moreover,  the optimization of their survival  and differentiation need to be 
improved before imagining using them in patients. In consequence, in this work, 
we evaluated an innovative and safe strategy based on regenerative medicine  for 
HD with modified MSCs and appropriate biomimetic scaffold.  
In regenerative medicine, an innovative approach is the association of 
modified cells with therapeutic molecules,  morphogens, materials or 
biomaterials with different physicochemical properties to enhance their 
biological effects and optimize cell therapy. Howe ver,  the use of adult  stem 
cells showed numerous limits with a significant death of the implanted cells 
quickly detected. In addition, relatively low rates of implanted cells 
differentiate into mature neurons.  The capacity of MSCs to undergo functional 
differentiation into neurons has been questioned over the years and remains 
controversial [181].  Despite the initial  skepticism regarding the capacity of 
MSCs to differentiate into neurons or glial cells , it  was discovered that MSCs 
express a considerable repertoire of neural genes, which l ikely contributes to 
the contested neurogenic predisposition of these cells [182,183]. In addition, 
bone marrow MSCs express higher neuronal markers [184]  compared to MSCs 
derived from other origins.  
In this work, we decided to use a homogenous subpopulation of bone 
marrow mesenchymal  stem cells, MIAMI cells, which have already 
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demonstrated their capacity to differentiate into dopaminergic neurons with 
appropriate electrophysiological properties of immature neurons  [95,185,88]. 
Nonetheless, in order to improve the differentiation and their integration in the 
parenchyma, we chose to knock-down REST. The approach used here is slightly 
different from strategies generally used for reprogramm ing MSCs into neurons. 
Indeed, recent studies have shown that over -expression of transcription factors 
can serve to promote neuronal differentiation and maintain a neuronal 
phenotype. Based on the same model to obtain induced Neurons cells (iNs) by 
forcing the expression of a set of neural lineage transcriptional factors [186],  
the differentiation of MSCs towards a neuronal lineage has been achieved with 
Neurogenin1, LMX1 and/or PDX1 (For a review see [187]).  Very few studies 
using the opposite strategy to knock -down and not over-express transcription 
factors have been performed to improve neuronal commitment [102,175].  In 
those studies, knock-down of REST was effective with lentivirus and plasmids 
allowing a stable inhibition of REST.   
In this study, we preferred to safely modify the MSCs and focused  on 
transitory inhibition with siREST carried by non -viral  vectors to boost the 
differentiation. We thus designed and characterized two different nanocarriers 
LNC and SP-AP to efficiently deliver siRNA. Normally,  epigenetic 
manipulation of stem cells is a delicate and complex task. Their remarkable 
capacity of proliferation makes them poor candidates for non -viral vectors, 
electroporation and nucleofection, and most stem cells are sensitive to antibiotic 
selection; hence, attempts to stably establish transf ected stem cells are rarely 
successful  [188]. But, in our hands both nanocarriers were perfectly able to 
delivery the siRNA with a varying degree of toxicity.  We also tried to reduce 
the off-target effect  usually described in the literature with cationic lipids for 
siRNA delivery[189] . These effects are  obtained due to si lencing of genes other 
than the intended one and thus compromise the use of a siRNA to study gene 
function and can even cause cell  death.  Furthermore, i t  has been observed that 
even scrambled sequences,  which theoretically do not target any mRNA, can 
have a moderate to high impact on the cell  viabil ity,  depending on the cell l ine 
and siRNA concentration [190,191]. In order to avoid this, particular care was 
provided, in this study and in previous ones, to design siRNA nanocarriers with 
liposomes representing only 20% of the system for the LNCs or without any 
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cationic lipids in the case of SP-AP nanocarriers [120,192]. Moreover,  viability 
assays were performed with both siREST and siCtle and no difference in terms 
of toxicity or not differential  expression of 2 housekeeping genes was observed 
which permits us to suppose that  the off -target effect  is reduced with these 
nanocarriers.  
Both of these systems were recently further optimized and developed. The 
optimization of the formulation of SP -AP allowed obtaining 70% of  siRNA 
complexation. Furthermore, a new method of detection has been performed to 
measure the encapsulation efficiency of siRNA -LNC which is now of 75%. Due 
to their characteristics, the use of other morphogens or therapeutic molecules 
together with siRNA-nanocarriers can be envisaged. Indeed, during this thesis, a 
collaborative study allowed determining that  the core of LNCs is not used [155] 
and the loading of different morphogens such as re tinoic acid, [193] in order to 
obtain GABAergic precursors,  could be added during the formulation. In this 
way a synergistic effect on neuronal commitment of stem cells could be 
obtained. In the same way the siRNA of SP -AP nanocarriers is  on the surface 
letting the matrix core free for addition of growth factors. In other words, 
combining delivery of a morphogen or a growth factor with a REST knock -down 
may be a useful strategy for generating functional neurons for therapeutic 
purposes and easily applied to LNCs or SP-AP. To our knowledge, the co-
delivery of siRNA and growth  factors with nanoparticles has  not been 
investigated until  now in regenerative medicine approaches,  but it  has already 
been performed for cancer treatment, demonst rating the possibility to use this 
approach [194].   
A previous PhD student (Nicolas Daviaud) demonstrated a limited effect  of 
EGF/bFGF pre-treated MIAMI cells in terms of neuroprotection or 
differentiation in the ex vivo  HD model.  After injecting these MIAMI cells pre -
committed towards the GABAergic l ineage, he described only 10-15% of stem 
cells expressing β3-tubulin,  very few committed MIAMI cells expressed 
DARPP32 and the expression of GAD67 was undetected even when cells were 
adhered onto LM-PAMs. Based on the literature [37,89,90]  we investigated a 
new 2-step protocol and we characterized the cells obtained four weeks after 
differentiation in vitro .  The first step consisted on t he neuronal commitment in 
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order to obtain LGE progenitors,  from which MSN derive,  and the second one 
on the final differentiation to obtain these GABAergic -like neurons. Specific 
media with Sonic Hedgehog was used during fourteen days after siREST 
transfection. SHH is a pleiotropic factor for the development of CNS driving 
proliferation, specification, and axonal targeting in multiple sites within the 
forebrain, hindbrain,  and spinal cord. Studies in embryonic CNS have shown 
how gradients of this morphogen are translated by neuroepithelial  precursors to 
determine the types of neurons and glial  cells they produced [195]. Using these 
conditions LGE progenitors were obtained  [89] (Figure 12) .  Nonetheless, in our 
work, we concluded that we over -passed this stage with the high expression of 
NFM and β3-tubulin as well as the decrease of DLX2 at the end of the 
commitment. In order to better understand those results the mechani sm and 
signaling forced by the inhibition of REST must be elucidated.  
REST expression is very high in ESCs compared to most other cell  
types[152],  and is thought to be involved in their self -renewal. REST is 
regulated directly by the pluripotent factors Oct4/Sox2 and Nanog, maintaining 
a high expression of REST, but its  function in the self -renewal transduction 
network is unclear  [196–198].  In this work, the inhibition of REST without any 
other differentiated media was enough to induce neuronal commitment of MSCs, 
which is not surprising due to the functionality of REST  [151,151]. But, at the 
end of this period we still  observed a slight diminution of REST.  This inhibition 
is not only explained by the prolonged release of REST with LNCs, because we 
did not observe any siRNA after 6 days (data not shown). We thus assume that 
siREST helped and accelerated the  commitment as described in mouse 
previously [198,199] and during neurogenesis in vivo[200] However,  various 
other explanations can be advanced. One  explanation relates to the levels of 
pluripotent factors such as Nanog. Indeed, the level of Oct4 and Nanog is lower 
in EGF/bFGF pre-treated MIAMI cells compared to non pre -treated MIAMI 
cells[185] and they should continue to decrease during the differentiation. In 
this way, they are unable to maintain or re -activate high levels of REST within 
the cell.  The microenvironnement is also very important for REST regulatio n. In 
a recent publication, Shing et al .,  investigated the role of laminin on 
pluripotency and demonstrated the reduction of self -renewal of ESCs on laminin 
coated surfaces  [201]. In this way, we chose to transfect MIAMI cells after 
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laminin adherence because laminin coated surfaces also play a modest  role in 
the loss of pluripotency [201].  Moreover, in vivo  reports describe the role of 
laminin in axonal regeneration of the CNS [202]. In our study, proliferation 
seems to diminish after transfection with siREST and some neurites appeared 
during the commitment step with SHH but in order to confirm those data the 
possible interaction between REST and kinase or cyclin proteins involved in the 
cell cycle needs to be explored.  Finally,  REST activity represses the expression 
of GluR2 in neurons destined to die,  indicating that  REST might play an 
important role in insult -induced death of neurons[203] [204].   
The final  differentiation step allowed obtaining GABAergic -like neurons in 
vitro .  The best condition was a 4 weeks treatment with the supplementation of 
Valproic acid and BDNF at the same time (Figure 12).  Those results will  be 
confirmed with repeated experiments, but they established the choice of BDNF 
as the growth factor to be delivered by the PAMs for the graft ing of committed 
MIAMI cells and PAMs.  Accordingly,  laminine was confirmed as the best 
molecule for functionalizing the surface of the PAMs. In this way we chose to 
graft  the EGF/bFGF MIAMI cells after commitment towards GABAergic 
precursors with siREST LNCs and SHH with or without laminine PAMs 
delivering or not BDNF. We already successfully showed the regenerative effect 
of EGF/bFGF MIAMI cells and PAMs releasing NT -3 in a PD model  
[84,88,174]. In addition, the transduction pathway allowing NT -3 to induce 
differentiation into a neuronal cell  type was studied in vitro  and it  was 
demonstrated that the fixation of NT-3 to its  receptor stimulated the kinase 
pathway MEK / ERK. Moreover, the action of Rac1b on this pathway to block 
proliferation and st imulate the development of neurites was also elucidated  
[205]. So, strong of those results, we could intend a similar strategy for HD.  
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Figure 12. The different steps observed during in vitro differentiation 
The preliminary evaluation of this combined regenerative medicine strategy 
has been performed with innovate organotypic brain slices modeling the 
GABAergic degeneration observed in HD. Indeed, taking into account the 
numerous advantages of organot ypic brain slices, we developed a simple model 
of HD, where GABAergic MSNs degeneration is due to mechanical  transection 
of the axonal pathway between the striatum and substantia nigra. We wanted to 
develop a simple, inexpensive and mono -parametric model of HD. Based on the 
same principle that  we have already developed to model Parkinson’s disease  
[206], we demonstrated that  the axis of sectioning is very important as only 
coronal sections allowed modeling the progressive degeneration of MSNs. The 
slices were viable at  least until day 19 as deter mined by Neu N expression as 
well as the MSN degeneration determined by the decrease of DARPP32 and 
GAD67 expression. The mechanism of degeneration is still  poorly understood i n 
this model,  and we hypothesize  that the regulation of the physiological state of 
these striatal neurons via dopamine is impaired. Nonetheless,  the determination 
of the dopamine-regulated ion channels could be performed by 
electrophysiological  studies.  In addition, a possible reduction in the striatal -
specific dopamine targets,  PKA, DARPP-32, ARPP-16, and ARPP-21 could be 
performed, with RT-qPCR or immunofluorescence.  
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  This ex vivo  model will allow screening the best strategy for HD and 
further comprehending the mechanisms involved in the regeneration of the 
GABAergic neurons as performed with an ex vivo  model of PD by our group 
[206]. For example, we can interrogate the amount of cells to be injected and if 
they should be injected as a bolus or repeated injections.  Furthermore, the 
evaluation of the behavior of stem cells after grafting must be performed at 
long-term. Therefore, we are going to follow NeuN and GAD67 over -time until 
30 and 60 days to evaluate the long-term viability of the sl ices and follow the 
degeneration of the GABAergic neurons.  A recent study allowed observing few 
axonal projections (0.017%) after 9 wee ks injection of differentiated ESC and 
more axonal projections after in utero implantation, suggesting integration of 
the donor cells into the neuronal network of the host brain [207]. But the poor 
quantity of axonal projection demonstrated the diff iculty to  hope replace 
GABAergic neurons.  Although transplanted cells integrated and were able to 
reduce the motor asymmetry in the QA-lesioned model, long-term studies are 
needed to assess circuit reconstruction and behavioral recovery. With our 
model, we can obtain cortico -striatal brain slices or the whole coronal section. 
In this way, we can screen the different regenerative medicine strategies and 
select the best approach showing benefits in terms of neuroprotection, not only 
in the striatum but also in the cortex and the globus pallidu s,  which are involved 
in HD.  
In adult  PD rat brain, we have first shown that  the 60 µm size and PLGA -
PAMS could be stereotactically implant ed in precise areas of the brain without 
causing damage to the surrounding tissue. Nonetheless in organotypic slices , we 
thought that 30 µm could be better. So, in this study, the triblock copolymer 
poloxamer P188 ((poly (ethylene oxide) (PEO)–poly(propylene oxide) (PPO)–  
PEO) linked to PLGA to form this PLGA-P188-PLGA co-polymer was used to 
formulate PAMs with 30 µm size.  Indeed, PLGA based implantable devices are 
FDA approved [208] but the efficient and sustained release of proteins from 
PLGA-PAMs remains a challenge, mainly due to protein instabili ty (adsorpti on, 
aggregation, and denaturation) during the formulation process or the release 
period. Therefore this polymer was used to formulate the PAMs in this study. 
Interestingly,  PLGA-P188-PLGA 60 µm microsphere releasing TGFb3, 
developed for cartilage tissue engineering, resulted in a prolonged and almost 
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complete TGFb3 release  [209]. They offered the advantage to limit  protein 
adsorption but also to stabilize the pH inside the microsphere thus preventing 
protein unfolding and denaturation. M oreover, an increase in MSC number was 
observed after 7 days in culture on fibronectin -covered PLGA-P188-PLGA 
PAMs compared to fibronectin-covered PLGA PAMs.  
In our study the 3D support  offered by the scaffold allowed cell retention 
within the striatum and, probably cell  survival as seen by the increased number 
of human cells with the PAMs compared to cells implanted alone. However,  
BDNF-PAMs also seemed to drive cell differentiation of pre -committed MIAMI 
cells,  demonstrated by the increase of DARPP32 mark ers compared to Blank-
PAMs. These results are in accordance with previous reports showing that  
BDNF increases DARPP32 expression in neurons of the striatum [210,211]. 
Moreover,  it  appears to induce significant neuroprotection of NMS neurons in in 
vivo  models of Huntington's disease [212,213].  A collaborative work allowed 
determining the release of BDNF from PAMs, which  corresponded perfectly to 
the amount (15 ng/day) needed by the cells for their differentiation [37,89,90] 
Nonetheless, we don’t know if the protective effect on MIAMI cells is due to 
the BDNF released from PAMs or BDNF secreted by MIAMI cells.  The 
neuroprotective effect of MIAMI on the GABAergic neurons is also another 
important part  of this project.  In the  present study, in preliminary results,  we 
observed in vitro  that MIAMI cells expressed BDNF and GDNF as well as a 
very high level of hVEGFA. BDNF and GDNF have both been reported as 
neuroprotective factors whose effects were,  in part,  mediated by autophag y 
regulation[214]  and oxidative stress diminution[215,216],  respectively.  The 
neuroprotective effect of BDNF and GDNF has been evaluated in pre -clinical 
studies in HD [217–219]. In this way,  pre-committed MIAMI cells are good 
candidates for neuroprotection. hVEGFA is playing a dual role,  indeed,  
hVEGFA can increase grafted cells survival by creating new blood vessels 
around the graft enhancing oxygen and nutrients supply and a neuroprotective 
effect. Indeed, in a more recent study, the delivery of hVEGFA via injectable 
hydrogels, to rats receiving striatal  injection of quinolinic acid to mimic 
neuronal loss and behavioral  deficits characteristic of HD, was shown to be 
neuroprotective at 3 weeks  [220]. As hVEGFA is well -known to have pro-
angiogenic effect , a quantification of blood vess els in the brain slices should be 
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performed. Complete analyses of the secretome of MIAMI cells are going on in 
order to better characterize proteins secreted by LGE -like progenitors.  
 
Figure 13. Schematic strategy finally used during this thesis and some advantages. 
However, a final assessment of this strategy includes the behavioral  
evaluation in an appropriate in vivo  model.  In this work, intracranial injection 
of MIAMI cells is envisaged and we think it  is the best  option as the cells and 
PAMs need to be close to their site of action to avoid  undesired side-effects. We 
can also consider delivery of siREST by implantation of the si -REST 
nanocarriers together with the cell graft.  Indeed, REST expression is increased 
in HD [221,222] and its  association with HTT in the cytoplasm is disrupted in 
HD due to the mutated HTT. This leads to increased nuclear REST and 
concomitant repression of several neuronal -specific genes,  including BDNF 
[67]. The finding described indicates that  inhibition of REST expression may 
offer a new therapeutic avenue for treatment of HD. Nowadays, innovative 
strategies including the use of RNAi to reduce REST expression [223] or decoy 
oligonucleotides or synthetic peptide nucleic acid (PNA) oligomers to seque ster 
REST away from its genomic sites  [224,225] are underway. All of these 
approaches lead to reduce interactions of REST with its  target  genes;  however,  
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translation of this into a useful therapeutic strategy requires safe and efficient 
delivery of these tools to the brain of HD patients. This is  no easy task and 
LNCs or SP-AP could be used for that, but this strategy needs to be care fully 
analyzed. More particularly,  a full characterization of this combined strategy 
will be evaluated during a post -doctoral  contract.  
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Title Combination of nano and microcarriers for stem cell therapy of 
Huntington's disease: new regenerative medicine strategy 
 
 
 
Résumé 
La combinaison de biomatériaux et cellules 
souches, a pour but de protéger des cellules 
endommagées et de ralentir la progression des maladies 
neurodégénératives, comme la maladie de Huntington 
(MH). Les cellules souches mésenchymateuses et 
particulièrement une sous-population, les cellules MIAMI, 
ont déjà démontré leur efficacité dans la maladie de 
Parkinson. Il est cependant essentiel d’améliorer leur 
différenciation neuronale, leur survie et évaluer leur 
sécrétome. L’objectif principal de ce travail fut de proposer 
une stratégie innovante de médecine régénératrice pour la 
MH associant cellules souches, nano et micro médecines. 
Pour l’évaluer, un nouveau modèle animale ex vivo de la 
MH a été mis en place. Nous avons ensuite développé et 
optimisé deux nano-vecteurs, des nanocapsules lipidiques 
et des nanoparticules solides de SPAN, et les avons 
associés à un inhibiteur de REST qui est un facteur de 
transcription qui empêche la différenciation neuronale. La 
transfection de ce siREST a montré une amélioration du 
phénotype neuronal. Ces cellules ainsi modifiées furent 
ensuite induites vers un phénotype GABAergic grâce à 
des facteurs de croissance. Puis elles ont été associées à 
un support 3D, les microcarriers pharmacologiquement 
actif (MPA) permettant une meilleure intégration des 
cellules après greffe. Les MPA sont des microsphères 
ayant une surface biomimétique de laminine et libérant de 
façon contrôlée un facteur trophique le « brain derived 
neurotrophic factor » (inducteur d’un phénotype neuronal 
et neuro-protecteur). Des résultats prometteurs ont été 
obtenus, encourageant à continuer l’évaluation de cette 
stratégie in vivo dans des modèles génétiques de la MH. 
 
Mots clés 
 
Médecine régénérative, cellules cellules souches 
mesenchymateuse, Maladie de Huntington, siREST, 
nanoparticules, microcarriers pharmacologiquement 
actif 
Abstract 
 
The combination of biomaterials and stem cells aims to 
protect damaged cells and slow the progression of 
neurodegenerative diseases such as Huntington's disease 
(HD). Mesenchymal stem cells, particularly a sub-
population known as MIAMI cells, have already 
demonstrated their effectiveness in Parkinson's disease. 
However, it is essential to improve their neuronal 
differentiation, survival, and to assess their secretome. The 
main objective of this work was to propose an innovative 
regenerative medicine strategy for HD by combining stem 
cells, micro and nano medicines. To perform this 
assessment, a new ex vivo animal model of HD has been 
set up. We then developed and optimized two nano-
vectors, lipid nanocapsules and solid SPAN nanoparticles, 
carrying an inhibitor of REST a transcription factor, which 
prevents neuronal differentiation. The transfection of this 
siREST showed an improvement in the neuronal 
phenotype. These modified cells were then induced into a 
GABAergic phenotype through growth factors. They were 
then associated with a 3D support, the pharmacologically 
active microcarriers (PAM) allowing a high rate of 
engraftment. The PAM are microspheres which have a 
biomimetic surface of laminin and release a trophic factor 
BDNF, brain derived neurotrophic factor (inducer of a 
neural phenotype and neuroprotective) in a controlled 
manner. Promising results were obtained, further 
encouraging continuing the evaluation of this strategy in 
vivo in genetic models of HD. 
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